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Abstract 
Breast cancer is the world’s most prevalent cancer. Although several drugs 
and chemotherapeutic strategies have been developed to tackle breast 
cancer, to date most patients eventually acquire resistance to these anti-
cancer therapies. Therefore, identifying ways to increase the efficiency of 
currently used chemotherapeutic drugs and the development of new drugs for 
breast cancer treatment is essential. One way to achieve this goal is by 
identifying cellular targets which play a pivotal role in tumourigenesis and 
tumour progression.  
Paclitaxel belongs to a class of naturally occurring anti microtubule agents 
used for the treatment of malignancies such as breast cancer. Previous work 
has shown that FoxO3a, a transcription factor downstream of the 
phosphotidylinsitol-3-kinase/Akt signalling pathway, mediates apoptosis and 
cell cycle arrest in breast cancer cells in response to paclitaxel treatment.  
In order to elucidate the significance of FoxO expression and activation in 
response to paclitaxel treatment and oxidative stress (which is caused by 
paclitaxel treatment), I investigated the regulation of FoxO in endometrial and 
breast cancer cells. Both paclitaxel and oxidative stress were found to up-
regulate FoxO expression at the protein, mRNA and gene-promoter levels. 
Moreover, treatment with paclitaxel and hydrogen peroxide were shown to 
increase FoxO3a protein stability. Paclitaxel treatment resulted in JNK 
mediated nuclear accumulation of FoxO3a with a corresponding reduction in 
Akt activity. JNK was also shown to induce FoxO3a gene-promoter activity 
and to phosphorylate FoxO3a at two sites. These phosphorylation events 
may be important in the regulation of FoxO3a stability and activity.   
I also investigated the function of FoxO3a, by studying the role of BTG1, a 
downstream target of FoxO3a. I found that BTG1 expression was induced at 
the gene-promoter level by FoxO3a in MCF-7 cells. The use of a BTG1 
inducible MCF-7 cell line revealed that over-expression of BTG1 results in 
changes in the expression levels of cell cycle regulators, reduction in cell 
growth and accumulation of cells in the G2/M phase of the cell cycle. 
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Taken together, these results show that FoxO expression and activity are up-
regulated following paclitaxel treatment and demonstrate that the 
PI3K/Akt/FoxO and JNK signalling pathways cross-talk at least at two levels. 
Furthermore, these results indicate that FoxO expression levels may serve 
as bio-marker for determining the effectiveness of paclitaxel treatment of 
breast cancer patients and that FoxOs may serve as a potential target for 
anti-cancer chemotherapeutic intervention. 
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G-Proteins Guanine nucleotide–binding proteins 
GSK3 Glycogen synthase kinase 3  
GTP Guanosine triphosphate  
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Abbreviation  Abbreviated Term 
H Hours 
HATs Histone acetyltransferases 
HAUSP/USP7 Herpes virus associated ubiquitin-specific protease  
HDACs Histone deacetylases 
HIF1α or HIF2α Hypoxia inducible factor α  1 or 2 
HRP Horseradish peroxidase  
HSP27 Heat shock protein 27   
ID1 Inhibitor of DNA binding 1 
IGF-1 Insulin-like growth factor-1  
IGFBP1 IGF-binding protein-1  
IKK IκB kinase  
ILK Integrin-linked kinase  
IP Immuno-precipitate  
JNK Jun N-terminal kinase 
LB Luria-Bertani  
MAFbx Atrogin-1  
MAPK Mitogen Activated Protein Kinase  
MBDs Methyl-binding domain proteins 
MDM2 Mouse Double Minute  
MIN Minutes 
MMR Mismatch repair 
MnSOD Manganese superoxide dismutase  
MKKs MAPK kinases  
MKKKs MAPK kinase kinases  
MNK-1,2 MAPK interacting kinase-1,2  
MKPs MAP kinase phophatases  
MLK3 Mixed lineage kinase 3  
MSK-1 Mitogen and stress activated protein kinase -1  
MST1 Mammalian Ste20-like kinase-1 
mTOR Mammalian target of rapamycin 
mTORC1 mTOR complex 1  
Na3VO 4    Sodium orthovanadate 
NaF Sodium fluoride  
NER Nucleotide-excision repair 
NF-κB Nuclear factor-κB 
NLSs Nuclear localization signals  
NP-40 Nonidet P-40 
OD Optical density  
PBS Phosphate buffer solution  
P/CAF CBP-associated factor  
PCR   Polymerase chain reaction 
PDGF Platelet-derived growth factor receptor  
PDGFR Platelet-derived growth factor receptor  
PDK 1 Phosphoinositide-dependent kinase 1 
PGC-1α Peroxisome-proliferator-activated receptor γ coactivator 1 α  
PH DOMAIN Pleckstrin-homology domain 
PEPCK Phosphoenolpyruvate carboxykinase  
PI Propdium Iodide  
PI3K Phosphatidylinositol 3-kinase 
PIK3CA p110α catalytic subunit 
PKA Protein Kinase A  
PKB Protein kinase B 
pRb Retinoblastoma 
pRBL2 (p130) Retinoblastoma-like 2 
PRMT1 Argentine methyl transferase 1  
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Abbreviation  Abbreviated Term 
PtdIns Phosphatidylinositol phospholipid 
PTEN Phosphatase and tensin homologue deleted in chromosome 10 
Rictor–TOR Target of rapamycin 
RNA  Ribonucleic acid 
ROS Reactive oxygen species  
RPM Revolutions per minute 
RT Room temperature 
RT-qPCR Quantitative Real Time PCR  
SDS Sodium Dodecyl Sulphate 
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis  
SERMs Selective estrogen receptor modulators  
SGKs Serum-and glucocorticoid-inducible kinases  
SH2 Rous-sarcoma-oncogene homology-2 domain 
SHIP1, SHIP2 Src-homology 2 (SH2)-containing phosphatases 
SIR2 Silencing information regulator  
SIRT1 Mammalian homologue of Silent Information Regulator-2 (SIR-2) 
SAPK Stress-activated protein kinase 
SRB  Sulphorhodamine B  
STE20 Sterile 20  
TBS Tris Buffered Saline 
TBS-T Tris Buffered Saline-Tween  
TCA Trichloroacetic acid 
TGFβ Transforming growth factor β 
TRADD TNF receptor type 1 associated death domain 
TRAIL TNF-related apoptosis-inducing ligand 
TRIS Tris (hydroxymethyl) aminomethane 
TWEEN 20 Polyoxyethylene-sorbitan monolaurate 
TSC1/2 Tuberous sclerosis protein1/2 
UV Ultraviolet 
VEGF Vascular endothelial growth factor  
W/V Weight to volume 
W/W Weight to weight ratio 
YAP Yes associate protein 
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1 Introduction 
1.1 Overview: cancer 
Cancer is a genetic disease of somatic cells (Knudson, 2002). Six vital 
changes occur in the cell physiology, which jointly lead to malignant growth: 
self-sufficient growth (no growth signals required), growth in the presence of 
growth-inhibitory (antigrowth) signals, ability to avoid the cell’s apoptotic 
programme, endless proliferative potential, constant angiogenesis (growth of 
new blood vessels), and ability to cause metastasis (spread of malignant 
cells) and invade tissue. The formation of metastasis is considered the most 
life threatening characteristic of cancer (Hanahan and Weinberg, 2000).  
According to national statistics and Cancer Research UK statistics 
(www.statistics.gov.uk, http://info.cancerresearchuk.org), one in three people 
develop cancer during their lifespan and one in four will die of cancer. The 
risk of getting cancer increases with age; of all cases diagnosed 74% of them 
are in people aged 60 and over and only 0.5% of them are in children 
(younger than 15 years). There are more than 200 types of cancer. The four 
most common types are breast, lung, bowel and prostate, together they 
account for over half of the new incidence. Women tend to develop cancer at 
an earlier age than men and this is mostly due to the high risk women have of 
developing breast cancer. Breast cancer is the most frequently diagnosed 
cancer in women aged 40-59 years in the UK and accounts for roughly half of 
all diagnosed cancers in this population.  
Three types of genes have been shown to play a role in tumourigenesis: 
oncogenes, tumour-suppressor genes and stability genes. Nonetheless, 
cancer is not caused by a mutation in just one of these genes, but rather 
mutations have to occur in several genes in order for cancer to develop. 
Therefore, each mutation that occurs in a one of these genes increases the 
chances that cancer will develop (Vogelstein and Kinzler, 2004).  
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1.1.1 Genetic basis of cancer 
Proto-oncogenes:.A proto-oncogene is a gene which codes for a protein that 
can positively regulate cell proliferation and/or cell growth. Often proto-
oncogenes encode proteins which play roles cellular signalling pathways, or 
are involved in transcriptional regulation. As long as an oncogene has no 
mutations and its function is regulated, it would be considered a proto-
oncogene. However, some mutations can turn proto-oncogenes into 
oncogenes. These types of  mutations in may result in the gene becoming 
either constitutively active or active under conditions different to that of the 
wild-type gene (Vogelstein and Kinzler, 2004). Mutations which can result in 
the activation of oncogenes include chromosomal translocation, gene 
amplifications or DNA point mutations (Vogelstein and Kinzler, 2004). An 
example of an oncogene is the phosphatidylinositol 3-kinase (PI3K) catalytic 
subunit, PIK3CA, which will be disscused in detail later on in this introduction. 
Briefly, PI3Ks activity leads to an increase in cellular growth, inhibition of 
apoptosis and increase in cell survival. In several human cancers such as 
colon, breast and lung, the PIK3CA gene has been found to be either 
amplified, deleted, or to harbour a somatic missense mutation that increases 
the activity of PI3K, leading to enhanced cellular proliferation (Karakas et al., 
2006).  
Tumour-suppressor genes: The proteins encoded by tumour-suppressor 
genes have been shown to play roles in processes such as inhibition of cell 
cycle, apoptosis and senescence. Mutations in tumour-suppressor genes 
reduce the activity of the protein encoded by the gene. Therefore, cells which 
express one wild type allele and one mutated allele are generally still able to 
prevent the development of cancer. Inactivation of tumour-suppressor genes 
usually results from either mutations which lead to the generation of a 
truncated protein, deletions, insertions or epigenetic silencing (Vogelstein and 
Kinzler, 2004).  
p53 is the best studied example of a tumour suppressor and has been shown 
to play a role in several cellular processes such as  inhibition of proliferation, 
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induction of cell cycle arrest, apoptosis and senescence. TP53, the gene 
which encodes p53, has been found to be mutated in most human tumours. 
Most TP53 germline mutations are missense mutations in the DNA binding 
domain of p53. Splicing mutations also occur frequently in germline, while 
germline deletion mutation in the TP53 gene are rare (Royds and Iacopetta, 
2006).  
Stability genes: Stability genes (also known as caretakers), when mutated, 
increase the likelihood of the development of cancer by a different 
mechanism to oncogenes and tumour suppressers. In healthy, non-
cancerous, cells these genes play a role in the repair of subtle mistakes that 
occur during DNA synthesis and replication, some of which may have been 
induced through exposure to mutagens. Members of this class include the 
mismatch repair (MMR), base-excision repair (BER) and nucleotide-excision 
repair (NER) genes. Processes such as mitotic recombination and 
chromosomal segregation are controlled by other stability genes such as 
BRCA1, BLM and ATM (Vogelstein and Kinzler, 2004). The main role of 
stability genes is to keep genetic alteration to a minimum; therefore when 
these genes become mutated and/or inactivated, mutations accumulate at an 
elevated rate in replicating DNA (Friedberg, 2003). Therefore, inactivation of 
stability genes leads to an increase in genetic alterations in all replicating 
genes; however only mutations that confer a cellular growth advantage 
contribute to the tumourigenesis process. As with tumour suppressor genes, 
both the maternal and the paternal alleles of stability genes must harbour 
inactivation mutations in order to generate a physiological effect.  
Mutations in all three classes can occur both in the germline and in single 
cells. Mutations in the germline cause a hereditary predisposition to cancer, 
while mutations in somatic cells lead to the development of sporadic tumours 
(Vogelstein and Kinzler, 2004). Individuals with a hereditary predisposition 
are more likely to develop multiple tumours at a relatively younger age 
compared with individuals who do not have an hereditary predisposition and 
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therefore must acquire all their cancer-gene mutations somatically, which 
statistically takes longer (Knudson, 2002).  
Epigenetics: Epigenetic changes refer to changes in expression levels of 
genes that occur via a mechanism independent of DNA encoding, by 
alteration to the structure of the chromatin, the histone-DNA complex. A more 
condensed chromatin structure, termed heterochromatin, restricts access of 
transcriptional factors, while a relatively open chromatin structure, termed 
euchromatin, enables relatively easy access of transcription factors to the 
DNA. Changes in chromatin structure result from post-translational 
modifications that occur on histone proteins and from DNA methylation 
(Quina et al., 2006). 
The histone proteins are spun around the DNA and are post-translationally 
modified, mainly by methylation, acetylation and ubiquitylation (Strahl and 
Allis, 2000). The term “histone code” is often used in reference to these 
histone modifications, and it is “read” by proteins which play a role in 
chromatin remodelling and transcriptional regulation. Hence, these  post-
translational modifcations have a large impact on gene transcription 
(Jenuwein and Allis, 2001). Histone acetylation is the most extensively 
studied chromatin modification and is thought to generate a more open and 
transcriptionally active chromatin structure, as opposed to histone de-
acetylation which condenses the chromatin, leading to a decrease in 
transcription. Histone acetyltransferases (HATs) covalently add an acetyl 
group to histones, while histone deacetylases (HDACs) catalyse the removal 
of acetyl groups from histone proteins; though the total level of histone 
acetylation is affected by the activity of both these enzymes (Struhl, 1998). 
DNA methyltransferases catalyse the covalent addition of a methyl group to 
the DNA on a cytosine base 5’ to a guanine base, in a structure called a CpG 
dinucleotide. CpG are found in clusters in the DNA, which are termed CpG 
islands. CpG islands are generally found near or within promoters of genes. 
DNA methylation on CpG is highly regulated and is an important epigenetic 
mechanism which enables the silencing and imprinting of genes and as a 
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rule, methylation of the human DNA occurs on non-coding DNA (Bird, 2002). 
A well studied example of genomic imprinting and silencing is the methylation 
of CpG islands that are located on one copy of the female X chromosomes 
leading to the imprinting of the methylated X-chromosome (Herman and 
Baylin, 2003). Methylation induces gene silencing by both sterically 
preventing the binding of the basal transcription machinery to the DNA, and 
by recruiting methyl-binding domain proteins (MBDs), which repress DNA 
transcription also recruit other transcriptional repressors (Quina et al., 2006). 
Epigenetic alterations have been implicated in tumourigenesis process. The 
genome of cancer cells has been shown to be DNA hypomethylated in 
comparison with non cancerous cells and, some gene-promoters have also 
been found to be hypermethylated leading to the silencing of expression of 
genes such as stability genes and tumour suppressors  (Feinberg and 
Vogelstein, 1983; Jones and Baylin, 2002). 
In summary, mutation in oncogenes, tumour suppressor genes and stability 
genes contribute to the initiation of cancer; however mutations must occur in 
a number of genes and not just in a single gene for cancer to occur 
(Vogelstein and Kinzler, 1993). Epigenetic changes may give rise to 
alterations in the expression levels of these three types of genes, which may 
increase the probability of the development of cancer. 
  
Research conducted in this thesis focuses on breast cancer. 
1.2 Breast cancer: overview and treatment  
Breast cancer is now the world’s most prevalent cancer and this rise in  
incidences has been attributed to changes in lifestyle (Parkin et al., 2005). 
The mammary gland develops from the skin epithelium and at 30 weeks from 
gestation the expression of Estrogen receptor (ER) alpha (ERα) gene is 
evident in the mammary epithelium and the expression levels ERα were 
found to rapidly increase after birth (Keeling et al., 2000). The majority of the 
mammary gland development process occurs at puberty in response to 
elevated levels of estrogen. Following puberty, the mammary gland is 
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subjected to cyclic proliferative activity, which occurs till menopause (Ali and 
Coombes, 2002). In addition to the ERα signalling pathway, which plays a 
critical role in the development of the mammary gland, other signalling 
pathways have also been shown to partake in this process and affect the 
development of the breast (Lewis et al., 1999). However, most therapies 
designed to treat breast cancer aim to block the activity of ERα because the 
ERα signalling pathway is involved in the regulation of processes such as cell 
proliferation (Levin, 2003). 
Only some (approximately 20%) of the cells in the mammary epithelium, 
express the ERα and these cells were shown to not proliferate in response to 
estrogen, while the ERα negative cells surrounding them were found to divide 
in response to estrogen. However, ERα expressing cells, derived from ERα-
positive breast tumour cells, were shown to divide and replicate in response 
to ERα (Clarke et al., 1997). In addition, over-expression of ERα in normal 
breast tissue has been suggested to increase the risk of developing breast 
cancer (Khan et al., 1998). Overall, this suggests that the presence of ERα 
may serve to indicate the probability of developing breast cancer and may 
also be indicative of sensitivity to therapy which targets the ERα signalling 
pathway (endocrine therapy). Pre-menopausal women with ERα -positive 
tumours either undergo surgery (oophorectomy) or receive endocrine 
therapy, which aims to either reduce the levels of estrogen in the blood or to 
block the ERα (Buchanan et al., 1986). Post-menopausal women with ERα -
positive breast cancer usually receive aromatase inhibitors, which block the 
production of estrogen (Ali and Coombes, 2002). 
Selective estrogen receptor modulators (SERMs) are ligands, which are used 
to lower ERα activity (Varshochi et al., 2005). SERMs include drugs such as 
ICI 182, 780, raloxifene and tamoxifen. Tamoxifen is the most commonly 
used SERM and in used for treatment of all stages of ERα -positive breast 
cancer (Varshochi et al., 2005). Tamoxifen has both agonistic and 
antagonistic functions, in the breast tamoxifen acts as an antagonist of 
estrogen while in the endometriumn, tamoxifen acts as an agonist of 
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estrogen. Although tamoxifen is frequently used, this therapy is not always 
highly effective and this because most breast cancer patients who initially 
benefited from the use of tamoxifen, ultimately gain resistance (Johnston et 
al., 1995). As mentioned above, therapeutic agents that prevent estrogen 
synthesis by inhibiting aromatase are also used for treatment of ERα positive 
breast cancer patients and can be used once resistance to tamoxifen has 
developed. Aromatase inhibitors include molecules such as exemestane and 
anastrazole and letrozole (Ali and Coombes, 2002). However, once a patient 
relapses on these therapies, other approaches need to be applied. 
Patients with ERα -positive tumours who became resistant to endocrine 
therapy and patients with ERα -negative tumours, which cannot benefit from 
endocrine therapy, are treated with inhibitors of growth factor activity. Well 
defined targets for breast cancer treatment are EGFR (epidermal growth 
factor receptor) and ERBB2/HER2/neu (a member of the EGFR family), 
which high levels of activity were found to associate with a bad disease 
prognosis (Spigel and Burstein, 2002). Several strategies have been 
deployed to target these growth factors signal transduction pathways, such 
as molecules that inhibit tyrosine kinase and monoclonal antibodies that 
target EGFR and HER2 (Nahta et al., 2003). The most known example is 
trastuzumab, a monoclonal antibody which targets the HER2 receptor and 
was shown to have clinical activity both as a single agent and in combination 
with chemotherapy in patients with tumours that over-express HER2 (Smith 
and Chua, 2006).  
 
Adjuvant chemotherapy is mostly used for treatment of younger women with 
moderate to high risk breast cancer. Chemotherapy usually involves 
treatment with a combination of three different drugs such as 
cyclophosphamide, methotrexate and fluorouracil (CMF). CMF is often 
combined with anthracyclines (inhibitors of DNA and RNA synthesis), such as 
doxorubicin or epirubicin, as this was shown to further increase survival. For 
patients with node positive cancer (when cancer cells from the tumour in the 
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breast can be found in the lymph nodes) it has been demonstrated that 
adding taxanes (paclitaxel and docetaxel) to anthracyclines further improves 
disease free survival in these women (Smith and Chua, 2006). Moreover, 
treatment with trastuzumab in combination with one the taxanes has been 
shown ti increase survival in patients with metastatic breast cancer (Luck and 
Roche, 2002). 
1.2.1 Taxanes in cancer treatment 
Taxanes, paclitaxel and docetaxel, are a type of chemotherapy used for 
treatment of cancers, such as breast and non-small cell lung cancer, 
(Gelmon, 1994). Paclitaxel, a complex diterpene, originates from the bark of 
the Pacific yew tree, Taxus brevifolia (Wani et al., 1971). Researchers 
examined the bark of the Pacific yew tree following positive results obtained 
from a previous screening process aimed at finding new drugs for treatment 
of cancer  (Altmann and Gertsch, 2007). In 1992 paclitaxel was launched for 
treatment of stage 4 ovarian cancer and is now also used for treatment of 
other cancers, as mentioned above. Since the production of paclitaxel proved 
to be an expensive process, mainly due to the lack of availability of barks of 
Pacific yew trees, docetaxel, a semi-synthetic paclitaxel analogue, was 
developed using the bark of the European yew tree and is now used almost 
interchangeably with paclitaxel. 
The anti-proliferative activity of paclitaxel has been attributed to the ability of 
paclitaxel to bind to polymerised αβ-tubulin, thereby stabilising cellular 
microtubules and causing mitotic arrest (Schiff et al., 1979). Paclitaxel was 
principally shown to inhibit the formation of mitotic spindles, which prevents 
chromosomes from segregating (Long and Fairchild, 1994). In addition, at 
therapeutic concentrations paclitaxel was shown to induce two forms of cell 
cycle arrest and each one was shown to lead to the induction of a different 
apoptotic pathway. Arrest at M phase was shown to induce cell death by a 
p53 independent pathway, while arrest at G1 was shown to induce apoptosis 
via a p53 dependent pathway (Woods et al., 1995). Nonetheless, paclitaxel 
was also shown to affect the activity of cellular signalling pathways.  
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Paclitaxel has been shown to activate the Jun N-terminal Kinase (JNK)/ 
Stress Activated Protein Kinase (SAPK) signalling pathway in cancer cells by 
activating either the apoptosis signal-regulating kinase (ASK1) or the Ras 
GTP binding protein (Wang et al., 1998). JNK may induce apoptosis by 
phosphorylation of the B-cell lymphoma 2 (Bcl-2) protein (Yamamoto et al., 
1999). Paclitaxel also activates p38 MAPK, another member of the SAPK 
family, and inhibition of this kinase was surprisingly found to protect cells from 
paclitaxel induced cell death (Seidman et al., 2001). Paclitaxel treatment has 
been shown to activate the mitogen-activated protein kinases (MAPK) 
extracellular signal-regulated kinase 1/2 (ERK1/2) and induce apoptosis 
(Bacus et al., 2001; Seidman et al., 2001). However, another report 
(MacKeigan et al., 2000),  showed enhanced apoptosis in cells in response to 
paclitaxel treatment following inhibition of  ERK1/2. Moreover, elevated levels 
of activation of the phosphatidylinositol 3-kinase (PI3K)/Akt (PKB) signalling 
pathway has been shown to protect cells from paclitaxel induced cell death 
(Page et al., 2000; VanderWeele et al., 2004). 
Recently, it has been demonstrated that increase in oxidative stress is one of 
the first events that occurs following paclitaxel treatment and is essential for 
the induction of cell death (Alexandre et al., 2006). This may be due to the 
suggested role reactive oxygen species (ROS) play in tumourigenesis 
process (Szatrowski and Nathan, 1991). Furthermore, while paclitaxel 
treatment was found to increase the levels of H2O2 in the cells; it  was shown 
that agents which decrease the levels of free radicals diminish paclitaxel 
induced cell cycle arrest and apoptosis (Ramanathan et al., 2005). It has 
been shown that enhanced ROS production leads to an increase in the 
activity of JNK and p38 MAPK and that oncogenically transformed cells, 
which are more sensitive to anticancer agents, have higher levels of ROS 
and JNK activity (Benhar et al., 2001). Taken together, this indicates that 
control of ROS levels and regulation MAPK signalling may affect cellular 
response and sensitivity to anticancer drugs, such as taxanes.  
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Taxanes have proven to be important chemotherapeutic agents in treatment 
of breast cancer. Taxanes do not target the ERα signalling pathway and 
therefore can be used for treatment of patients with ERα negative breast 
cancer tumours and for the treatment of patients which are resistant to 
endocrine therapy. Furthermore, it has been observed that paclitaxel 
treatment is more effective for treatment of patients with ERα negative breast 
tumours than for treatment of those with ERα positive tumours (Razandi et 
al., 2000; Stearns et al., 2003). A recent study has shown that expression of 
ERα in the ERα negative cell line, BCap37 reduces the ability of paclitaxel to 
induce apoptosis, but does not prevent paclitaxel induced mitotic arrest (Sui 
et al., 2007). The same study also showed that the addition of the anti-
estrogen ICI 182,780, overturned the resistance of ERα -positive BCap37 
cells to paclitaxel and increased the sensitivity of the MCF-7 and T47D cell 
lines to paclitaxel. Overall, these observations suggest a link between 
resistance to cancer therapy and expression of ERα, as it was shown that 
and imply that ERα paclitaxel can be used to which further confirms the 
correlation between ERα and drug resistance in ERα positive tumour cells. 
These findings suggest that ERα expression and activity facilitate resistance 
to paclitaxel-induced apoptosis in breast cancer cells.  
 
In summary, while ERα signalling is important for the development of healthy 
breast tissue it also plays a significant role in breast cancer tumourigenesis. 
To date, the most successful way to treat breast cancer has been by either 
blocking ERα activity or by reducing estrogen concentrations. However, these 
treatments are not beneficial against ERα negative tumours. Furthermore, 
most patients with ERα positive breast cancer tumours eventually develop 
resistance to endocrine therapy. Chemotherapy is mostly used for treatment 
of younger women with moderate to high risk breast cancer, and the most 
commonly used regimens are combination therapies with drugs such as CMF 
together with anthracyclines and/or taxanes. Taxanes, paclitaxel and 
docetaxel, stabilise cellular microtubule and induce a number of cellular 
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signalling events. The exact mechanism taxanes exploit to induce cell death 
has not been fully elucidated; but has been linked to the increase observed in 
the level of ROS following treatment with paclitaxel. Elevated levels of ROS 
have been shown to stimulate the activity of MAPK signalling pathways such 
as JNK. The efficacy of treatment of breast cancer patients with paclitaxel 
has also been shown to be influenced by the activity of the PI3K/Akt 
signalling pathways, as elevated levels of PI3K/Akt activation were shown to 
protect cells from the apoptotic effect of paclitaxel.  
 
The PI3K signalling pathway regulates cellular processes, such as cell cycle 
entry, cell survival, proliferation, growth, metabolism and cell migration. 
Elevated levels of PI3K/Akt activity have been shown to contribute to the 
tumourigenesis process and to the protect cells from cytotoxic effects of 
chemotherapy, with agents such as paclitaxel (Page et al., 2000; 
VanderWeele et al., 2004). Hence, understanding the role and regulation of 
this signal transduction pathway in healthy and cancerous cells may 
significantly contribute to cancer therapy development  
1.3 The phosphatidylinositol 3-kinase (PI3K)/ Akt (PKB) 
signalling pathway 
1.3.1 Overview of PI3K pathway and family members 
The PI3Ks constitute a large family of lipid and serine/threonine kinases 
which include a number of phosphatidylinositol kinases, such as ataxia 
telangiectasia and Rad3 related (ATR) kinase and the related DNA-
dependent protein, ataxia telangiectasia mutated (ATM) kinase (Fruman et 
al., 1998; Hennessy et al., 2005). This family of proteins initiate and take part 
in the signal transduction.  
The PI3K family of proteins are activated by a receptor that could be a G-
protein coupled receptor or a trans-membrane tyrosine kinase receptor. The 
receptors bind to their ligands (growth factor or hormone molecule) on the 
outer-side of the membrane, and then activate the signal transduction 
through the PI3K family of proteins. This process translates a 
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chemical/hormonal extracellular signal into an intra-cellular phosphorylation 
cascade, initiated by the PI3K proteins.  
The PI3K family of proteins have been divided into three classes (I II and III) 
(Fruman et al., 1998; Vanhaesebroeck et al., 1997). PI3K class I are defined 
by a heterodimeric form, and consist of an associated regulatory subunit and 
a catalytic subunit. Class I has been further divided into sub-classes; class 1A 
PI3K enzymes are heterodimers of one of the p110α, p110β or p110δ 
catalytic subunits and one of the p50-55/p85 regulatory subunits. The Class 
IB PI3K enzymes are heterodimers of the p110γ catalytic subunit bound to 
either p101 or p84 regulatory subunits. Class 1A and class 1B PI3Ks are 
initially activated by membrane bound tyrosine kinases and G-protein-
coupled receptors, respectively. Following their activation, class I PI3Ks 
phosphorylate phosphatidylinositol phospholipid (PtIns) and PtdIns(4,5)P2 
giving rise to PtdIns(3,4,5)P3. PtdIns(3,4,5)P3, are also membrane bound, 
serve as an anchor for a subgroup of pleckstrin-homology (PH) domain 
proteins (Hawkins et al., 2006; Wymann and Marone, 2005).  
Class II of PI3Ks are large proteins (170–210 kDa) that consist the 
phosphoinositide kinases conserved “PIK domain” and a catalytic kinase 
domain which is only 45–50% similar to class I of PI3Ks (Fruman et al., 
1998). Class II PI3Ks seem to preferentially phosphorylate PtdIns and 
PtdIns(4)P In vitro (Fruman et al., 1998). Three class II isoforms have been 
identified in mammals; PI3K-C2α isoform and the less ubiquitously expressed 
isoforms, PI3K-C2β, and liver-specific PI3K-C2γb (Hennessy et al., 2005).  
Class III of PI3Ks are heterodimers that are made of a catalytic (Vps34, 100 
kDa) subunit and an adaptor (p150) subunit. Class III PI3Ks phosphorylate 
only PtdIns to give rise to PtdIns(3)P. Class III PI3Ks are associated with 
endocytosis, receptor internalisation, vesicle trafficking, and have been 
implicated in regulation of autophagy, a process which enables survival under 
stress conditions (Lemmon, 2003; Wymann and Marone, 2005).  
 
 30
Of all three classes of PI3Ks, class I is the best characterised. PI3K class I 
are activated by a large number of cell surface receptors, which include the 
majority of growth factors, many inflammatory stimuli, hormones, 
neurotransmitters and antigens (Hawkins et al., 2006). Furthermore, 
mutations in the PI3Kα, a PI3K class IA member, whose catalytic domain is 
encoded by PIK3CA, has been found to be associated with several tumour 
types and have been suggested to have oncogenic potential (Samuels and 
Ericson, 2006) 
1.3.2 PI3K class I: regulation and role 
PI3K class IA are activated by growth factor receptor following binding to their 
ligands. The receptors are tyrosine kinase receptors may autophosphorylate 
or phosphorylate their substrates. The phosphorylated tyrosines on the 
receptors intracellular domains or on their substrate molecules are 
recognised by the SH2 domains (Rous-sarcoma-oncogene homology-2 
domain), and the p85 subunit directly interact with the activated receptor 
tyrosine kinase. Consequently, this interaction relieves an inhibitory effect on 
the p110 subunit which can now catalyse the phosphorylation of its 
substrates, the PtdIns, at their 3’ position (Samuels and Velculescu, 2004; 
Cantley, 2002). The regulatory p85 subunit interacts with the  transmembrane 
tyrosine kinase-linked receptors, but tyrosine kinase receptors are only part of 
its activators, as it also binds to and incorporates signals from a range of 
intracellular proteins such as Rac, Rho, hormonal receptors, protein kinase C 
(PKC), mutated Ras and Src (Hennessy et al., 2005). It has been suggested 
that the main role of class IA PI3Ks is to direct energy into cell growth and 
proliferation (Wymann and Marone, 2005). The p110 and p85 are the only 
class IA PI3Ks isoforms associated with tumours (Samuels and Velculescu, 
2004). p110 and p85 have isoform specific processes, but share some 
overlap in their function as reviewed by Henessy et al (Hennessy et al., 
2005). 
PI3Kγ, the only class IB member (locus PIK3cγ), heterodimerises with either  
a p101 or p87 regulatory subunits (Wymann and Marone, 2005). The PI3Kγ 
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heterodimer is activated, at the membrane, by the guanine nucleotide-binding 
proteins (G proteins) on a G-protein coupled receptor. PI3Kγ is highly 
expressed in lymphocytes, and is  involved in controls processes of 
inflammation and allergy (Deane and Fruman, 2004; Wymann et al., 2003). 
PI3Kγ is also associated with the control of vascular tone and heart 
contractility (Crackower et al., 2002; Oudit et al., 2004; Patrucco et al., 2004; 
Vecchione et al., 2005). 
1.3.3 Downstream activities of class I PI3K 
The product of active PI3Ks are the PtdIns(3,4,5)P3 (PIP3) generated by 
phosphorylations of phosphatidylinositol-4,5-bisphosphate PtdIns(4,5)P2 
(Hawkins et al., 2006; Wymann and Marone, 2005). PIP3 are secondary 
messengers, and recruit downstream target substrates for phosphorylation by 
binding to pleckstrin-homology (PH), Phox (PX) and other lipid-binding 
domains in these substrates. Genetic screens in model organisms have 
identified the serine/threonine kinase Akt (Protein Kinase B), a member of the 
AGC family of serine/threonine kinases, as the primary downstream mediator 
of the effects of PI3K. Another target protein activated by PIP3 is the 
phosphoinositide-dependent kinase 1 (PDK 1) molecule (Vivanco and 
Sawyers, 2002). 
The PI3K signalling is stopped by segregation of the PI(3,4,5)P3. There are 
two known phosphatises that remove the phosphate group of PI(3,4,5)P3. the 
phosphatase and tensin homologue (PTEN) phosphatase and the Src-
homology 2 (SH2)-containing phosphatases (SHIP1 and SHIP2)  (Cantley, 
2002).  
SHIP1 and SHIP2 dephosphorylate the 5’ position of the inositol ring leading 
to the production of PI(3,4)P2, while PTEN dephosphorylates the 3’ position 
of PI(3,4,5)P3 to produce PI(4,5)P2. deficiency in SHIP2 leads to insulin 
hypersensitivity, suggesting that this phosphatase is a crucial regulator of the 
PI3K signalling pathway downstream of insulin (Clement et al., 2001).  
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PTEN deficiency and mutations are associated with advanced malignancies 
in human, suggesting that uncontrolled, constitutively active PI3K pathway is 
highly tumourigenic (Maehama and Dixon, 1999). 
 
The main downstream target of PI3K pathway is the Akt (PKB) protein. Akt 
phosphorylates several downstream target proteins and is involved in 
processes of cell growth, cell cycle and survival. 
1.3.4 Akt activation 
Akt (PKB) is an important signalling intermediate for controlling metabolic 
activity, growth and proliferation. There are 3 AKT isoforms which share 
homology with the viral v-Akt and with the AGC kinase family. The three Akt 
isoforms are derived from distinct genes (Akt1/PKBα, Akt2/PKBβ and 
Akt3/PKBγ) (Manning and Cantley, 2007).  
Cytoplasmic Akt is recruited to the plasma membrane by the PIP3 molecules 
which bind the N-terminal PH domain on Akt. The PIP3 interaction results in 
conformational change that exposes Akt to phosphorylation on two separate 
residues (threonine 308 and serine 473 in Akt1). Threonine 308 is 
phosphorylated by PDK1, a constitutively active kinase that is recruited by the 
PH domain as well. Serine 473, located within the hydrophobic C-terminal 
domain, is phosphorylated by PDK2 (an unknown molecule yet). All this takes 
place in a complex that is anchored to the plasma membrane by PIP3 
molecules. Phosphorylation of Akt on threonine 308 stabilises Akt’s activation 
loop, while phosphorylation of serine 473, activates Akt (refers to Akt1, only) 
(Alessi et al., 1996; Blume-Jensen and Hunter, 2001).  
Several reports have suggest that cyclic adenosine monophosphate (cAMP)-
elevating agents activate AKT in a independently of PI3K, indicating that Akt 
is a possible phosphorylation target of protein kinas A (PKA). Neither the PH 
domain of Akt, nor phosphorylation of Serine 473, is required for PKA 
induced activation of Akt However, phosphorylation of Threonine 308 is 
essential. The mechanism by which PKA activates Akt remains to be 
elucidated as well (Filippa et al., 1999; Sable et al., 1997). 
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Another site of phosphorylation that is probably meaningful to the regulation 
and activation of Akt is tyrosine 474. It is phosphorylated in response to 
insulin. This phosphorylation has been implied to be involved in the activation 
of Akt (Conus et al., 2002). Since tyrosine 474 is widely conserved in the 
AGC family, it is possible that this mechanism of regulation may be 
evolutionary conserved, however, more data is required to determine the 
importance of this phosphorylation (Conus et al., 2002).  
More proteins that regulate Akt’s activity have been suggested as alternatives 
to PI3K activation. The Carboxyl-terminal modulator protein (CTMP) was 
found to bind to Akt resulting in a reduction in phosphorylation on Threonine 
308 and Serine 473, thereby inhibiting the activity of Akt (Maira et al., 2001). 
Positive regulators of Akt have also been identified. For example; the heat 
shock protein 27 (Hsp27) that was first suggested to activate Akt (Konishi et 
al., 1997). The function of Hsp27 has been further investigated by Rane et al, 
who have demonstrated that the interaction between Hsp27 and Akt up-
regulates Akt activity and inhibits apoptosis in neutrophils (Rane et al., 2003).  
 
Akt plays an important role in increasing cell survival, cell growth and to 
inhibit apoptosis and cell cycle arrest. A schematic overview of Akt activation 
and downstream cellular targets is presented in figure 1.1. 
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Figure 1-1: PI3K pathway targets AKT in mammalian cells with clear evidence of 
involvement in promotion of survival.   
Adapted from Song et al., 2005 and Downward 2004. 
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1.3.5 Downstream targets of Akt 
The downstream targets of Akt play a role in enhancing cell survival, cellular 
metabolism, cell growth and proliferation. Some targets are directly regulated 
by Akt, while other cellular signalling pathways, such as the NF-κB, SAPK 
and p53 signalling pathways may be affected by Akt activation in a manner 
that increases pro-survival signalling.  
Akt plays a role in increasing cell survival in more than one way. The best 
established mechanism include inactivation through phosphorylation of pro-
apoptotic proteins such as BAD, a Bcl-2 homology domain 3 (BH3)-only 
protein (Datta et al., 1997; del Peso et al., 1997). Furthermore, it has been 
reported that activated Akt can phosphorylate procaspase-9, resulting in a 
decrease in the protease activity of caspase-9 activity (Cardone et al., 1998). 
Another mean by which Akt promotes cell survival is by phosphorylation of 
glycogen synthase kinase 3 (GSK3), which results in inhibition of its activity 
and an increase in storage of glucose as glycogen (Cross et al., 1995). 
Although it has been demonstrated that inhibition of GSK3 protects against 
apoptosis in many conditions, the molecular basis for this is not fully 
understood but has been linked to the role of Akt in cell metabolism (Pap and 
Cooper, 1998). 
Akt downstream effects are mostly associated with the promotion of cell 
growth. This predominantly occurs by activation of mammalian target of 
rapamycin (mTOR) complex 1 (known as either mTORC1 or mTOR-raptor 
complex) (Manning et al., 2002). mTORC1 is controlled by cell signalling that 
is stimulated by growth factors and nutrients, and it plays a central role in 
translation initiation complexes and ribosome biogenesis (Wullschleger et al., 
2006). Akt indirectly activates mTORC1 by phosphorylating and by inhibiting 
the mTORC1 negative regulator, tuberous sclerosis protein-2 (TSC2) 
(Manning et al., 2002). mTORC1 inhibitors, such as rapamycin have been 
shown to have an inhibitory effect over proliferation of cancer cells in vitro 
and in tumours in mouse models that were shown to posses oncogenic 
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activity due to increased PI3K/Akt pathway,  suggesting that mTORC1 is an 
essential downstream target of Akt (Sabatini, 2006). 
More AKT important targets are the cyclin-dependent kinase inhibitors p27Kip1 
and p21Cip1. Akt has been found to stimulate cell proliferation by blocking the 
p27Kip1 and p21Cip1 CDK inhibitory activity by phosphorylating of p27Kip1 and 
p21Cip1 (Liang et al., 2002; Zhou et al., 2001a), resulting detention of p27Kip1 
and p21Cip1 from the nucleus, therefore, leading to an attenuation in their 
ability to inhibit the cell cycle (Sekimoto et al., 2004; Zhou et al., 2001b).  
The GSK3 and TSC2 proteins are targets for Akt dependent phosphorylation. 
The phosphorylated GSK3 mediates the downstream phosphorylation of 
cyclins and transcription factors which play a role in the transition from the G1 
phase to the S phase of the cell cycle, the phosphorylation by GSK mark the 
substrate proteins for an E3 ligase that ubiquitylates  these proteins for 
proteasome degradation. Therefore, the phosphorylations of GSK3 by Akt 
inhibits its activity and stabilises cyclins and transcription factors that promote 
G1-S transition, and induce cell cycle progression and proliferation (Diehl et 
al., 1998; Wei et al., 2005; Welcker et al., 2003; Yeh et al., 2004). 
Furthermore, Akt phosphorylation of TSC2 and subsequent activation of 
mTORC1 leads to a complementary increase in translation of proteins that 
are important for cell cycle progression such as CDKs (Mamane et al., 2004).  
As mentioned above, Akt signalling pathway cross-talks with other cellular 
signal transduction pathways, resulting in an overall positive response on cell 
survival, proliferation and growth. Akt can phosphorylate kinases upstream of 
SAPK, such as Apoptosis signal-regulating kinase 1 (ASK1), a MAP kinase 
kinase kinase (MKKK), which results in the inhibition of ASK1 induced 
apoptosis (Kim et al., 2001). Akt has also been shown to phosphorylate the 
mixed lineage kinase 3 (MLK3), thereby, inactivating MLK3 and promoting of 
cell survival (Barthwal et al., 2003). 
Akt also affects the p53 pathway by regulating the main p53 controller 
protein, the mouse double minute (MDM2 or HDM2 in humans), an E3 
ubiquitin ligase that marks p53 for proteasome degradation. Akt 
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phosphorylates MDM2,  which translocates MDM2 into the nucleus, leading 
to MDM2 interaction with p53 and subsequent degradation of p53 (Mayo and 
Donner, 2001; Zhou et al., 2001b). Reduction of the amount of p53 in the cell, 
allows quicker cell proliferation. p53 is a transcription factor that 
transactivates the expression of genes that are associated in induction of 
apoptosis, such as the BH3-only proteins Puma and Noxa (Villunger et al., 
2003).  
Akt downstream phosphorylation also reduces the activity of other p53 family 
members like p73. p73 induces apoptosis by up-regulating the expression of 
similar target genes as p53 (Strano et al., 2001).  Akt phosphorylates the Yes 
Associated Protein (YAP), a transcriptional co-activator which complexes with 
p73 to induce its transcription factor activity. The phosphorylated YAP is 
exported to the cytoplasm,  therefore, inhibiting p73 activity (Basu et al., 
2003).   
Positive cross-talk between the Akt and NF-κB pathways results in the 
expression of pro-survival genes, such as Bcl-xL and caspase inhibitors 
(Barkett and Gilmore, 1999). Akt has been reported to phosphorylate cAMP 
response element binding protein (CREB) transcription factor, up-regulating 
the transcriptional activity of CREB (Du and Montminy, 1998).  
The best studied Akt downstream targets involved in transcriptional control of 
cell survival are three members of the FoxO subfamily of Forkhead 
transcription factors, FoxO1, FoxO3a, FoxO4 (previously known as FKHR, 
FKHRL1 and AFX) (Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999). 
Several downstream targets of FoxO are important in apoptosis, for instance, 
Fas ligand (Brunet et al., 1999), TRAIL (TNF-related apoptosis-inducing 
ligand) (Modur et al., 2002), TRADD (TNF receptor type 1 associated death 
domain) and Bim (Bcl-2 interacting mediator of cell death) (Burgering and 
Medema, 2003). Other targets of FoxO have been implicated in inhibiting cell 
cycle progression, such as p27Kip1 and cyclin G2 (Martinez-Gac et al., 2004; 
Medema et al., 2000; Nakamura et al., 2000).  
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The activity of the PI3K/Akt pathway increases following growth factor 
stimulation. However, uncontrolled activation of the PI3K/Akt pathway leads 
to an increase in cell growth and survival, which ultimately, results in a 
selective growth advantage, metastatic competence and occasionally therapy 
resistance. Furthermore, deregulation of the PI3K/Akt pathway is a frequent 
cause in cancer and in neoplastic transformation.  
1.3.6 Deregulation of PI3K/Akt pathway in cancer 
Angiogenesis: The vascular endothelial growth factor (VEGF) activates the 
Pi3/Akt pathway in endothelial cells (Olsson et al., 2006). In turn, the Akt   
phosphorylates and activates endothelial nitric oxide (NO) synthase (eNOS) 
(Dimmeler et al., 1999; Fulton et al., 1999) and the NO that is released, 
induces angiogenesis (generation of new blood vessels) (Morbidelli et al., 
2003). Moreover, the active Akt pathway, increases the levels of the 
transcription factors hypoxia inducible factor α (HIF1α and HIF2α) which 
induce the expression and secretion of VEGF and other angiogenic factors, 
thus, inducing angiogenesis both in an autocrine and paracrine fashion 
(Gordan and Simon, 2007). 
Another manner, in which deregulation of the PI3K/Akt pathway may occur 
and contribute to tumourigenesis, is via mutations in the p110α catalytic 
domain of PI3K. Functional analyses of mutations in the gene coding for 
PIK3CA (the gene which encodes the p110α subunit) revealed that mutations 
that increase p110α enzymatic activity, can lead to constant Akt activation 
and result in growth-factor independent cell growth and increased cell 
invasion and metastasis.  
PIK3CA mutations in human cancers are somatic, cancer-specific and 
heterozygous. Most of the mutations are missense mutations and to date, no 
truncations or nonsense mutations were detected (Samuels and Ericson, 
2006; Campbell et al., 2004; Lee et al., 2005b; Samuels and Velculescu, 
2004). The PIK3CA cancer specific mutations are recurrent in patient 
samples, suggesting that these mutations provide a proliferative advantage. 
PIK3CA mutations map to three separate sites in p110α. Mutations that occur 
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any of the three sites, result in increased enzymatic activity (Kang et al., 
2005; Samuels and Velculescu, 2004).  
Mutations in p110α and other mechanisms that activate PI3K signalling seem 
to be mutually exclusive (Bader et al., 2005). For example, mutations in the 
p85α subunit and chromosomal translocations are generally rare, but have 
been detected in some human cancers. A human lymphoma cell line was 
shown to express a C-terminal truncated form of p85 (Jucker et al., 2002). 
Mutant p85 subunits render the PI3K/Akt signalling pathway constitutively 
active (Borlado et al., 2000; Jimenez et al., 1998; Philp et al., 2001). 
Nonetheless, in breast cancer, the most common genetic alterations are 
somatic missense mutations in the PIK3CA gene and these mutations are 
mostly found in HER2-amplified and ERα -positive breast cancers (Campbell 
et al., 2004).  
Other targets of genetic aberrations, in this pathway, are PTEN and Akt. Akt2 
is frequently amplified, at the genome level, in pancreatic, breast and ovarian 
cancers and Akt3 is frequently over-expressed, in hormone-insensitive breast 
and prostate tumours (Testa and Bellacosa, 2001). These observations are in 
agreement with findings that indicate that the different isoforms of Akt have 
specific tumourigenic functions, Akt2 in motility and invasion and Akt3 in 
hormone independence (Arboleda et al., 2003). 
The PI3K/Akt pathway may be desregulated by aberrations in molecules and 
signalling pathways that are related to the PI3K/Akt, but are not part of it, for 
example, in pancreatic cancers which frequently harbour Ras mutations that 
activate PI3K, or mutations in EGFR (epidermal growth factor receptor) which 
mediates an oncogenic effect through the PI3K/Akt pathway and increases 
PI3K activity. (Almoguera et al., 1988; Nelson et al., 1996; Rodriguez-Viciana 
et al., 1997; Yanez et al., 1987). 
However, unlike tumour-suppressors related cancers, such as p53, p73 and 
Rb, which become oncogenic due to loss of function, signal transduction 
pathways, such as the PI3K pathway are highly active in cancer, making it a 
convenient target for therapeutic intervention, because inhibition of its 
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activation is easier than replacing a loss of tumour suppressor function. In 
addition, mutated kinases are ideal therapeutic targets, in particular when 
mutated forms of these proteins are solely expressed in cancerous cells 
(Bader et al., 2005; Hennessy et al., 2005). 
Taken together, these observations suggest that the PI3K/Akt signalling 
pathway may serve as an ideal target for the development of novel cancer 
therapeutics.  
1.3.7 Targeting the PI3K/Akt pathway in cancer drug development 
To date, no drugs developed, which exclusively target the PI3K/Akt pathway, 
have entered cancer clinical trials. Nonetheless, some drugs in clinical use or 
preclinical evaluation which were developed for other purposes but have 
been shown to target the PI3K/Akt signalling pathway in either a direct or 
indirect manner.  
These compounds include mTOR inhibitors (Sabatini, 2006), which appear to 
exclusively target the PI3K/Akt pathway and the small protein kinase inhibitor 
imatinib, which is used to treat chronic myeloid leukaemia (CML) patients by 
inhibiting the effects of BCR-ABL which constitutively activate the PI3K 
pathway (Burchert et al., 2005). However, imatinib (Glivec) has only partial 
success in treatment and it has been suggested that imatinib also activates 
mTOR, and therefore, a combination of mTOR inhibitors might improve 
treatment of CML patients.  
New therapies have been suggested to work in combination with the tyrosine 
kinase inhibitor imatinib, such as the use of specific monoclonal antibodies 
which target the receptor on the outer membrane of the cell (Adachi et al., 
2004). 
The P110α mutations are tumour-specific and cause gain-of-function, 
suggesting that they contribute to the malignant phenotype of the cell. Small 
molecule inhibitors that target the mutant kinase could be developed into a 
novel anti-cancer drug. These drugs may be found to demonstrate sufficient 
anti-tumour activity alone, or may require combination approaches with other 
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signal transduction inhibitors, chemotherapy and radiation therapy to reach 
optimal efficacy for treatment of patients  
 
As mentioned above, one of the best studied downstream targets of Akt are 
FoxO transcription factors. These transcription factors have been implicated 
in cellular events such as apoptosis, cell cycle arrest, oxidative stress 
resistance, differentiation and longevity. Hence, these proteins may play a 
significant role in determining sensitivity to chemotherapeutic agents, such as 
paclitaxel. FoxOs are members of the large family of transcription factors 
named Forkhead transcription factors.  
1.4 Forkhead transcription factors 
1.4.1 Overview: Forkhead transcription factors 
All members of the forkhead family of transcription factors posses a highly 
conserved DNA-binding domain dubbed the ‘Forkhead domain’. The family 
gained their name from the initial observation that in Drosophila, mutations in 
the first gene identified as a member of this family, result in homoeotic 
transformation of certain gut structures, which leads to the substitution of the 
fore- and hind- gut by ectopic protruding head structures (Weigel et al., 
1989). The 110 amino acid DNA binding domain is highly conserved in over 
100 forkhead genes identified in species ranging from yeast to human. The 
number of forkhead genes varies from species to species, there are 4 known 
members in Saccharomyces cerevisiae and over 45 forkhead family 
members in mouse and human (Wijchers et al., 2006). Several years ago, a 
unified nomenclature was introduced, which based on phylogenetic analysis 
of the forkhead domains led to the assignment of most of these genes into 19 
subclasses named FoxA to FoxS (Kaestner et al., 2000). Breifly, The word 
Fox indicates the presence of a forkhead box and the following letter 
represents the subfamily and the number represents the member of the 
subfamily. Upper case or lower case letters represent the species which the 
gene is derived from; uppercase letters for human (e.g. FOXO1), only a 
 42
capital F for mouse (e.g. Foxo1) and the first and subclass letters appear in 
uppercase for all other chordate species (e.g. FoxO1) (Kaestner et al., 2000; 
Wotton and Shimeld, 2006). 
1.4.1.1 Forkhead chromosomal distribution, structure and regulation 
Forkhead genes are distributed throughout the genomes and only the human 
suclasses FOXC, FOXF, FOXL1 and FOXQ1 were found to form clusters that 
map to two areas of the human genome; the genes FOXL1, FOXC1, FOXF2 
are mapped to chromosome 16 and the genes FOXC2, FOXF1 and FOXQ1 
are mapped to chromosome 6 (Mazet et al., 2006). Studies suggest, on the 
basis of the observation that amphioxus orthologues of these Forkhead 
genes are found clustered in one region of the amphioxus genome, that block 
duplication of this region occurred in vertebrates during the evolutionary 
development of chromosomes 6 and 16 loci (Mazet et al., 2006).  
Based on its similarity to the shape of butterflies, the term “winged helix” is 
often used to describe the 3D structure of a forkhead DNA binding domain 
(Clark et al., 1993). The forkhead domain is comprised of α-helices, β-sheets 
and loops. The number of α-helices  β-sheets and loops varies (Liu et al., 
2002; Stroud et al., 2006; van Dongen et al., 2000; Weigelt et al., 2001). 
 Most forkhead transcription factors, except from some members of the FoxP 
subfamily, bind target DNA sequences as monomers (Li et al., 2004). The 
initial binding of Forkhead to the DNA occurs through the third α-helix, known 
as the recognition helix and it binds the target DNA in the major groove. The 
binding of the second loop leads to the interaction between the forkhead 
domain and the minor groove of the DNA. This affects the stability and 
specificity of the binding  (Clark et al., 1993; Marsden et al., 1998). Forkhead 
factors bind to a core DNA consensus binding sequence, A/C-A-A-C/T-A, 
which is essential but not sufficient to enable this interaction (Pierrou et al., 
1994). The forkhead domain of most family members also contains nuclear 
localisation signals (NLSs). Aside from these similarities, within the 
conserved forkhead domain, forkhead proteins largely differ in other regions 
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and only members of the same subclass posses additional conserved 
domains or motifs (Barthel et al., 2005). 
Forkhead transcription factors can act as both positive or negative 
transcriptional regulators, depending on the type of complex they associated 
with; whether an activator or a repressor complex (Wijchers et al., 2006). 
Forkhead activity is predominantly regulated by post-translational 
modifications, whilst phosphorylation of FoxO proteins by Akt following 
stimulation with insulin and growth factors is the most studied post-
translational modification. Phosphorylation of FoxOs by Akt results in nuclear 
exclusion and localisation of FoxO proteins in the cytosol, which inhibits the 
activity of  FoxO (Brunet et al., 1999; Rena et al., 1999). FoxA2 is also 
regulated by Akt in response to insulin, this also results in cytosolic 
localisation of FoxA2 (Wolfrum et al., 2003).  
Forkhead factors are involved in diverse biological process, such as cell cycle 
regulation (FoxM1, FoxO, FoxA1, FoxG1, FoxK1), survival (FoxO), 
metabolism (FoxA, FoxC, FoxO), immunoregulation (FoxP3, FoxJI, FoxN1, 
FoxO, FoxD2, FoxP1) and embryonic development (all except FoxB, FoxG, 
FoxK, FoxO, FoxQ, FoxS). Therefore, deregulation of the expression of FOX 
gene through mechanisms such as gene amplification, chromosomal 
translocation, or impaired transcriptional regulation can lead to the 
development of physiological disorders and cancer (Lehmann et al., 2003). 
1.5 FoxO transcription factors 
1.5.1  Overview: FoxO transcription factors 
Mammalian FoxO transcription factors have conserved Akt phosphorylation 
sites located either near or with their forkhead DNA binding domains. These 
family of proteins are the mammalian orthologues of the soil-dwelling 
nematode worm, Caenorhabditis elegans DAF-16 (abnormal DAuer 
Formation-16 (Lin et al., 1997; Ogg et al., 1997). Research conducted in 
C.elegans has proved there is a link between the insulin-like signal 
transduction pathway and longevity, which is mediated by the activity of FoxO 
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transcription factors. Mutations resulting in the inactivation DAF-2, the 
C.elegans insulin receptor and upstream regulator of DAF-16, were shown to 
increase the lifespan of C.elegans and require functional DAF-16 (Lin et al., 
1997; Ogg et al., 1997)  
 
There are 4 members in human family of FOXO factors: FOXO1, FOXO3a, 
FOXO4 and FOXO6. FOXO1, FOXO3a, and FOXO4 were first identified in 
chromosomal translocations in human tumours, suggesting they may play a 
role in the development of cancer. FOXO1 was found in childhood tumour 
alveolar rhabdomyosarcoma (Davis et al., 1994; Shapiro et al., 1993) and 
FOXO3a and FOXO4 in acute myeloid leukaemia (Parry et al., 1994; So and 
Cleary, 2003). These chromosomal translocations result in a fusion protein, 
composed of the C-terminal region of FOXO fused to the N-terminal region of 
transcription factors, such as Pax3 or Pax7 (del Peso et al., 1999). FOXO1, 
FOXO3a, and FOXO4 mRNAs are expressed in most human tissues but in 
distinct and diverse levels (Anderson et al., 1998), while  FOXO6 mRNA is 
chiefly expressed in the developing brain (Biggs et al., 2001;Jacobs et al., 
2003). 
Based on the results of genetic studies, it appears that FoxO factors have 
distinct but overlapping functions. A study conducted using FoxO1, FoxO3a 
and FoxO4 null mice (Hosaka et al., 2004) showed that FoxO4 and FoxO3a 
null mice are generally indistinguishable from wild-type mice; however, 
female FoxO3a-null mice have an age dependent infertility phenotype 
combined with abnormal ovarian follicular development. FoxO1-null mice 
were found to have the most prominent phenotype, these mice were found to 
be  embryonic lethal at day 10.5, due to defects in vascular development 
(Hosaka et al., 2004). In addition, results from another study (Nakae et al., 
2002), in insulin resistant mice has shown that haploinsufficiency of the 
FoxO1 gene can rescue a diabetic phenotype. However, the same study also 
showed that a gain of function mutation in the FoxO1 gene in the liver and 
pancreatic beta-cells of mice leads to the development of diabetes, indicating 
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the important role FoxO1 plays in insulin downstream signalling. Taken 
together, these studies suggest the functions of FoxO factors are diverse, but 
that a degree of redundancy also exists. Furthermore, the observed 
differences in the phenotypes of FoxO-null mice may be caused by variations 
in the levels of expression of each isoform in the specific tissues.   
Since FoxO proteins are transcription factors, they can only function when in 
the nucleus. Monomers of FoxO bind to a consensus DNA sequence 
(G/C)(T/A)AA(C/T)AA, named the FoxO-recognised element (FRE) (Biggs et 
al., 1999; Furuyama et al., 2000; Gilley et al., 2003). All the FoxO factors 
appear to be able to regulate the expression of the same target genes. This 
further strengths the hypothesis that these proteins function with a certain 
degree of redundancy.  
A schematic overview of the function and regulation can be found in figure 
1.2. 
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Figure 1-2: FoxO regulation, shuttling and downstream targets.  
Most of the known post-translational modification of FoxO protein, which affect FoxO 
shuttling and/or FoxO activity, are summarized in this figure. Some of the modifications 
presented have, to date, been shown to be isoform specific. β-catenin binding to FoxO 
enhances transcriptional activity. The role of acetylation of FoxO proteins is currently 
unresolved, however the general consensus is that SIRT1 deacetylation of FoxO induces 
transcription of genes important for stress resistance and longevity. * JNK phosphorylation of 
FoxO4 has been shown to induce transcription of genes involved in oxidative stress 
detoxification. FoxO proteins are believed to be able to transcribe genes when 
phosphorylated by both Akt and JNK under oxidative stress conditions in the presence of 
growth factors. Adapted from Huang and Tindall 2007 
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1.5.2 Regulation of FoxO transcription factors in response to 
survival factors and cellular stress  
FoxO transcription factors are expressed in most adult tissues in a specific 
yet overlapping manner (Anderson et al., 1998; Biggs et al., 2001). All FoxO 
proteins appear to bind the same consensus DNA binding site (Biggs et al., 
1999; Furuyama et al., 2000). Taken together, these observations suggest 
that regulation on FoxO activity is not predominantly achieved by isoform 
specific expression or binding to the DNA. In fact, the regulation of FoxO 
transcription factors seems to occur mainly at post-translational level. The 
factors which drive the activity of post-translational modifiers are mostly 
extracellular signals. Post-translational modifications of FoxO factors include 
phosphorylation, ubiquitylation and acetylation. A schematic summary of the 
various post-translational modifications FoxO1, FoxO3a and FoxO4 are 
subjected to, can be found in figure 1.3. The effects of these post-
translational modifications on FoxO activity are illustrated in figure 1.2. 
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Figure 1-3: Post-translational modifications of FoxO proteins.  
Schematic representation of post-translational modifications of FoxO. The enzymes 
responsible for the modification are noted where known. Akt and SGK phosphorylate the 
same sites. FKH-forkhead domain, NLS-nuclear localisation signal, NES-nuclear export 
sequence, TA-transactivation domain. Adapted from van der Horst et al., 2007. 
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1.5.2.1 Phosphorylation of FoxO factors which leads to inactivation of FoxO 
activity 
Several kinases have been found to phosphorylate FoxO transcription factors 
leading to their inactivation, which is generally achieved by nuclear exclusion 
of these proteins. Phosphorylation of FoxO factors following stimulation with 
insulin was the first identified and best characterised post-translational 
modification of FoxO. As mentioned above, the first indication that FoxO 
factors are downstream targets of the PI3K/Akt signalling pathway came from 
studies conducted in C.elegans which showed that the DAF-16 is 
phosphorylated  and hence, negatively regulated by DAF-2 (Lin et al., 1997; 
Ogg et al., 1997). This mechanism of regulation was found to also occur in 
mammalian cells. Stimulation by growth factors, such as insulin and insulin 
like growth factor (IGF-1), results in the activation of PI3K and subsequent 
Akt phosphorylation. Phosphorylation of Akt results in the activation of Akt 
and thereby phosphorylation of FoxO1, FoxO3a and FoxO3a at three  
evolutionary conserved residues, leading to the inactivation of FoxO 
transcription factors (Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999; 
Rena et al., 1999; Tang et al., 1999). The mechanism underlying the 
inactivation of FoxO following phosphorylation by Akt, appear to be the 
resulting nuclear exclusion of these factors. Phosphorylation of FoxO factors 
by Akt leads to the binding of 14-3-3 proteins to FoxO and this interaction 
appears to occur in the nucleus. The 14-3-3 FoxO complex is then exported 
from the nucleus to the cytoplasm. The interaction of 14-3-3 proteins with 
FoxO proteins seems to mask the FoxO NLS and therefore, may be the 
mechanism which causes FoxO proteins to translocate to the cytoplasm and 
not re-enter the nucleus (Brunet et al., 2002; Zhao et al., 2004). FoxO6 lacks 
the third Akt regulatory site, and although phosphorylated by Akt, at two sites, 
leading to its inactivation, it does not translocate to the cytoplasm (van der 
Heide et al., 2005) and is therefore, not further discussed.  
Serum and glucocorticoid inducible kinases (SGKs) are serine/threonine 
kinases, which were found to phosphorylate FoxO3a, at the same residues 
as Akt (Brunet et al., 2001). Like Akt, SGKs are downstream targets of the 
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PI3K pathway and localise in the nucleus following exposure to survival 
factors. Hence, the same extracellular stimuli leads to both SGK and Akt 
activation, both which results in the phosphorylation of FoxO3a at the same 
three residues leading to the nuclear export and inactivation of FoxO3a 
(Brunet et al., 2001). Similarly, FoxO1 was also found to be phosphorylated 
by a member of the SGK family leading to its inactivation ( Liu et al., 2000).  
Several additional mechanisms of regulation by phosphorylation, resulting in 
FoxO inactivation, have been identified for specific FoxO isoforms. In addition 
the residues subjected to this phosphorylation are generally not conserved 
from C.elegans to mammals and have been only shown to occur in 
mammalian cells. FoxO1 has been shown to be phosphorylated  by the dual-
specificity tyrosine-phosphorylated and regulated kinase (DYRK) at serine 
329,  resulting in a decrease in FoxO1 transcriptional activity (Woods et al., 
2001). The cyclin-dependent kinase 2 (CDK2) was shown to phosphorylate 
FoxO1 at serine 249, leading to FoxO1 inactivation and re-localisation in the 
cytoplasmic compartment (Huang et al., 2006). 
IKK (IκB kinase) was found  to phosphorylate FoxO3a on serine 644 leading 
to the inhibition of FoxO3a activity and its cytoplasmic localisation (Hu et al., 
2004). This mechanism of regulation was found to be independent of Akt 
activity and therefore, IKK may be regarded as an Akt-independent inhibitor 
of FoxO3a activity (Hu et al., 2004).  
 
Following stimulation with growth factors and/or insulin, FoxO factors 
translocate from the nucleus to the cytoplasm. Nonetheless,  following 
exposure to oxidative and genotoxic stress inducing agents, FoxO proteins 
localise to the nucleus, despite induction with growth factors and insulin  
(Brunet et al., 2004; Essers et al., 2004; Huang et al., 2006). This implies that 
other factors affect the cellular distribution of FoxO. 
1.5.2.2 Phosphorylation of FoxO factors in response to cellular stress 
Oxidative stress affects the activity of cellular transduction pathways such as 
the JNK signalling pathway (Davis, 2000). FoxO has been shown to be 
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regulated by JNK in several organisms. In Drosophila, JNK was found to 
induce the nuclear translocation and activation of Drosophila FoxO (Wang et 
al., 2005). In C.elegans, it was shown that following heat stress the JNK 
orthologue can bind to and phosphorylates DAF-16 and this is assumed to 
lead to nuclear localisation of DAF-16 (Oh et al., 2005). In mammalian cells, 
following the induction of oxidative stress, JNK was also found to be able to 
phosphorylate a member of the FoxO family, FoxO4, at two sites, threonine 
447 and threonine 451. This was found to be dependent on the activation of 
the small GTPase Ral and result in the accumulation of FoxO4 in the 
nucleus, leading to the transcription of downstream targets (Essers et al., 
2004). JNK has also been shown to also induce the nuclear translocation of 
FoxO indirectly, by the phosphorylation of 14-3-3. This leads to the 
dissociation of FoxO from 14-3-3, which enables FoxO to re-localise to the 
nucleus (Sunayama et al., 2005). Similarly, the mammalian Ste20-like kinase-
1 (MST1), a MAPKKKK, upstream of JNK was found to phosphorylate 
FoxO3a at a conserved site, located in forkhead domain (serine 207). This 
has been shown to affect the interaction between FoxO3a and 14-3-3 
resulting in the release of FoxO3a from the complex with 14-3-3, thereby 
promoting the ability of FoxO3a to translocate to the nucleus (Lehtinen et al., 
2006). 
. 
Taken together, folowing exposure to oxidative stress and oxidative stress 
induing agents, such as paclitaxel (Sunters et al., 2003), FoxO factors 
predominately localise to the nucleus. One of the mechanisms underling 
FoxO nuclear translocation/retention appears to be mediated, at least 
partially, by the activity of JNK and other members of the JNK signal 
transduction pathway.  
1.5.2.3 Acetylation 
In addition to phosphorylation, FoxO proteins are subjected to post-
translational regulation by acetylation. FoxO proteins have been found to 
form complexs with an abundance of gene expression regulators; co-
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activators and co-repressors, some of which affect the acetylation status of 
FoxO proteins. The acetylation status of FoxO has been suggested to tip the 
balance between positive and negative regulation of the cell fate. As a result, 
the set of FoxO downstream genes transcribed may change (Greer and 
Brunet, 2005). 
Mammalian FoxOs are acetylated by HATs, such as, p300, core binding 
protein (CBP) and CBP-associated factor P/CAF. Deacetylation of FoxOs is 
carried out by histone deacetylases (HDAC); the best studied being sirtuin 
(SIRT1), which is the mammalian orthologue of SIR-2 (silent information 
regulator-2), which remove acetyl groups from both histones and other 
proteins (Brunet et al., 2004; Daitoku et al., 2004; Fukuoka et al., 2003; 
Kobayashi et al., 2005; Mahmud et al., 2002; Motta et al., 2004; Perrot and 
Rechler, 2005; van der Horst et al., 2004; Yang et al., 2005b). Most probably, 
SIRT1 is not the only HDAC that regulates FoxO activity, as inhibition of other 
HDACs results in increased FoxO acetylation (Brunet et al., 2004; Frescas et 
al., 2005; Matsuzaki et al., 2005; Motta et al., 2004; van der Horst et al., 
2004).  
In C.elegans, the over-expression SIR-2 gene of significantly increased the 
lifespan of the worms by a mechanism which was shown to dependent on the  
activation of DAF-16 (Tissenbaum and Guarente, 2001). This implying that 
DAF-16 is regulated, to some extent, by acetylation and deacetylation 
(Tissenbaum and Guarente, 2001). In addition, SIR-2 dependent increase in 
lifespan seems to be mediated, at least partially, by 14-3-3 proteins 
(Berdichevsky et al., 2006; Wang et al., 2006). DAF-16 was shown to interact 
with 14-3-3; therefore, as suggested by van der Horst et al, the connection 
between SIR-2 and DAF-16 may be conducted through the interaction of both 
proteins with 14-3-3 (van der Horst and Burgering, 2007).  
The regulatory significance of FoxO acetylation and deacetylation (by SIRT1) 
is currently inconclusive. Some studies suggest that acetylation inhibits FoxO 
activity, as there is evidence that SIRT1 activates FoxO (Daitoku et al., 2004; 
Frescas et al., 2005; Gan et al., 2005; Kobayashi et al., 2005; van der Horst 
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et al., 2004). Another approach, as suggested by Motta et al, is that the 
acetylation activates FoxO (Motta et al., 2004). Brunet and colleagues, 
proposed a context-specific regulation mechanism, in which SIRT1 stimulates 
the expression of FoxO-induced target genes which play important roles in 
cell cycle regulation and stress resistance, while de-acetylation by SIRT1 
inhibits the expression of FoxO induced pro-apoptotic target genes (Brunet et 
al., 2004). This model is based on three observations; following exposure to 
stress, SIRT1 intetracts with and deacetylates FoxO factors in the nucleus 
(Brunet et al., 2004; Kitamura et al., 2005), SIRT1 expression up-regulates 
FoxO3a induced cell cycle arrest by upregulation of p27Kip1 expression 
(Brunet et al., 2004), and the inhibition of SIRT1 increases the expression of 
FoxO3a downstream apoptotic target genes, such as Bim, (Brunet et al., 
2004). Therefore, SIRT1 interaction was suggested to tip the activity of 
FoxO3a from apoptosis and cell death towards stress resistance and cell 
survival (Greer and Brunet, 2005).  
 
FoxO family of proteins are subjected to another type of post-translational 
modification which is ubiquitylation, the addition of ubiquitin groups.  
1.5.2.4 Ubiquitylation 
There are two known types of protein ubiquitylation; polyubiquitylation and 
monoubiquitylation. Polyubiquitylation is irreversible and tags the protein for 
degradation by the proteasome, while monoubiquitylation is reversible and 
does not culminate in the degradation of the protein. 
The amounts of FoxO1 and FoxO3a proteins in mammalian cells have been 
shown to be regulated by PI3K/Akt pathway dependent polyubiquitylation of 
these proteins and proteasome degradation (Matsuzaki et al., 2003; Plas and 
Thompson, 2003). The phosphorylation of FoxO1 by Akt on serine 256  leads 
to  the recruitment of Skp2, the substrate recognition component of the E3 
ligase complex the SCF (SKP1-CUL1-F- box protein) (Huang et al., 2005). 
The interaction results in the polyubiquitylation of FoxO1 and subsequent 
degradation by the proteasome (Huang et al., 2005). Similarly, the IKK 
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mediated phosphorylation of FoxO3a at serine 644 (discussed later on in the 
introduction) also results in ubiquitylation and subsequent degradation by 
proteasome. The E3 ligase responsible has not yet been identified (Hu et al., 
2004). To date, only FoxO1 and FoxO3a have been shown to be regulated 
post-translationally by polyubiquitylation. However, FoxO4 was found to be 
monoubiquitylated, at the conserved residues, lysine 199 and lysine 211. This 
post-translational modification occurs after exposure of cells to oxidative 
stress and leads to FoxO4 nuclear localisation and to upregulation in FoxO4 
dependent transcription of target genes (van der Horst et al., 2006). FoxO4 
was shown to interact with the herpesvirus associated ubiquitin-specific 
protease (HAUSP/USP7), resulting in the inhibition of FoxO4 activity. 
Therefore, it is plausible that USP7 interaction with FoxO4 leads to the 
removal of monoubiquitin from FoxO4 (van der Horst et al., 2006).  The E3 
ligase responsible for the addition of the ubiquitin group is unknown, yet. 
Taken together, monoubiquitylation of FoxO4 may be a form of post-
translational regulation following oxidative stress. Hence, monoubiquitylation 
of FoxO4 is probably a mechanism which enables the upregulation of FoxO4 
transcriptional activity. 
 
In summary, the main determinates that regulate the sub-cellular distribution 
and activities of FoxO transcription factors are growth factors, insulin and 
oxidative stress. Abundance in growth factors and insulin result in the 
phosphorylation of FoxO by Akt, which leads to cytoplasmic localisation and 
inactivation of FoxO factors. By contrast, oxidative stress results in nuclear 
retention and activation of FoxO proteins. The mechanism underlying 
regulation of FoxO proteins following exposure to oxidative stress is complex. 
Several post-translational modifications, such as phosphorylation by JNK and 
MST1 were found to retain FoxO in the nucleus, even after treatment with 
insulin, whilst deacetylation of FoxO is presumed to lead to transcription of 
FoxO target genes involved in detoxification of ROS and cell cycle arrest. 
Monoubiquitylation of FoxO has also been implicated in oxidative stress 
regulation of FoxO, leading to FoxO re-localisation and retention in the 
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nucleus. The next section discusses the end result of FoxO regulation, the 
function of FoxO transcription factors. 
1.5.3 The function and downstream targets of FoxO 
FoxO downstream targets have been implicated in several cellular activities, 
such as glucose metabolism, cell cycle arrest, apoptosis, DNA repair, 
detoxification of oxidative stress and differentiation. As mentioned above, 
phosphorylation of FoxO proteins by Akt results in inhibition of FoxO activity, 
therefore, taken together, this may result in a pro-survival anti-apoptotic 
advantage to the cells, which could lead to uncontrolled proliferation and 
reduced sensitivity to chemotherapeutic agents. FoxO transcription factors, 
influence the following physiological activities; glucose metabolism, 
apoptosis, DNA repair and detoxification, cell cycle and differentiation. 
1.5.3.1 Glucose metabolism 
FoxO transcription factors transactivate the expression of genes that are 
involved in gluconeogenesis. It has been found that FoxO transcription 
factors can upregulate the expression of the metabolic enzyme, glucose 6 
phosphatase (G6Pase), which converts glucose 6 phosphate to glucose and 
the expression of phosphoenolpyruvate carboxykinase (PEPCK), an enzyme 
that converts oxaloacetate to phosphoenolpyruvate (Nakae et al., 2001; 
Puigserver et al., 2003; Schmoll et al., 2000; Yeagley et al., 2001). As FoxO 
activity is controlled by insulin signalling, it can be suggested that insulin 
affects glucose metabolism by repressing FoxO activity, thereby, decreasing 
gluconeogenesis. 
1.5.3.2 Apoptosis 
FoxO factors induce apoptosis via both the mitochondria dependent and 
independent pathways. In the mitochondria independent pathway, FoxO 
factors were found to up-regulate the expression of the death receptors 
ligand genes, Fas-Ligand (FasL) and TRAIL. The FasL gene, which encodes 
a protein that activates the Fas death receptor, was found to have three 
consensus FRE sequences, to which the binding of FoxO3a was shown to 
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result in de novo transcription of FasL (Brunet et al., 1999). TRAIL was 
identified in a study, conducted using prostate cancer cells, to be regulated 
by FoxO3a (Modur et al., 2002).  
In the mitochondrial dependent (intrinsic) pathway, FoxO proteins were 
shown to induce apoptosis by up-regulating the transcription of Bim. The Bim 
gene-promoter was found to posses two functional FRE sites (Gilley et al., 
2003) and FoxO factors were shown to induce the transcription of Bim in 
haematopoietic cells deprived of growth factors (Dijkers et al., 2000a; Stahl et 
al., 2002). In addition, the transcriptional repressor Bcl-6, which expression 
results in the down-regulation of the expression of Bcl-XL, a pro-survival Bcl-
2 family member, was found to be induced by FoxO4 (Tang et al., 2002) and 
bNIP3, another proapoptotic member of the Bcl-2 family, was also identified 
as a FoxO target gene (Tran et al., 2003).  
Taken together, the significance of the role of FoxO transcription factors play 
in the induction of apoptosis is illuminated but the fact that FoxO factors can 
up-regulate cell death by both mitochondria dependent and independent 
pathways.   
1.5.3.3 DNA repair and detoxification: a role for FoxO in oxidative stress 
resistance and longevity  
The role of FoxO in the detoxification of oxidative stress: FoxO transcription 
factors have been implicated in oxidative stress detoxification based on the 
identification of FoxO downstream transcriptional targets and the role FoxO 
factors play in haematopoietic stem cell resistance to physiologic oxidative 
stress. The manganese superoxide dismutase (MnSOD) and catalase genes, 
both which encode antioxidant scavenger proteins, were found to be 
positively regulated at the transcriptional level by FoxO factors (Kops et al., 
2002a; Nemoto and Finkel, 2002). In a conditional knock out of FoxO1, 
FoxO3a and FoxO4 in adult mouse models, the importance of FoxO proteins 
was shown in the haematopoietic system. The haematopoietic stem cells 
have lost their longevity (and self renewal) under conditions of elevated 
oxidative stress, in comparison with wild-type haematopoietic stem cells; a 
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phenotype which can be reversed following treatment with an antioxidant 
agent. These observations indicate that FoXO play a role in the maintenance 
and longevity of the heamatopietic stem cells and resistance to oxidative 
stress (Tothova et al., 2007). The maintenance of the haematopoietic stem 
cells has implications on lifespan. This is in accord with the increase in 
lifespan observed in C.elegans which has been linked to the activity of FoxO 
and JNK orthologues as detailed below. 
Oxidative stress results in JNK-dependent activation of FoxO leading to an 
increase in lifespan: Cross talk between the JNK signal transduction pathway 
and PI3K/Akt/FoxO pathway has been suggested based on the results of 
several studies (De Ruiter et al., 2001; Essers et al., 2004; Lehtinen et al., 
2006; Oh et al., 2005; Sunayama et al., 2005). It is a well established fact that 
the JNK signal transduction pathway becomes active following exposure to 
oxidative stress (Davis, 2000). JNK activity has also been shown to decrease 
the levels of ROS and extend lifespan in Drosophila  (Wang et al., 2005) 
However, more recently, it has been shown  that in Drosophila, JNK 
activation induces FoxO to localise in the nucleus and to transcribe genes 
involved in growth regulation and stress defence (Wang et al., 2005). 
Similarly, heat stress was also found to extend lifespan in C.elegans in a 
manner dependent on both DAF-16 and JNK-1 (Oh et al., 2005). In 
mammalian cells FoxO factors accumulate in the nucleus, even following 
treatment with growth factors (Brunet et al., 2004). In mouse cells, it was 
shown that following treatment with H2O2 FoxO4 becomes phosphorylated at 
threonine 447 and threonine 451 in a JNK dependent manner, resulting in the 
accumulation of FoxO4 in the nucleus (Essers et al., 2004). JNK was also 
found to phosphorylate 14-3-3, which leads to the dissociation of 14-3-3 
proteins from FoxO, which most likely enables FoxO factors to re-enter the 
nucleus and antagonise PI3K/Akt activity (Sunayama et al., 2005). In 
addition, in primary mammalian neuron cells, an upstream regulator of JNK, 
MST1, a MAPKKKK, was shown to phosphorylate FoxO3a at the conserved 
serine 207, which is located in the DNA binding domain site. This 
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phosphorylation event causes the FoxO3a-14-3-3 complex to dissociate, 
resulting in re-localisation of FoxO3a in the nucleus (Lehtinen et al., 2006), 
Taken together, activation of MST1/JNK following oxidative stress neutralises 
the activity of the PI3K/Akt pathway, by inducing FoxO nuclear localisation 
and transcription of target genes involved in cellular responses to stress. 
FoxO deacetylation following oxidative stress tips FoxO activity towards cell 
cycle arrest and oxidative stress resistance: FoxO transcription factors have 
been implicated in various cellular functions and have been shown to have 
diverse cellular roles which often may seem to be contradicting. However, the 
results of research conducted on the acetylation and de-acetylation by SIRT1 
of FoxO factors, has helped to shed some light on this topic (Brunet et al., 
2004; Daitoku et al., 2004; Fukuoka et al., 2003; Kobayashi et al., 2005; 
Mahmud et al., 2002; Motta et al., 2004; Perrot and Rechler, 2005; van der 
Horst et al., 2004; Yang et al., 2005b). In yeast, the increase in lifespan 
following caloric-restriction was found to be dependent on the SIR-2 gene, 
which encodes the silencing protein Sir2p (Lin et al., 2000). While in 
C.elegans, it was shown by the use of strains which contain a chromosomal 
duplication of the region encompassing the SIR2.1 gene, a gene highly 
homologous to the yeast SIR-2 gene, that SIR-2 plays a role in the prolonging 
lifespan and that this function is dependent on the downstream DAF-16 
protein (Tissenbaum and Guarente, 2001). In mammalian cells, it has been 
demonstrated that following exposure to oxidative stress stimuli, such as 
H2O2, SIRT1, one of the human orthologues of SIR-2 forms a complex with 
FoxO3a and deacetylates FoxO3a. This interaction between FoxO3a and 
SIRT1 and the subsequent deacetylaytion of FoxO3a have been shown to 
induce the ability of FoxO3a to upregulate resistance to oxidative stress and 
induce cell cycle arrest, but to impair the ability of FoxO3a to upregulate 
apoptosis. Taken together, oxidative stress leads to deacytelation of FoxO3a 
by SIRT1, thereby, shifting the activity of FoxO3a from cell death to 
detoxification of oxidative stress and longevity (Brunet et al., 2004). 
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FoxO4 monoubiquitylation following oxidative stress results in the nuclear 
retention of FoxO4, and transcriptional activation of FoxO4: In mammalian 
cells, monoubiquitylation of FoxO4 at lysine 199 and lysine 211 occurs 
following  exposure to H2O2 and was shown to result in FoxO4 nuclear 
accumulation and upregulation of target gene transcription (van der Horst et 
al., 2006). Interestingly, lysine 199 and lysine 211 were also shown to be 
acetylated by CBP/p300 following exposure to oxidative stress (van der Horst 
et al., 2004); however, the kinetics of these reactions appears to be different. 
While monoubiquitylation appears to occur almost instantly after treatment 
with H2O2 (within 5 minutes), acetylation occurs at a later time (after longer 
than 60 minutes). This suggests that oxidative stress results, initially in 
FoxO4 monoubiquitylation and activation and that this is later followed by 
FoxO4 deubiquitylation and acetylation, resulting in FoxO4 inactivation (van 
der Horst et al., 2006).  
β-catenin induces FoxO activity in detoxification of oxidative stress: 
Experiments conducted in both C.elegans and mammalian cells have 
suggested that  β-catenin, a multifunctional protein which plays a role in Wnt 
signalling, can bind to FoxO following treatment with H2O2. This was shown to  
result in an increase in FoxO transcription of target genes (Essers et al., 
2005). In mammalian cells, exposure to oxidative stress stimuli was shown to 
result in the binding of β-catenin to FoxO4 and an increased transcription the 
FoxO downstream transcriptional target, p27Kip1. In C.elegans, it was 
demonstrated that the expression of the DAF-16 target gene, superoxide 
dismutase 3 (sod-3), the MnSOD homologue, following exposure to an 
oxidative-stress inducing agent is dependent on BAR-1, the β-catenin 
orthologue (Essers et al., 2005). Taken together, it appears that β-catenin 
interaction with FoxO4 is induced following oxidative stress, leading to an 
increase in FoxO4 dependent transcription of target genes, such as p27Kip1, a 
gene important in cell cycle regulation.  
FoxO factors may also play a role in reducing genotoxic stress: CDK2, a 
kinase which activity is reduced following DNA damage, has been shown to 
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phosphorylate FoxO1; an event which leads to a decrease in FoxO1 
transcriptional activity (Huang et al., 2006). Based on this observation, it is 
possible that genotoxic stress may be another stress factor which induces the 
activity of FoxO transcription factors.  
 
Overall, oxidative stress results in changes in the regulation and activity of 
multiple cellular targets, some of which have been found to affect the activity 
of FoxO factors. This is predominantly achieved by altering FoxO post-
translational modifications, which mainly affect the sub-cellular distribution of 
FoxO, but also may have an impact on the array of genes transcribed by 
FoxO.   
1.5.3.4 Cell cycle transitions  
The cell cycle process is a tightly regulated process that is promoted by a 
family of proteins called cyclins and cyclin dependent kinases (CDK) and is 
inhibited by cyclin kinases inhibitors (CKI), such as, p21Cip1 and p27Kip1. 
Cyclins and their kinases form complexes. The balance between cyclin-CDK 
complexes and CKIs promotes or inhibits the progression of the cell cycle 
(Hunter and Pines, 1994; Sherr, 1994; Sherr and Roberts, 1995, 1999).  
The cell cycle responds to growth factor stimulation, as quiescent cells (G0) 
move into the G1 phase of the cell cycle. The transition increases the 
transcriptional activity in the cell, include degradation of p27Kip1 protein and 
up-regulation of cyclin D expression, this activates cyclin D–CDK4 and cyclin 
E–CDK2 complexes and results in progression of the cells into S phase.  
The growth factor signal is carried through the cell by signal transduction 
pathways. The signal molecule interact with a receptor on the outer side of 
the cell membrane, which translates the hormonal/growth factor signal into a 
phosphorylation signal which cascades down until it concludes in consequent 
gene expression and cell growth. One of the main signal transduction 
pathways is the PI3K/Akt pathway. Activation of the PI3K/Akt signalling 
pathway leads to the entry of quiescent cells (G0) into G1-phase. 
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FoxO proteins have a role in cell cycle regulation. Growth factor stimulation of 
cells results in activation of the PI3K/Akt signalling pathway and in activation 
of FoxO. In the presence of a growth signal by exposure of the cells to the 
transforming growth factor β (TGFβ), FoxO proteins were found to bind the 
promoter of p21Cip1 gene, a cell cycle inhibitor, leading to an induction in cell 
cycle arrest (Seoane, 2004). Therefore, in the absence of growth factors, 
FoxO activity is sustained resulting in up-regulation of p27Kip1, p130 and 
cyclin G2 expression, as well as, inhibition of cyclin D1 and D2 expression, 
thereby insuring maintenance of a quiescent state. 
over-expression of FoxO1, FoxO3a and FoxO4 induce G1 arrest via p27Kip1 
expression (De Ruiter et al., 2001; Medema et al., 2000; Nakamura et al., 
2000; Stahl et al., 2002; Tanaka et al., 2001). FoxO proteins reduce the 
expression of cyclin D1 and cyclin D2 and may induce cell cycle arrest 
independently of p27Kip1 ( Schmidt et al., 2002; Ramaswamy et al., 2002). 
The FoxO transcription factors have been shown to regulate the transcription 
of p27Kip1 and cyclin D by binding the promoters of these genes. On the 
promoter of p27Kip1 there is a canonical FRE sequence to which FoxO 
proteins can directly attach (Medema et al., 2000; Nakamura et al., 2000). 
However, binding of FoxO to the cyclin D promoter is probably indirect, via 
interaction with other proteins, or by binding to non-canonical sequence, as 
cyclin D promoter lacks the FRE sequence (Ramaswamy et al., 2002; 
Schmidt et al., 2002).  
FoxO has been suggested to be directly involved with the regulation of cell 
quiescence (G0) in cell lines (Kops et al., 2002b) and in vivo in the regulation 
of the quiescent haematopoietic stem cells (Tothova et al., 2007). Possible 
pathways in which FoxO may induce cell quiescence, may involve the 
retinoblastoma (Rb), by transactivation of the p130 gene (pRBL2, 
retinoblastoma-like 2), in a FRE dependent manner, resulting in the 
accumulation of p130 protein (Kops et al., 2002b).  p130, is expressed at low 
levels in dividing cells, but is highly expressed during quiescence (Grana et 
al., 1998). Moreover, p130 is hypo-phosphorylated and bound to the 
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transcription factor E2F-4 that is associated with activation of cell-cycle 
promoting genes. In complex with p130 E2F-4 is inhibited and re-entry to the 
cell cycle is blocked, thereby maintaining the quiescent state (Stahl et al., 
2002).  
Therefore, it is possible to summarise that the PI3K/Akt signalling pathway 
controls the abundance of p130 during the cell cycle via FoxO regulation and 
hence, controls the cell cycle and quiescent status of the cell.  
Another pathway in which FoxO proteins are involved in cell quiescent is 
through the by increasing cyclin G2 gene transcription (Martinez-Gac et al., 
2004). Cyclin G2 is an unconventional cyclin that is highly expressed in 
quiescent cells, but is down-regulated in a manner dependent on activation of 
the PI3K/Akt signalling pathway as cells enter the cell cycle (Bennin et al., 
2002; Horne et al., 1997).  
In addition to G0 and G1 arrest, FoxO was also found to be able to induce G2 
delay and arrest (Furukawa-Hibi et al., 2002; Tran et al., 2002). DNA 
microarray analysis has implicated the GADD45α (growth arrest and DNA 
damage-inducible protein 45 alpha) as a potential mediator of G2 arrest 
induced by FoxO activation (Furukawa-Hibi et al., 2002; Tran et al., 2002). 
GADD45α induces the dissociation of the cyclin B–CDK1 complex which is 
required for G2 transition (Zhan et al., 1999). FoxO directly binds to and 
activates the promoter of the GADD45α gene, thereby increasing the amount 
of GADD45α protein (Furukawa-Hibi et al., 2002; Tran et al., 2002)  
1.5.3.5 Differentiation  
As the function of FoxO is linked to cell cycle, it has also been found to be 
involved in a special type of cell division that is differentiation. Cellular 
differentiation is a polar cell division which gives rise to two different cells. 
One daughter cell resembles the cell they derived from and the other has a 
different phenotype.  
The role of FoxO factors in differentiation may be linked to their function in 
tumourigenesis. FoxO factors have been implicated in both blocking and 
promoting differentiation, depending on the FoxO isoform and the cell type. 
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Therefore, it is plausible that impaired FoxO activity in differentiation may 
result in a differentiation block, the accumulated cells will still be capable of 
proliferation, though the might have an increasing tumourigenic potential 
(Arden, 2006). 
The most studied differentiation system is the hematopoietic system. It is a 
highly regulated system (Lapidot et al., 1993). Deregulation of 
haematopoiesis results in leukaemia. For example, the disruption of PI3K/Akt 
pathway in haematopoietic cells as a result of the expression of the fusion 
gene BCR/ABL, results in leukaemia (Era et al., 2002). FoxO3a and FoxO4 
are fusion partners of MLL and cause acute myeloid leukaemia (Parry et al., 
1994).  
A recent publication has demonstrated that FoxOs have a significant role in 
maintaining the haematopoietic stem cell (HSC) compartment. The HSCs are 
a population of quiescent cells, with enhanced survival, which maintain for 
very long time (the life time of a human) (Tothova et al., 2007). Knock out 
mice of the FoxO1, FoxO3a and FoxO4 resulted in severe defects to the HSC 
compartment, as a result, with decreased ability of the cells to react to ROS 
(Tothova et al., 2007). FoxO3a appears to induce erythroid differentiation. 
This has been shown to be potentially linked to the ability of FoxO3a to bind 
to the promoter of the Id1 (inhibitor of differentiation1), ultimately resulting in 
reduced transcription of Id1 activity (Birkenkamp et al., 2007). Another mean 
by which FoxO3a has been implicated in differentiation is the induction of 
erythroid differentiation is by transactivation of the B-cell translocation gene 1 
(BTG1). The activated BTG1 causes, in an unknown manner, methylation of 
arginine residues on substrate proteins. This methylation activity results in 
increased erythroid differentiation (Bakker et al., 2004).  
In other tissues such as adipocytes and myoblasts, expression of a 
constitutively active FoxO1 inhibits differentiation in vitro (Nakae et al., 2003; 
Hribal et al., 2003). In adipocytes, differentiation block has been linked to 
FoxO1 ability to up-regulate p21Cip1 expression (Nakae et al., 2003). FoxO4 
has been implicated in the repression of differentiation of smooth muscle cells 
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by interacting with myocardin resulting in a disruption of the transcriptional 
activity (Liu et al., 2005b).  
 
In chapter 4 of the thesis, I investigate the function of FoxO3a by examining 
the role and activity of BTG1, a novel downstream target gene of FoxO3a, 
initially identified in B-cells. BTG-1 was first identified as a downstream target 
of FoxO3a in erythroid progenitors and has been implicated in differentiation. 
Despite this fact, the exact function of BTG1 is currently unknown. 
Examination of the activity of this downstream target of FoxO3a was 
performed regardless to its suggested role in differentiation, the sole purpose 
being characterisation of BTG1 activity in breast cancer and not in 
differentiation.  
1.5.4 B-Cell Translocation Gene -1 (BTG1) 
The BTG/Tob family of proteins consists of six known members in 
vertebrates, BTG1, BTG2/TIS21/PC3, BTG3/ANA, PC3B, Tob and Tob2 
(Matsuda et al., 2001). All members of this family posses a highly conserved 
110-amino-acid N-terminal domain, named the BTG/Tob homology domain. 
BTG proteins have been shown to play a role in restriction of cell growth 
(antiproliferative activity) and differentiation (Guardavaccaro et al., 2000; 
Guehenneux et al., 1997; Raburn et al., 1995; Rodier et al., 1999). The 
BTG/Tob homology domain consists of two highly homologous regions, 
named box A and box B. BTG1 and BTG2 bear homology to each other in 
another region called box C, which associates with protein arginine methyl 
transferase 1 (PRMT1).  
Research conducted on the function and role of BTG2 has revealed that 
BTG2 is a p53 downstream target gene; BTG2 is up-regulated as a response 
to exposure to DNA damaging agents.  BTG2 also plays a role in down-
regulation of cyclin D1 transcription and has been shown to induce the 
inhibition of cell cycle progression at G1 by decreasing the levels of 
phosphorylated Rb (Rouault et al., 1996).  
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BTG has a specific role in the normal mammary gland development and in 
initiation and progression of breast cancer. In the rat mammary gland model, 
BTG2 was found to be expressed in epithelial cells and its levels were shown 
to decrease in pregnant and lactating animals. However, BTG2 levels 
increased during involution. Estrogen and progestin were found to suppress 
BTG2 expression, implying that these steroids, which stimulate proliferation 
of mammary cell, also down-regulate BTG2. Furthermore, the expression 
levels of BTG2 in human breast cancer cell lines are lower than in non-
tumourigenic mammary cells and BTG2 was found to be stimulated in breast 
cancer cells by activation of NF-κB (Kawakubo et al., 2004). Loss of BTG2 
was shown to occur in the early stages of the tumourigenesis process. Taken 
together, this suggests that down-regulation of BTG2 may be play a 
significant role in  the development of mammary tumours (Kawakubo et al., 
2006). 
To date, little is known about the function and regulation of BTG1, however 
over-expression of BTG1 was found to inhibit proliferation of NIH3T3 (Bogdan 
et al., 1998) cells and in QM7 quail myoblasts cells BTG1 localises in the 
nucleus of non-dividing cells and to the cytoplasm of proliferating cells 
(Rodier et al., 1999). DNA microarray identified the BTG1 gene as a FoxO3a 
target in erythroid progenitors and FoxO3a was also found to regulate the  
transcription of BTG1 (Bakker et al., 2004). The BTG1 induced proliferation 
inhibition is abolished by deletion of box C in BTG1, the PRMT1 binding 
domain (Bakker et al., 2004). Furthermore, BTG1 expression is induced in 
response to DNA damage (Cortes et al., 2000), this appears to be at least 
partially mediated by the activity of stress stimuli induced JNK signal 
transduction pathway (Devary et al., 1991; Kawasaki et al., 2000; van Dam et 
al., 1995). The CRE (cAMP-responsive element) site in the BTG1 promoter 
has been shown to recruit c-Jun and/or Atf-2. c-Jun and Atf2 are positively 
regulated by JNK, binding of Creb/Atf1 to the CRE site in the BTG1 promoter 
induces FoxO3a-mediated expression late in differentiation, while binding of 
c-Jun/Atf2 following JNK activation is presumed to increase FoxO-mediated 
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expression in response to oxidative or genotoxic stress (Bakker et al., 2007). 
BTG1 lacks enzymatic activity but contains several protein interaction 
domains, which suggests that BTG1 may be an adaptor/scaffold protein or a 
regulatory co-factor (Bakker et al., 2004). 
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Overall aims and thesis outline 
FoxO transcription factors target genes have been implicated in cell cycle 
arrest, apoptosis, oxidative stress detoxification and DNA repair. Therefore, I 
hypothesised that FoxO transcription factors play a vital role in prevention of 
cancer. To date, most of the research conducted regarding the regulation of 
FoxO transcription factors focused on post-translational regulation of these 
transcription factors, however not much is known about the regulation of 
FoxOs at the transcriptional level. Therefore, I decided to examine whether 
FoxO transcription factors are regulated at the transcriptional level, in 
particular in response to treatment with the drug paclitaxel, which is used to 
treat cancer patients, including those suffering from breast and endometrial 
cancer. This drug has been shown to increase the expression of FoxO3a at 
the protein level. Hence, my hypothesis was that in addition to the regulation 
of FoxO at the post-translational level, these proteins are also regulated at 
the transcriptional level and that treatment with chemotherapeutic drugs 
increase FoxO transcription. The results of these experiments are presented 
and discussed in chapter 3. 
In chapter 4, I focused on the function of FoxO3a. My aim was to investigate 
whether BTG1, a novel downstream target of FoxO3a identified in erythroid 
progenitors, also played a role in epithelial cells. To this end, I examined the 
effects of BTG1 over-expression in the MCF-7 breast cancer cell line. 
In addition to FoxO3a, JNK1/2 activity has also been shown to be up-
regulated following paclitaxel treatment. Therefore, my aim was to examine 
whether the JNK1/2 signalling pathway plays a positive role in the regulation 
of FoxO3a in response to paclitaxel treatment. To this end, I examined the 
effect of the JNK1/2 signalling pathway on FoxO3a sub-cellular distribution, 
on the stability of FoxO3a protein expression and the activity of FoxO3a. The 
results of these experiments are summarised and discussed in chapter 5. 
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2 Materials and Methods 
2.1 Mammalian cell culture 
2.1.1 Cell media  
Human breast cancer cell lines (MCF-7, BT-474) and COS-1 (Green monkey 
kidney epithelial cells) were obtained from ATCC and maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% foetal calf 
serum (FCS), 2mM glutamine, and 100U/ml of penicillin/streptomycin. 
(Invitrogen, Paisley, UK)  MCF-7 Tet-Off BTG1 cells were selected and 
maintained in the presence of 100μg/ml of G418 (InvivoGen) and 200μg/ml 
hygromycin (InvivoGen), in a humidified incubator in an atmosphere of 10% 
CO2 at 37°C. Human endometrial cancer cells (HEC-1-B and Ishikawa cells) 
were maintained in Dulbecco’s modified Eagle’s medium/F12 (GIBCO 
Industries Inc., Carlsland, CA, USA) supplemented with 10% foetal bovine 
serum (Hyclone, Logan, UT, USA), 2mM L-Glutamine and 100 U/ml 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA), in a humidified 
incubator in an atmosphere of 5% CO2 at 37°C. 
Inhibitors and drugs which were added to cell media: LY294002, SP600125 
and Triciribine were obtained from Calbiochem and dissolved in dimethyl 
sulphoxide (DMSO). Paclitaxel was obtained from Sigma-Aldrich (Poole, UK) 
and dissolved in DMSO. MG-132 was obtained from Merck Biosciences Ltd. 
(Nottingham, UK) and dissolved in DMSO. 30% w/w H2O2 in H2O was 
obtained from Sigma-Aldrich (Poole, UK). 
2.1.2 Sub-culturing of adherent cells 
Cells were grown until a sub-confluent (80% confluence) state was reached. 
The media was then removed and the monolayer of cells was washed once 
with PBS. The monolayer was then detached using 1x trypsin-EDTA 
(ethylenediaminetetraacetic acid), 2ml were used for 100mm dish, for 3 min 
at 37ºC) and the trypsin-EDTA was then inactivated by adding 7ml of 
complete media. The cells were then either plated at a defined ratio (1 in 5 of 
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the total cells were re-plated), or were counted using a haemocytometer and 
plated at the required density, and were then maintained at 37ºC in either 
10% or 5% CO2 (according to cell line type).  
2.1.3 Preservation of cells 
Adherent cells from a sub-confluent (~80% confluence) dish were trypsinized, 
washed once in complete media and spun down at 700 xg for 5 min to 
remove any traces of trypsin, and re-suspended at 106 cells/ml in FCS with 
10% DMSO (BDH). 1ml aliquots were wrapped in several layers of tissue 
paper, transferred to cyrotubes and frozen at -80ºC. The tubes were then 
transferred to liquid nitrogen after 48 h.  
2.1.4 Recovery of frozen cells  
Cells were removed from liquid nitrogen storage and thawed rapidly at 37ºC. 
1ml of the cell suspension was added to 9ml of complete media in a 15ml 
falcon tube and then spun at 700 xg for 5 min to remove the DMSO-
containing media. The pellet was then re-suspended in 6ml of complete 
media and transferred to a 25cm2 flask and incubated at 37ºC incubator 
(either 5% or 10% CO2 depending on cell line type) until sub-confluence was 
reached, at which point the cells were sub-cultured.  
2.1.5 Generation of a BTG1 inducible cell line 
In order to determine the function of the BTG1 gene in breast cancer a stably 
transfected breast cancer cell lines which is able to express BTG1 in an 
inducible manner was generated. Initially both the ‘Tet-On’ and ‘Tet-Off’ 
systems were used. These systems enable expression of a gene under 
specifically regulated conditions. In the Tet-Off system, gene expression is 
up-regulated when doxycycline (Dox) or tetracycline (Tet) is removed from 
the medium, while expression is up-regulated in the Tet-On system by the 
addition of either Dox or Tet to the medium. Both systems regulate gene 
expression in response to Tet and Dox concentration (Clontech manual for 
Tet-On/Off systems).  
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The Tet system in made up of two components, the first one being the 
regulatory protein, which in the Tet-Off system is the tetracycline-controlled 
transactivator (tTA) and in the Tet-On system it is a "reverse" Tet repressor 
(rTetR). Both of the plasmids these plasmids have a neomycin-resistance 
gene (Clontech manual for Tet-On/Off systems). The second component is 
the response plasmid, which expresses the gene of interest under the 
regulation of the tetracycline-response element (TRE). When cells contain 
both the regulatory (pTet-Off or pTet-On) and the response (e.g. pTREhyg-
gene B) vectors, gene B is expressed only when either the tTA or rtTA 
proteins bind to the TRE. In the Tet-Off system, tTA binds the TRE and 
activates transcription in the absence of Tet and Dox. In the Tet-On system, 
rtTA binds to the TRE and activates transcription in the presence of Tet and 
Dox. In both systems, transcription is turned either on or off in response to 
either Tet or Dox in a dose-dependent fashion (Clontech manual for Tet-
On/Off systems). Hence, the coding region of BTG1 was amplified by PCR 
and cloned into the pTRE2hyg vector. MCF7 Tet-Off and MCF7 Tet-On cells 
were transfected with these constructs and the empty pTRE2hyg vector as a 
control. The transfected cells were grown in selective DMEM media that 
contained 100μg/ml of G418 (InvivoGen) and 200μg/ml hygromycin 
(InvivoGen). The media of the transfected MCF-7 Tet-Off cells also contained 
Dox at the concentration of 1μg/ml in order to abstain from BTG1 expression 
in case it may have a toxic effect on the cells. Single cell cloning was 
performed on the transfected cell populations. The clones isolated were 
screened for the incorporation of pTRE-BTG1 using PCR as detailed in 
section 2.5.8. 
2.1.6 Sulphorhodamine B (SRB) assay 
Cells were either untreated or treated and then plated, in quadruplicate, in a 
96 well tissue culture plate at 3000 cells/well. After 24 h cells were fixed by 
adding 100µl of 40% ice cold TCA (Trichloroacetic acid) to each well and 
incubating at 4ºC for 1 h. The plate was then washed five times with water. In 
order to stain the fixed cells, 100µl of 0.4% SRB in 1% acetic acid were 
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added to each well and the plate was incubated at RT (room temperature) for 
1 h. The plate was then washed five times with 1% acetic acid. The plate was 
left to dry for 1 h at RT. In order to determine the amount of total protein in 
each well, 100µl of 10mM Tris were added to each well and the plate was left 
to shake for 30 min at RT and optical density (OD) was measured at 492nm.  
2.1.7 DNA transfection of mammalian cells 
2.1.7.1 Promoter assay  
In preparation for transfection of MCF-7, COS-1, Ishikawa and BT-474 cells; 
cells were cultured in 96-well dishes in 100µL of complete media at 
approximately 7000cell/well. The following day the cells were transfected 
using the Fugene 6 transfection reagent (Roche, UK) according to 
manufacture’s instructions. The transfections were performed in 
quadruplicates. 20ng of pGL3 firefly-luciferase reporter plasmid (with the 
appropriate promoter sequence cloned in the MCS of this vector) and 5ng of 
pRLTK Renilla plasmid (Promega Southampton, UK) were added to 0.075μl 
of Fugene diluted in 5μl of DMEM without serum per well. The mixture 
incubated at RT for 15 min prior to adding it to the cells.   
HEC-1-B cells were transfected using lipofectamine 2000 (invitrogen). 
Similarly to transfection carried out with Fugene 6, cells were cultured in 96-
well dishes in 100μl of complete media at approximately 7000cell/well. The 
following day the cells were transfected using lipofectamine 2000 according 
to manufacture’sinstructions. The transfections were performed in triplicates. 
160ng of pGL3-FoxO1 and 40ng of pRLTK Renilla plasmid were diluted in 
25µl of serum free DMEM media; 0.5µl of lipofectamine 2000 were also 
diluted in 25µl of serum free DMEM media. After 5 min incubation at RT of 
lipofectamine 2000 with the serum free media, the two tubes were combined 
and incubated for a further 10 min at RT. The mixture was then added to the 
cells. 
For both types of transfections, the cells were left to recover for 16 h before 
treatment with drugs or inhibitors begun. At the appropriate time-points cells 
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were harvested for renilla and luciferase activity assay (described in 2.1.7.3) 
and kept at -20ºC till all samples were ready to be read.  
2.1.7.2 Co-transfection reporter assay 
In preparation for co-transfection MCF-7, COS-1 and were cultured in 96-well 
dishes at approximately 7000cell/well in a total volume of 100µL of complete 
DMEM per well. The transfections were performed in triplicates. The cells 
were transfected with a constant total amount of 85ng DNA/well which 
consisted of 20ng of the various pGL3 promoter constructs, 5ng of pRLTK 
Renilla plasmid (Promega Southampton, UK) and of 0-50ng of a protein 
expression constructs. In order to maintain an equal amount of total DNA 
transfected per well, 10-60ng of the empty expression vector backbone were 
added to the mix. The DNA mixture was then added to 0.255μl of Fugene 
diluted in 5μl DMEM without serum. The DNA-Fugene mix was incubated at 
RT for 15 min and then added to the cells. After 24 h incubation at 37ºC, cells 
were harvested for firefly/renilla luciferase assay.  
2.1.7.3 Luciferase assay protocols 
Luciferase assay was performed either with Dual-Luciferase Reporter Assay 
System (Promega) according to manufacture’s instruction or LucLite 
Luminescence Reporter Gene Assay System (Perkin ElmerTM Life Sciences, 
Monza (Milano), Italy) coupled with native coelenterazine (n-CTZ, Lux 
Biotechnology, Edinburgh, UK). 
When using the Dual-Luciferase Reporter Assay System, cells were lysed in 
100μl 1x of the provided passive lysis buffer for 15 min at RT. Then 10μl were 
transferred to a 96 well microplate (OptiPlate-96, Perkin ElmerTM Life 
Sciences) and 50μl of Luciferase Assay Reagent II were added and firefly 
luciferase activity was measured. The luminescence was read by Packard 
TopCount Luminometer (Perkin–Elmer Life Sciences), two wells are read 
simultaneously for duration of one second, and counts per second are 
determined. Afterwards 50μl Stop & Glo Reagent was added and Renilla 
activity was measured, using the same machine and programme used for 
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reading luciferase activity. In LucLite Luminescence Reporter Gene Assay 
System, cells were lysed in 1xLucLite Reagent for 15 min at RT. 100μl of 
lysate were transferred to OptiPlate-96 (Perkin ElmerTM Life Sciences) and 
firefly luciferase activity was read with TopCount Luminometer (Perkin 
ElmerTM Life Sciences), as described above. Afterwards, 25μl of RenLite 
reagent [Coelenterazine (50μg/ml) in Renilla Buffer (0.5M HEPES, pH7.8, 
40mM EDTA)] were added and the mixture was incubated for 20 min in the 
dark at RT before measurement of renilla activity, using the same programme 
and machine as mentioned above. The relative luciferase activity levels were 
determined by dividing experimental luciferase values by renilla 
luminescence values. As a negative control, renilla and luciferase values 
were measured in two types of negative controls, one type was blank wells, 
which contained only the lysis buffer, luciferase buffer and renilla buffer and 
the second type was wells which contained non-transected non-transfected 
cells and all of the three buffers.  This was performed in order to give an 
indication on the efficiency of the co-transfection and to determine if the 
levels of luciferase and renilla activity were higher than the background 
reading.  
Below is an example of raw data readings for luciferase and renilla obtained 
from three independent experiments performed in triplicates:  
 
Luciferase  Renilla  Replicas 
1278576 16144 Experiment A 
1197968 14016  
1181304 17312  
1266032 20056 Experiment B 
1186976 17760  
1190646 17456  
1108456 13960 Experiment C 
1000328 12968  
1077628 14328  
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2.2 FACS (Fluorescence Activated Cell Sorting) analysis 
2.2.1 Fixing cells for FACS  
 Cells were trypsinized as usual and pelleted at 700 xg for 5 min, washed 
twice with 1 X PBS. Subsequently cells were fixed by re-suspending them in 
90% ethanol in PBS, transferred in to a round bottomed polypropylene tube 
(Falcon) and incubated at 4ºC for at least 30 min until ready for FACS 
analysis.  
2.2.2 Propdium Iodide (PI) staining of fixed cells for PI FACS (cell 
cycle) analysis 
Fixed cells were pelleted at 700 xg for 5 min and were washed in 1ml of PBS 
prior to staining. Cells were then re-suspended in a staining solution of PBS, 
containing 10μg/ml propidium iodide (Sigma, Poole, UK) and 5ug/ml RNase A 
(Sigma, Poole, UK) to ensure that RNA is not stained. The cell suspension 
was subsequently passed through a 0.6mm bore needle in order to generate 
a single cell suspension. Tubes were wrapped in foil and incubated at 37°C 
for 30 min before fluorescence-activated cell sorting analysis was performed 
using a FACSCalibur (Becton Dickinson, Cowley, UK).  
2.2.3 PI FACS analysis 
All FACS analysis was carried out using FACSCalibur (Beckton Dickinson, 
Cowley, UK) and the Cell Quest software (Becton Dickinson, Cowley, UK). 
Further analysis was carried out using FlowJo (Tree Star, Oregon, USA).  
2.3 Reactive Oxygen Species (ROS) measurement 
Cells were grown in 6-well tissue culture plates to 80% confluence. Shortly 
before performing the experiments, the ROS indicator (a mixture of reduced 
fluorescein and calcein) (C6827, Molecular Probes) was made up to a 
concentrated stock solution (50µM in DMSO). The cells were then removed 
from growth media via scarping and centrifugation at 700 xg. Cells were re-
suspended in 1ml of pre-warmed PBS containing the ROS indicator probe 
diluted to the final working concentration of 5µM and incubated 37ºC for 15-
20 min. After which, cells were centrifuged and re-suspended in pre-warmed 
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PBS. Cells that were not treated with oxidative stress inducing reagents and 
were not incubated with the probe were used to determine the level 
autofluorescence in healthy cells and to calibrate the forward and side scatter 
of the flow cytometer. Negative controls, cells which were treated only with 
the probe, were used to asses the levels of ROS in healthy cells. Positive 
controls were generated by treating cells with 100µM H2O2 for 15 min before 
incubation with probe. The levels of fluorescence of experimental samples 
were compared to those of the negative and positive controls.  
2.4 Immunofluorescence  
MCF-7 cells were grown on sterile 13mm-diameter coverslips and fixed in 4% 
formaldehyde before being permeabilized in 0.01% v/v Triton X-100 for 10 
min. Coverslips were blocked for an h in PBS containing 3% bovine serum 
albumin (BSA) and antibody recognizing FoxO3a (06-951, Upstate) was 
added at 80ug/mL. Rabbit IgG at the same concentration was used as 
negative control. After washing three times for 5 min with PBS-Tween 
(0.05%), samples were incubated in the dark at RT for 30 min with a 1:1000 
dilution of a secondary antibody conjugated to Alexa 488 anti-rabbit 
(Invitrogen, Paisley, UK). The cells were then washed three times for 5 min 
with PBS-Tween (0.05%), and were then mounted with Vector Shield anti-
fade with DAPI (Vector Laboratories, Peterborough, UK). Analysis was 
performed using a Zesis confocal microscope with LSM meta 510 software.  
2.5 Methods in molecular biology 
2.5.1 Bacterial manipulation 
2.5.1.1 Bacterial strains 
In most cases, the XL1-Blue Subcloning-Grade competent E. coli cells 
(Stratagene) were used for plasmid preparation (standard transformation). 
The XL1-Gold Ultra competent cells (Stratagene) were used when cloning 
was performed (i.e. preparation of FoxO3a and BTG1 constructs).  
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2.5.1.2 Media and maintenance 
Competent cells were grown in either Luria-Bertani (LB) broth or LB Agar. 
LB broth was made up by mixing 20g/L of LB broth powder (Sigma-Aldrich) 
with deionised water and autoclaving for 20 min at 120ºC. LB Agar was made 
by mixing 37g/L of LB agar pellets (Miller) with deionised water and 
autoclaving as above. Where necessary, ampicillin (Sigma-Aldrich) was 
added to a final concentration of 100μg/ml. 
2.5.1.3 Preparing chemically competent cells 
XL-10 Gold E.coli (originally provided by Stratagene) were streaked on to a 
LB agar plate and incubated overnight at 37ºC. A single colony was picked 
from the plate and grown overnight in 2ml of LB at 37oC in a shaking 
incubator. 1ml of the overnight culture was used to inoculate 100ml LB (a 
1:100 dilution) in a 1000ml flask. The bacteria were grown until they reached 
an Optical Density (OD) of 0.4 at 600nm. The bacteria were then spun down 
at 8000 xg for 10 min at 4oC. The pellet was then re-suspended in 100 ml ice 
cold MgCl2 (100mM) and incubated on ice for 30 min. The bacteria were then 
pelleted as before and the pellet was re-suspended in 100 ml ice cold CaCl2 
(100mM) and incubated on ice for another 30 min. The cells were pelleted 
again at 8000 xg and then re-suspended in 10ml freezing medium (30mM 
CaCl2, 15% (v/v) Glycerol). The competent cells were snap-frozen in 100μl 
aliquots on dry ice and then stored till use at -80oC. 
2.5.1.4 Bacterial transformations  
A single 100μl aliquot of frozen competent bacteria was thawed on ice. 1μl of 
plasmid DNA (0.5-1μg/μl) was mixed with the thawed cells and left on ice for 
30 min. Cells were then subjected to heat shock by immersing them in a 42ºC 
water bath for 45 seconds and subsequently, kept on ice for a further 2 min. 
1ml of LB medium (without ampicillin) was then added and the transformed 
bacteria were incubated at 37ºC in a bacterial shaker for 1h. Transformed 
bacteria were then plated onto Agar plates containing ampicillin and 
incubated overnight at 37ºC.  
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2.6 DNA manipulation  
2.6.1  DNA quantification 
The concentrations of DNA preparations were determined by measuring the 
optical density of the samples at 260nm (OD260) using a BioRad 
spectrophotometer (Bio-rad Smart SpecTM3000 Spectrophotometer). DNA 
concentration was calcμlated using the relationship:  
 
1 OD unit at 260nm = 50µg/ml DNA 
2.6.2 Sequence analysis 
DNA sequences and PCR products were compared to the wild type DNA 
sequence using BLAST and BLAST two sequences 
(http://www.ncbi.nlm.nih.gov/blast). Localising of promoter regions and start 
transcription sites were performed using UCSC Genome Bioinformatics 
(http://www.genome.ucsc.edu) and Ensembl (www.ensembl.org). Mapping of 
transcription factors consensus binding sites in the various promoter-
constructs was performed using TESS (http://www.cbil.upenn.edu/tess). 
2.6.3 Restriction digests 
Restriction digestions of DNA plasmids were performed using restriction 
endonucleases (New England Biolabs, Hitchin. Hertfordshire, UK). Briefly, the 
10X buffer provided for each enzyme was diluted to 1 X in the final reaction 
mixture. Incubation time and temperature were adjusted according to the 
conditions specified by the manufacturer. 
2.6.4 DNA ligation 
DNA fragments with compatible over-hang ends were covalently joined using 
Rapid DNA Ligation Kit (Roche Applied Science) according to manufacture’s 
protocol.  
2.6.5 DNA agarose gel electrophoresis  
DNA fragments mixed in a final 1x Orange G loading dye (6x, Promega 
Southampton, UK) were separated by electrophoresis in 1-2% (w/v) agarose 
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gel (incorporated with 0.5μg/ml ethidium bromide) in 1% TAE (40mM Tris-
acetate and 2mM EDTA) buffer. The gel image was recorded with a UVIpro 
Gel Documentation system (Uvitec, Cambridge, UK). DNA fragments which 
were to be extracted from the gel were exposure to only 70% UV light in 
order to reduce DNA damage through generation of thymine dimers 
(Grundemann and Schomig, 1996). 
2.6.6 Extraction and purification of DNA 
DNA was purified from the gel using either QIAquick Gel Extraction Kit or 
MinElute Gel Extraction Kit (Qiagen, Crawley, West Sussex, UK) according to 
manufacture’s instructions. 
2.6.7 DNA precipitation 
DNA precipitation was performed when either the concentration of DNA in the 
sample was lower than desired, or when farther purification of the sample 
was required, i.e. purifying the DNA from restriction enzymes. Ethanol 
precipitation was carried out as follows: 1 volume of DNA was mixed with 0.1 
volumes of 3M sodium acetate pH 5.2 and 2.5 volumes of 100% ethanol. The 
mixture was stored at -20ºC for at least 2 h and then centrifuged using a 
bench top centrifuge at 13,000 rpm for 15 min at 4ºC. The pellet was washed 
using 70% ethanol and re-centrifuged at 13,000 rpm for 15 min at 4ºC. The 
supernatant was then discarded and the DNA pellet was left to air-dry for 15 
min. The DNA was re-suspended in the appropriate volume of 10mM Tris or 
sterile water. 
2.6.8 Polymerase Chain Reaction (PCR) for DNA 
For PCR amplification of genomic or plasmid DNA reactions were carried out 
using the Qiagen Taq DNA polymerase kit. PCR reactions were set up in a 
total volume of up to 50μl consisting of 1x PCR buffer (Qiagen), 1x Q solution 
(Qiagen), 2mM dNTP (each) (Qiagen), 0.5μM of each forward and reverse 
primers, 0.1μl/10μl of Taq polymerase (Qiagen) and sterile water. The PCR 
was carried out using a Gene Amp® PCR system 9700 (Applied Biosystems) 
using the the following PCR programme:  
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1) 950C   5 min 
2) 950C   30 seconds 
3) Tm    30 seconds 
4) 720C   1min/Kb 
Repeat steps 2-4 30 times 
5) 950C   30 seconds 
6) Tm    30 seconds 
7) 720C   10min/Kb 
8) 40C    hold 
(Tm- melting temperature) 
 
A List of the primers used for PCR can be found in Table 1  
 
Primer Sequence 5'-3' 
262FHBTG TCCGCAGCATTCGAAGATC 
1210RHBTG GCGTTATATCTGCTTTCAGTAACTGG 
BTG1HF AAAAAGCTTCCCCATGCATCCCTTCTACA 
BTG1HR AAAATCGATGCCCACCCAAAGCAAAAA 
BTG2HF AAAAAGCTTACTTCCCACCCGAGACCTCT 
BTGHR AAAATCGATTCACGGCAGCATGAGCAC 
F-1514PFOXO3aNHE CTAGCTAGCTCTCTCTCCTTCCTTAGAATTTTACTCG 
R-2968HPFOXO3aXHO CCGCTCGAGAGCAGCACAAAGTTATAGACACACG 
mMEF2F3F GTCTTTGGGCAAAAGTCAAAAATGCCCACG 
mMEF2F3R TTTGACTTTTGCCCAAAGACGTATCCTTTA 
mef2FO3a-2F GGATTTTCGGAAAAATATTTATGAACTAG 
mef2FO3a-2R AAATATTTTTCCGAAAATCCTTGTAAGTCAC 
hFO17FKPN GGCCGGTACCCCTAATTTTTCCTTTTTTCCCCTC 
HFO11845RH3 CCGGAAGCTTGAGTGGAAGCGCGAGCC 
mef2FO1-1F GGACAAGATAGCGAAAACCCTACTGTGCAT 
mef2FO1-1R GGGTTTTCGCTATCTTGTCCAAAAGGACAG 
mef2FO1-2F TATTCTTCCTGCGAAAGCAAAAGCATAACA 
mef2FO1-3R ACCTTTTGGCAAATGCTAGAAATGAGGAAC 
GL2 CTTTATGTTTTTGGCGTCTTCCA 
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Primer Sequence 5'-3' 
RV3 CTAGCAAAATAGGCTGTCCC 
M13F GTAAAACGACGGCCAGT 
M13R GGAAACAGCTATGACCATG 
BTG1ex2-R61 TACAACGGTAACCCCGATA 
Rev-Hy-F2200 AGGTCGCCAACATCTTCTTC 
Restriction sites are indicated in bold.  
Mutations in primer sequence for site-directed mutagenesis are underlined. 
Table 1: List of primers used for PCR amplification of DNA 
 
2.6.9 PCR for screening MCF-7 Tet-On/Off BTG1 cell colonies 
In order to screen MCF-7 Tet On/Off colonies for incorporation of the pTRE-
BTG1 plasmid a PCR was performed using the Advantage 2 Polymerase mix 
(Clontech, California, USA). The template for the PCR was prepared as 
follows: Cell pellets were boiled in 10µl of 5mM Tris pH 7.5 and 0.5mM EDTA 
for 6 min and then centrifuged using a bench top centrifuged at 6000 rpm for 
2 min at RT. 3µl of the supernatant were used as template for the PCR. The 
PCR was set out in a total volume of 50 µl consisting of 5µl buffer Ad2 PCR, 
1µl dNTPs (10mM each), 10µM Rev-Hy-F2200 primer, 10µM BTG1ex2-R61 
primer, 1µl Ad2 polymerase mix and 38µl sterile water. The empty vector 
(pTRE-hyg) was used as template for the negative control and the pTRE-
hBTG1 plasmid was as template for the positive control. The PCR was 
carried out using the following programme : 95ºC for 3 min, 40 cycles of : 
95ºC for 20 seconds, 60ºC for 30 seconds, 68ºC for 90 seconds and a final 
cycle: 95ºC for 30 seconds, 60ºC for 3 min, 68 ºC for 3 min.  
2.6.10 Plasmid constructs 
2.6.10.1 Plasmids used in this study  
Plasmids used to carry out the work presented in this thesis are listed in 
Table 2: 
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Plasmid  Reference/source 
pLPC-FoxO3a(wt) (Brunet et al., 1999; Fernandez de Mattos et 
al., 2004) 
pLPC-FoxO3a(A3) (Brunet et al., 1999; Fernandez de Mattos et 
al., 2004)  
pCDNA3-FOXO3a (Kwon et al., 2004) 
pCMV-FOXO3a(wt) Dr. Simon Arthur, MRC Unit, Dundee 
pCMV-FOXO3aS294A Dr. Simon Arthur, MRC Unit, Dundee 
pCMV-FOXO3aS425A Dr. Simon Arthur, MRC Unit, Dundee 
pCMV- FOXO3a S294A, S425A Dr. Ho Ka Kei, CRUK Labs, Imperial College  
pCMV-FOXO3aS294D, S425D Dr. Ho Ka Kei, CRUK Labs, Imperial College 
pGL3-FOXO3a(-1480/-25)(full-length-FL) This study 
pGL3-FOXO3a(-1349/-25) Dr. Ines Soeiro, CRUK Labs, Imperial College 
pGL3-FOXO3a(-1155/-25) Dr. Ines Soeiro, CRUK Labs, Imperial College 
pGL3-FOXO3a(-984/-25) Dr. Ines Soeiro, CRUK Labs, Imperial College 
pGL3-FOXO3a(-478/-25) Dr. Ines Soeiro, CRUK Labs, Imperial College 
pGL3-FOXO3a(FL)mut1(-921/-918) This study 
pGL3-FOXO3a(FL)mut2(-1072/-1069) This study 
pGL3-FOXO3a(FL)mut1+2                       
(-1072/-1069, -921/-918) This study 
pGL3-FOXO1(-1609/+230)(FL) This study 
pGL3-FOXO1(FL)mut1(-1444/-1441) This study 
pGL3-FOXO1(FL)mut2(-1368/-1365) This study 
pGL3-FOXO1(FL)mut3(-836/-833) This study 
pGL3-p27Kip1(-679/+1) (Lynch et al., 2005) 
pGL3-p21Cip1 (-2325/+8) (Koutsodontis et al., 2002; Lam et al., 1992) 
pGL3-cyclin D1(−1179/+162) (Leung et al., 2001) 
pGL3-Bim(-689/+1)(wt) (Essafi et al., 2005) 
pGL3-Bim(-689/+1)(mut -164/-170) (Essafi et al., 2005) 
pCDNA3-HA-JNKK2-JNK1 Dr. Axel Behrens (Zheng et al., 1999) 
pGL3-BTG1(-871/+47) This study 
pTRE-BTG1 This study 
pBABE-BTG1 (Bakker et al., 2004) 
Table 2: Plasmids used in this study 
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2.6.10.2  Plasmid construction  
Plasmids constructed for this study using Polymerase Chain Reaction (PCR) 
are listed in Table 3 and Table 4: 
 
Resulting plasmid Template used 
for PCR 
Primers used for PCR Product 
size 
pGL3-BTG1(-871/+47) human genomic 
DNA 
262FHBTG, 1210RHBTG 948bp 
pTRE-BTG1 human cDNA 
library 
BTG1HF, BTG1HR 583bp 
pGL3-FOXO3a(-1480/-25)  human genomic 
DNA 
F1514PFOXO3aNHE,  
R2968HPFOXO3aXHO 
1455bp 
pGL3-FOXO3a(FL)mut1             
(-921/-918) 
pGL3-
FOXO3a(FL) 
mMEF2F3F, GL2 
mMEF2F3R, RV3 
580bp 
950bp 
pGL3-FOXO3a(FL)mut2             
(-1072/-1069) 
pGL3-
FOXO3a(FL) 
mef2FO3a-2F, GL2 
mef2FO3a-2R, RV3 
430bp 
1100bp 
pGL3-FOXO3a(FL)mut1+2          
(-1072/-1069, -921/-918) 
pGL3-
FOXO3a(FL)mut1 
(-921/-918) 
mef2FO3a-2F, GL2 
mef2FO3a-2R, RV3 
430bp 
1100bp 
pGL3-FOXO1(-1609/+230)(FL) human genomic 
DNA 
hFO17FKPN, 
HFO11845RH3 
1839bp 
pGL3-FOXO1(FL)mut1               
(-1444/-1441) 
pGL3-FOXO1(FL) mef2FO1-1F , GL2 
mef2FO1-1R, RV3 
180bp 
1480bp 
pGL3-FOXO1(FL)mut2                
(-1368/-1365) 
pGL3-FOXO1(FL) mef2FO1-2F , GL2 
mef2FO1-2R, RV3 
260bp 
1400bp 
pGL3-FOXO1(FL)mut3                
(-836/-833) 
pGL3-FOXO1(FL) mef2FO1-3F, GL2 
mef2FO1-3R, RV3 
900bp 
760bp 
Table 3: PCR carried out to generate the plasmids 
 
 
Resulting plasmid Vector  Enzymes used for 
digestion and cloning 
pGL3-BTG1(-871/+47) pGL3   Bgl I, BamH I 
pTRE-BTG1 pTRE2hyg Cla I, Hind III 
pGL3-FOXO3a (-1480/-25) pGL3 Nhe I, Xho I 
pGL3-FOXO3a(FL)mut1(-921/-918) pGL3 Nhe I, Xho I 
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Resulting plasmid Vector  Enzymes used for 
digestion and cloning 
pGL3-FOXO3a(FL)mut2(-1072/-1069) pGL3 Nhe I, Xho I 
pGL3-FOXO3a(FL)mut1+2(-1072/-1069, -921/-918) pGL3 Nhe I, Xho I 
pGL3-FOXO1(-1609/+230) pGL3 Kpn I, Hind III 
pGL3-FOXO1(FL)mut1(-1444/-1441) pGL3 Kpn I, Hind III 
pGL3-FOXO1(FL)mut2(-1368/-1365) pGL3 Kpn I, Hind III 
pGL3-FOXO1(FL)mut3(-836/-833) pGL3 Kpn I, Hind III 
Table 4: Restriction digest and cloning of PCR products performed in order to generate the 
plasmids 
 
2.6.11 Screening for recombinant bacteria colonies 
2.6.11.1 Colony PCR 
A colony was picked from the agar plate using a 10μl pipette tip and placed in 
an eppendorf containing 10μl of sterile water. The samples were boiled for 10 
min and then spun down. 1μl of supernatant was used as template in a 20μl 
PCR reaction using vector specific forward and reverse sequencing primer to 
determine if an insert was present in the colony. 
2.6.11.2 Small scale plasmid preparation and restriction digest  
DNA was purified from the overnight culture using Miniprep Plasmid 
Purification Kit (Qiagen) according to manufacture’sinstructions. Restriction 
digests were designed to determine whether the plasmid contained the 
correct insert in the right orientation. 
2.6.11.3 DNA sequencing 
The DNA sequence of all plasmids was verified by DNA sequencing on a 
PerkinElmer 3700 automated DNA analyser in the DNA core laboratory using 
terminator cycle sequencing ready reaction kit (Applied Biosystems, 
Warrington, UK). 10μl of sequencing sample was prepared with 3.2 pmol 
sequencing primer and 200-500ng/3kb plasmid DNA or 30-90ng/1kb PCR 
product. The obtained chromatogram was analysed using either DNA strider 
(http://cellbiol.com/DNAStrider1_1_sit.bin) or Chromas 1.45 software 
(http://www.technelysium.com.au/chromas.html). 
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2.6.11.4 Large scale plasmid preparation  
Once DNA sequence was verified large scale preparation of the DNA sample 
was performed. Larger amount of DNA was isolated from 250 ml of overnight 
bacteria culture using Maxiprep Plasmid Purification Kit (Qiagen) according to 
the manufacture’s instructions. 
2.7 RNA manipulation 
2.7.1  Total RNA extraction 
Total RNA was isolated using the RNeasy Mini kit (Qiagen) according to 
manufacture’sinstructions without DNase treatment as the silica-membrane 
spin column removes DNA.  The concentrations of RNA preparations were 
determined by measuring the optical density of the samples at 260nm (OD260) 
using a BioRad spectrophotometer (Bio-rad Smart SpecTM3000 
Spectrophotometer).  
RNA concentration was calculated using the relationship: 
 
1 OD unit at 260nm = 40 µg/ml RNA 
2.7.2 Real Time quantitative-PCR (RT-qPCR) 
2.7.2.1 First strand cDNA synthesis 
Two-step reverse transcription PCR (RT-PCR) was used use to generate 
cDNA from RNA samples. . Depending on the RNA yield, 1-5 μg of total RNA 
was reverse transcribed to first strand cDNA using the Superscript III reverse 
transcriptase and oligo T primers (Invitrogen). 
2.7.2.2 Preparation of cDNA samples for RT-qPCR 
The resulting cDNA samples were used as template for RT-qPCR. In order to 
generate a standard, cDNA samples were pooled to a final concentration of 
1μg/μl and four 1:5 serial dilutions were performed. For experimental cDNA 
the samples were further diluted to a final concentration of 10ng/μl. 5μl of 
each cDNA (standard and experimental) was used as template for a 25μl RT-
qPCR.  
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2.7.2.3 Designing primers for RT-q PCR 
 Gene-specific primer pairs were designed using the ABI Primer Express 
software (Applied Biosystems). Primers with amplicon size 50-150bp 
spanning intron/exon boundary were selected whenever possible to avoid 
potential amplification of genomic DNA in cases were cDNA samples may be 
contaminated. Specificity of each primer was determined using NCBI BLAST 
module. Primer optimisation was performed as follows: Each primer set was 
optimised using the highest concentration of standard cDNA (final 
concentration of cDNA in the reaction was 40ng/μl) in order to determine the 
minimum concentration required for maximum yield (ΔRn) and minimum non-
specific amplification. Dilutions of 50-900nM of forward and reverse primers 
in different combinations were tested. The concentration that gave the lowest 
Ct value (10 -35) with standard DNA and highest Ct value (40) with water was 
selected for use in further experiments. Specificity of PCR product was 
confirmed by dissociation curve analysis. 
Primers used for Real Time PCR are listed in table 5 
2.7.2.4 Quantification of gene expression  
Real time PCR was performed using and Power SYBR® Green PCR Master 
Mix (Applied Biosystems Brackley, UK) and an ABI PRISM® 7700 Sequence 
Detection System (Applied Biosystems). All measurements were performed 
in triplicates. The PCR programme used was as follows: 50oC for 2 min, 95oC 
for 10 min and 40 cycles of: 95oC for 15 seconds followed by 60oC for 1 
minute. L19, a ribosomal housekeeping gene, was used as an internal control 
to normalize input RNA. The quantification of gene expression was analysed 
with Sequence detection software v1.7 using the relative standard curve 
method. Standard deviation of the normalised value was calculated using the 
following formula:  
SD= (m1/m2)x[(s1/m1)2+(s2/m2)2]0.5 
(m=mean, s=standard deviation, 1=sample, 2=endogenous gene L19 control) 
Efficiency of PCR was determined from the slope of standard curve:  
Eff = 10(-1/slope) -1 
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Ideal slope values are between -3.1 to -3.6. 
 
The list of primers use for RT-qPCR can be found in Table 5. 
Primer Sequence 5'-3' 
human FOXO1-sense  TGGACATGCTCAGCAGACATC 
human FOXO1-antisense TTGGGTCAGGCGGTTCA 
human FOXO3A-sense TCTACGAGTGGATGGTGCGTT 
human FOXO3A-antisense CGACTATGCAGTGACAGGTTGTG 
human L19-sense GCGGAAGGGTACAGCCAAT 
human L19-antisense GCAGCCGGCGCAAA 
human cyclin E1-sense GATGACCGGGTTTACCCAAA 
human cyclin E1-antisense GAGCCTCTGGATGGTGCAAT 
human cyclin D1-sense CTGGCCATGAACTACCTG 
human cyclin D1-antisense GCCTCTGGCATTTTGGAGA 
human p27-sense ACGGGAGCCCTAGCCTGGAGC 
human p27-antisense TGCCCTTCTCCACCTCTTGCC 
human p21-antisense AGGAACCTCTCATTCAACCGC 
human BTG1-sense AGACCTTCAGCCAGAGCCTG 
human BTG1-antisense GCGAATACAACGGTAACCCG 
Table 5: Primers used for RT-qPCR  
 
2.7.3 Statistical analysis of RT-qPCR and luciferase data 
A two-tailed unpaired homoscedastic student’s t-test was performed in order 
to statistically analyse the results of luciferase and RT-qPCR experiments. 
This test enables the comparison of two arrays of data to each other in order 
to determine whether the values in the arrays are statistically different. p<0.05 
and p<0.01, indicate that arrays are statistically different. While p<0.001 
indicates that the arrays are different and that this is of higher statistical 
significance.  
2.8 Protein analysis 
2.8.1 Preparation of total protein extracts 
For the lysis of adherent mammalian cells, cells were washed twice with ice 
cold 1 X PBS, scraped into 1ml of ice cold 1 X PBS and subsequently 
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transferred to a eppendorf tube. Alternatively, cells were washed once with 1 
X PBS and then trypsanized. The cells were then centrifuged at 700 xg at 4ºC 
for 5 min and the pellets were then immediately frozen at -80ºC until lysis was 
performed. Frozen pellets were lysed on ice for 15 min in 2 volumes of NP40 
lysis buffer (1% (v/v) Nonidet P-40, 100mM NaCl2, 20mM Tris-HCl (pH 7.4), 
10mM NaF, 1mM Sodium orthovanadate, 30mM β-glycerophosphate and 
protease inhibitors (‘Complete’ protease inhibitor mixture, as instructed by the 
manufacturer, Roche Applied Science). Cellular debris was spun down using 
a bench top centrifuge at 13000 rpm for 15 min at 4ºC. The lysate was 
transferred to a fresh tube and its protein concentration was assayed.  
2.8.2 Determination of protein concentration  
Protein concentrations were determined using the Bio-Rad Dc protein assay 
(Bio-Rad Laboratories), a protein assay based on the Lowry assay (Lowry et 
al., 1951). Working reagent A was made by adding 20µl of reagent S (Bio-
Rad) to each ml of reagent A (Bio-Rad) as instructed by the manufacturer. A 
standard curve was established by assaying 5 dilutions of a protein standard 
within the range of 0.2mg/ml to 1.5mg/ml protein. 100µl of reagent A+S was 
added to 2µl of each dilution and subsequently mixed with 800µl of reagent B 
(Bio-Rad). Absorbance was read at 750nm after 15 min and a standard curve 
was established. Absorbance at 750nm was then measured for each of the 
experimental samples and their concentrations were determined by 
multiplying the absorbance of the sample by the standard curve’s regression 
coefficient.  
2.8.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made by using a 30% (w/v) 
Acrylamide/Bis stock solution (containing a ratio of 29 acylamide: 1 NN’-
methylenebisacrylamide; Bio-Rad). As a polymerisation catalyst, 25% (w/v) 
ammonium persulphate (APS) and TEMED were used. For all percentages of 
resolving gels, a 5% (w/v) stacking gel was used. SDS-PAGE gels were 
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topped with 2cm of stacking gel (see Table 6). 
 
Ingredient 
  
Resolving gel Stacking gel  
 7% 10% 12.5% 5% 
30% Acrylamide 7.0 ml 10.0 ml 12.5 ml 1.67 ml 
1M Tris∗ 11.2 ml 11.2 ml 11.2 ml 1.25 ml 
10% SDS 0.3 ml 0.3 ml 0.3 ml 100 μl 
25% APS 100 μl 100 μl 100 μl 25 μl 
TEMED 40 μl 40 μl 40 μl 20 μl 
H2O 11.5ml 8 ml 6 ml 7 ml 
∗ The resolving gels were made using 1M Tris.HCl pH 8.8,whereas the stacking gels were 
made using 1M Tris.HCl pH 6.8 
Table 6: Proportions of the constituents of SDS-PAGE resolving and stacking gels 
 
For separation of the proteins, 20μg of each cell lysate was mixed with 1 
volume of 2 X SDS loading buffer (4% (w/v) SDS, 62.5mM Tris-HCl (pH 6.8), 
1% (v/v) Glycerol, 0.01% (w/v) Bromophenol blue, 100mg dithiothreitol (DTT)) 
and boiled at 100ºC for 5 min. Samples were then loaded in to the stacking 
gel and fractionated by electrophoresis on SDS-PAGE gels (7%, 10% or 
12.5%) for 2 h in running buffer (25mM Tris-base, 190mM Glycine, 0.1% 
(w/v) SDS) using a Mini-Protean III apparatus (Bio-Rad Laboratories, Hemel 
Hempstead, UK). Proteins were separated alongside broad-range pre-stained 
SDS-PAGE standards (Full-Range Rainbow Molecular Weight Markers, 
Amersham Biosciences).  
2.8.4 Western blotting of SDS-PAGE 
Following separation via SDS-PAGE, proteins were transferred to a 0.45μm 
Protran nitrocelluose membrane (Schleicher and Schuell) by electrophoretic 
transfer in a wet tank blotting system (Mini Trans-Blot Electrophoretic 
Transfer Cell, Bio-Rad Laborartories). The transfer was carried out in transfer 
buffer (25mM Tris, 190mM glycine and 20% (v/v) methanol) for 1-2 h at a 
constant current of 0.4A at RT. The nitrocellulose membrane was then 
blocked by incubating the membrane for 1 h at RT in either 5% (w/v) 
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skimmed milk powder (Marvel, Premier Brands) dissolved in Tris Buffered 
Saline-Tween (TBS-T) (20mM Tris-base, 136mM NaCl, adjusted to pH 7.6 
supplemented with 0.05% Tween) or in 5% (w/v) bovine serum albumin 
(BSA) in Tris buffered solution with 0.05% Tween-20 (TBST, pH 7.5). The 
filter was then incubated for 2 h at room temperature (or overnight at 4ºC) 
with the primary antibody (see table 7) diluted (according to 
manufacture’srecommendations) in 5% BSA-TBS-T. The filter was then 
washed five times (10 min each at room temperature) in TBS-T prior to a 30 
min incubation with horseradish peroxidase (HRP) conjugated secondary 
anti-mouse, anti-rabbit or anti-goat conjugates as appropriate (DAKO UK 
Ltd., Ely, UK). The membrane was then washed 5 more times, in TBS-T and 
visualized by enhanced chemiluminescence (Amersham Biosciences, UK). 
The membrane was then exposed to an auto-radiographic film (Amersham 
Biosciences, UK) for times varying from 10 seconds to 1 h.  
 
Primary Antibody Supplier 
Akt  (9272) Cell Signalling Technologies 
Phospho-Akt (Ser473) (9271S) Cell Signalling Technologies 
β-actin (I-19)  Santa Cruz Biotechnology Inc 
BTG1 (N-20) Santa Cruz Biotechnology Inc. 
β-tubulin (H-235) Santa Cruz Biotechnology Inc. 
CDK2 (M2) Santa Cruz Biotechnology Inc. 
CDK4 (C-22) Santa Cruz Biotechnology Inc. 
Cyclin A (C-19) Santa Cruz Biotechnology Inc. 
Cyclin B1 (H-33) Santa Cruz Biotechnology Inc. 
Cyclin D1 (HD11) Santa Cruz Biotechnology Inc. 
Cyclin E1 (2925) Cell Signalling Technologies 
ERK1/2 (9102) Cell Signalling Technologies  
Phospho-ERK Thr202/Tyr204 (9101) Cell Signalling Technologies  
Flag M2 (F1804) Sigma-Aldrich 
FoxO1 (9462) Cell Signalling Technologies 
FoxO3a (06-951) Upstate 
FoxO3a (N-16) Santa Cruz Biotechnology Inc. 
Phospho-FoxO3a Thr32 (06-953) Upstate 
 90
Primary Antibody Supplier 
JNK1/2 (9252) Cell Signalling Technologies 
Phospho-JNKThr183/Tyr185 (9251) Cell Signalling Technologies 
Phospho-JNK(Ser294) Dr.Simon Arthur, MRC Unit, Dundee 
Phospho-JNK(Ser425) Dr.Simon Arthur, MRC Unit, Dundee 
p21Cip1 (C24420) Transduction Laboratories 
p27Kip1 (C-19) Santa Cruz Biotechnology Inc. 
p38 (9212) Cell Signalling Technologies 
Phospho-p38Thr180/Tyr182(9211) Cell Signalling Technologies 
Plk (F-8) Santa Cruz Biotechnology Inc. 
pRB (554136) BD Pharmingen 
Phospho-pRB Ser807/811(9308) Cell Signalling Technologies 
Phospho-pRB Thr821 44-582G Biosource 
Table 7: Antibodies used for western blotting 
 
2.8.5 Subcellular fractionation 
Cells were pelleted and re-suspended in 100μl of cytosolic extraction buffer 
(10mM HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 2mM DTT, and 
complete protease inhibitor cocktail) for 15 min on ice. NP-40 was added to 
final concentration of 1% (v/v) and vortexed for 10 seconds in order to lyse 
the cells. The lysate was centrifuged at 13,000 rpm using a bench top 
centrifuge at 4ºC. The supernatant fraction, which contains the cytosolic 
proteins, was snap frozen on dry ice. The pellet (containing nucleic extract), 
was then washed in 50μl of cytosolic buffer in order to reduce contamination 
of the nucleic fraction with cytosolic proteins and re-suspended  and vortexed 
in 30μl of high salt nuclear extraction buffer (10mM HEPES, 10mM KCl, 
0.1mM EDTA, 0.1mM EGTA, 2mM DTT, 400mM NaCl, 1% NP40, and 
protease inhibitors). Afterwards, the lysate was rotated in the cold room for 15 
min and centrifuged at 13,000 rpm for 5 min. The supernatant obtained was 
the nuclear extract. The protein concentration was determined as described 
in section 2.8.2. After calculating the yield of the protein extraction a ratio of 
3:1 cytosolic to nucleic was determined. Therefore, 6µg of nuclear extract and 
20µg of cytoslic extract were loaded on to a SDS-PAGE gel. 
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2.8.6 Immunoprecipitation 
Cells were grown in 60mm plates to 60-70% confluency in the appropriate 
medium and growth conditions. Cells were washed twice with ice cold PBS 
and then scraped in a total volume of 50-100μl of NP40 lysis buffer (1% 
NP40, 150 mM NaCl, 20 mM Tris pH7.4, 10 mM sodium molibdate, 1 mM 
sodium orthovanadate, 1 mM sodium fluoride and Complete Mini protease 
inhibitors (Roche)) and incubated on ice  for 15 min. The lysate was then 
centrifuged at 13,000 rpm, using a bench-top centrifuge, at 4°C for 15 min 
and the supernatant was transferred to a fresh centrifuge tube. 100μl of 50% 
slurry of protein A or G beads (Sigma) in PBS was then added to the cell 
lysate and incubated at 4°C for 1 h on an orbital shaker in order to pre-clear 
the lysate. The beads were then removed by centrifugation and the pre-
cleared lysate was assayed for protein concentration. The cell lysate was 
diluted to approximately 1mg/ml in PBS and the recommended volume of 
immunoprecipitating antibody was added to 1ml of lysate. 15μl of the 50% 
protein A or G sepharose slurry was added to the cell lysate/antibody mix and 
the samples were incubated at 4°C for 3-4 h on an orbital shaker. Following 
incubation, the beads were collected by pulse centrifugations (5 seconds at 
13,000 rpm) and washed 5 times with 500μl of lysis buffer. The beads were 
then re-suspended in 20μl of loading buffer and boiled for 5 min to dissociate 
the immuno-complexes from the beads. The beads were separated from the 
loading buffer by centrifugation and the supernatant was either frozen or 
loaded onto SDS-PAGE gels for protein fractionation. 
2.8.7 Presentation of western blot data 
For all western blot experiments presented in this thesis, I obtained results 
demonstrating a similar trend at least twice. Furthermore, results for some 
western blotting experiments are further confirmed by immunofluorescence 
experiments (chapter 5, figures 5.1, 5.2) or by sets of similar experiments 
performed in different cell lines (chapter 3), or experiments based on the 
results attained in the previous experiment (time-course following dose-
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response- chapter 3, figures 3.1, 3.2). Experiments showing similar trends to 
the blots presented in the result chapters (chapters 3-5) can be found in the 
supplementary data (chapter 7). 
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3 Regulation of FoxO Genes in Breast Epithelial and 
Endometrial Cells 
3.1 Background and objectives  
Breast cancer is one of the most common cancers affecting women in the 
Western world and occurs following the accumulation of mutations which 
either increase the rate of cellular proliferation or reduce the levels of 
apoptosis. Mutations often arise following exposure to extracellular stimuli. 
Signal transduction pathways are responsible for transmitting extracellular 
signals to transcription factors, leading to changes in the expression of 
downstream target genes. These changes can often lead to the initiation of 
processes such as cell growth, differentiation and apoptosis. The PI3K 
pathway signal transduction pathway is highly conserved in eukaryotes and is 
activated following stimulation with growth factors, such as insulin and IGF-1. 
Activation of the PI3K signalling pathway results in activation and 
phosphorylation of Akt (Vanhaesebroeck et al., 1999; Vanhaesebroeck et al., 
1997). A key downstream target of Akt is the FoxO family of transcription 
factors (Engstrom et al., 2003; Guo et al., 1999). Following activation of the 
PI3K pathway, FoxO is phosphorylated by Akt, leading to the export of FoxO 
from the nucleus, thereby inhibiting FoxO dependent transcription of target 
genes (Biggs et al., 1999). Two important target genes of FoxO are the 
cyclin-dependent kinase inhibitor (CKI) p27Kip1, which inhibits cell cycle 
progression and Bim, a BH3-only protein implicated in the induction of 
apoptosis. Therefore, activation of the PI3K pathway leads to the inactivation 
of FoxO and thereby FoxO induced growth arrest and apoptosis (Dijkers et 
al., 2000a; Dijkers et al., 2000b; Gilley et al., 2003; Medema et al., 2000). 
Generally, breast cancer is treatmed with surgery and endocrine therapy. 
Endocrine therapy targets the ERα, by two different mechanisms, one by 
blocking the binding of estrogen to ERα by the use of drugs such as 
tamoxifen the second by blocking the estrogen synthesis process by the use 
of drugs such as aromatase inhibitors which reduce the concentration of 
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estrogen (Ali and Coombes, 2002). Although endocrine therapy is usually 
effective in treating estrogen dependent tumours, some tumours are resistant 
or develop resistance to these therapies and therefore other therapies such 
taxanes are used (Ali and Coombes, 2002;Blagosklonny and Fojo, 1999; 
Symmans, 2001). Although taxanes primarily target the microtubules, 
understanding of the signal transduction pathways involved in taxanes-
induction apoptosis in breast cancer is incomplete. However, it has recently 
been shown that accumulation of H2O2 is an required for paclitaxel-induced 
cell death (Alexandre et al., 2006). Sunters and colleagues (Sunters et al., 
2003) were able to demonstrate an induction in FoxO3a expression following 
paclitaxel treatment, which resulted in an increase in cell death following an 
increase in the expression of Bim. The molecular basis for the up-regulation 
in FoxO3a protein expression in response to paclitaxel has not yet been 
elucidated. In addition the role of oxidative stress in the regulation of FoxO 
transcription and protein expression has not been determined. Therefore, I 
decided to examine the regulation of FoxO1 and FoxO3a transcription in 
cancer cell lines, in particular in response to paclitaxel treatment and 
oxidative stress.  
 
3.2 Results  
3.2.1 FoxO1 and FoxO3a expression levels  
3.2.1.1  Paclitaxel treatment induces the expression of foxO3a in MCF-7 cells 
Previous research conducted in Prof. Lam’s lab (Sunters et al., 2003), has 
shown that paclitaxel treatment can up-regulate FoxO3a expression in MCF-7 
cells. Initially, I decided to confirm these results and to determine the 
minimum concentration of paclitaxel required for up-regulation of FoxO3a 
expression in MCF-7 cells. This would enable me to determine at which 
concentrations I should treat the cells in order to examine the ability of 
paclitaxel treatment to induce transcription of FoxO genes. Hence, I 
conducted a dose response experiment, in which MCF-7 cells were treated 
 95
with increasing concentration of paclitaxel (0-0.5µM) for 16 h and examined 
the level of FoxO1 and FoxO3a expression by western blot (Fig 3.1).  
Western blot analysis (Fig 3.1) revealed that a basal level of FoxO3a 
expression is detectable in MCF-7 cells, as cells treated with the DMSO 
vehicle (0nM paclitaxel) expressed FoxO3a. An induction in FoxO3a 
expression was noticeable at the low concentrations of paclitaxel (e.g. 1nM 
paclitaxel). However, a dramatic increase and peak in FoxO3a expression 
levels were observed at the higher concentration of 10nM paclitaxel. FoxO3a 
expression remained high at 20nM paclitaxel, but an evident decrease in the 
level of FoxO3a expression was noted at 50nM paclitaxel. When cells were 
treated with higher doses of paclitaxel (200 and 500nM) the level of FoxO3a 
expression was low and comparable to non-treated cells, indicating that at 
these high doses, paclitaxel is ineffective in inducing the expression of 
FoxO3a. Examination of FoxO1 expression levels in MCF-7 cells revealed 
that the level of FoxO1 expression in MCF-7 cells was below western blot 
detection level.  
I also decided to examine the activity of the up-stream regulator of FoxO3a, 
Akt, by monitoring the phosphorylation level of this protein at Ser-473, a site 
implicated in the activation of Akt (Alessi et al., 1996). In MCF-7 cells that 
were not treated with paclitaxel, I expected to see high levels of phospho-Akt 
expression, as these cells were grown at their optimum conditions in medium 
supplement with 10% foetal calf serum. However, although the level of 
expression of phosphorylated Akt was detectable, it appeared that only a 
small proportion of the total Akt expressed in the cells was phosphorylated at 
this site. Nonetheless, this still indicates that the Akt signalling pathway was 
activated in the non-treated MCF-7 cells and that therefore FoxO3a should be 
inactive and cytoplasmic. Interestingly, although the levels of total Akt 
expression remained constant throughout the dose response experiment, 
changes in presence of phospho-Akt were detected; at lower concentrations 
of paclitaxel a gradual increase in phospho-Akt was observed. The up-
regulation in phospho-Akt reached its peak at the concentration of 50nM 
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paclitaxel, which is a higher dose than that required for FoxO3a expression to 
peak. In fact, at the concentration of 50nM paclitaxel there was a clear 
decrease in the expression of FoxO3a in comparison to the lower doses. A 
decrease in the level of phosphorylated Akt was observed at 100nM and 
200nM paclitaxel, with a significant decrease in the presence of phospho-Akt 
at 500nM paclitaxel, the highest dose of paclitaxel examined. 
Apart from the PI3K/Akt signalling pathway, other signalling pathways may 
also affect paclitaxel sensitivity. The mitogen-activated protein kinases 
(MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2) has been shown 
to be activated following paclitaxel treatment (Bacus et al., 2001) and an 
increase in paclitaxel related cellular toxicity has also been noted following 
ERK1/2 inhibition (MacKeigan et al., 2000). In addition, p38 MAPK and JNK 
signalling pathways have also been shown to be activated following paclitaxel 
treatment (Amato et al., 1998; Lee et al., 1998; Seidman et al., 2001). 
Therefore, I decided to examine the activity of these signalling pathways in 
response to the different concentrations of paclitaxel. The expression levels 
of total JNK were not affected by the use of increasing concentrations of 
paclitaxel; although a small stable increase in the expression of JNK1 (faster 
migrating band) was observed at 1-100nM paclitaxel, which decreased when 
cells were treated with higher concentrations of paclitaxel (e.g. 200nM and 
500nM). However, significant changes in the phosphorylation levels of JNK at 
Thr183/Tyr185 were detected. A prompt increase in phospho-JNK was 
observed at 1nM paclitaxel, the lowest concentration of paclitaxel examined. 
Phosphorylation levels remained high at the concentrations of 10nM and 
20nM paclitaxel. A slight decrease in phospho-JNK was observed at 50nM 
paclitaxel, but a rapid decrease in the expression levels of phospho-JNK was 
observed at 100nM paclitaxel, with virtually undetectable levels of 
phosphorylated JNK at the higher concentrations of paclitaxel (e.g. 200nM 
and 500nM).  
Comparable levels of p38 expression were observed when cells were treated 
with 1-200nM paclitaxel. The level of p38 expression at these concentrations 
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was higher than that observed for non-treated MCF-7 cells. Nonetheless, 
dramatic changes in the phosphorylation status of p38 (Thr180/Tyr182) were 
observed. While in untreated cells phospho-p38 levels were undetectable, an 
increase in phosphorylated p38 was observed at 1nM paclitaxel and the 
phospho-p38 levels continued to gradually increase, peaking at 50nM 
paclitaxel. At concentrations of 100-500nM, a decrease in phosphorylated 
p38 was observed with no detectable phospho-p38 at 500nM paclitaxel. 
The expression levels of total ERK1/2 remained predominantly the same 
throughout the doses of paclitaxel tested, although an increase in 
phosphorylated ERK1/2 (Thr202/Tyr204) was observed at 1nM paclitaxel. 
The levels of phospho-ERK1/2 then remained stable and a decrease was 
only observed at the higher concentrations of 200nM and 500nM paclitaxel.  
Analysis of the data obtained in this experiment led to the decision to treat the 
MCF-7 breast cancer cell line with 10nM paclitaxel. Cells treated at this 
concentration for a period of 16 h showed a high level of FoxO3a expression 
that correlated with activation of the JNK, p38 and ERK signalling pathways, 
which have all been implicated in cellular response to paclitaxel.   
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Figure 3-1: Dose-dependent effect of 16 h paclitaxel treatment of MCF-7 cells.  
MCF-7 cells were treated with 0-500nM paclitaxel for 16 h. Following treatment cell lysates 
were prepared, separated on SDS-polyacrylamide gels and immunoblotted with specific 
antibodies. The expression levels of FoxO3a were analysed using a total FoxO3a antibody. 
The activity of FoxO3a upstream regulator, Akt and the activity of stress induced signalling 
pathways, JNK, p38 and ERK were analysed using specific phospho (indicated by a P in-
front of the protein name) and total antibodies. β-actin was used as a loading control. An 
experiment showing the same trend can be found in the supplementary data, figure 7.1. 
0 1 10 20 50 100 200 500 nM
P-Akt 
Akt
FoxO3a
JNK
P-JNK
p38
P-p38
ERK
P-ERK
ß-actin
FoxO1
 99
I next decided to monitor, by western blot, the effect of treatment of MCF-7 
cells with 10nM paclitaxel on FoxO3a expression during the course of 72 h. 
As shown in figure 3.2, treatment of MCF-7 cells with 10nM paclitaxel caused 
an up-regulation in total FoxO3a expression. A noticeable increase in 
FoxO3a expression occurred at 8 h, with the expression peaking 48 h after 
treatment begun. At 72 h a decrease in FoxO3a expression was observed, 
although the level of expression of FoxO3a remained elevated in comparison 
to the non-treated cells (0 h). Examination of the phosphorylation status of 
FoxO3a on the Akt phosphorylation site, Thr32 revealed an increase in 
phosphorylation of FoxO3a commencing at 8 h post treatment and ending 48 
h post treatment. Interestingly, this pattern of expression was similar to that of 
total FoxO3a, which may suggest that the increase observed in total FoxO3a 
consisted also of Akt phosphorylated FoxO3a, which is inactive. Therefore, I 
decided to also examine the levels of total Akt and active Akt (phosphorylated 
on Ser-473), in order to determine if indeed an increase in Akt activity 
occurred following paclitaxel treatment. Western blot analysis revealed that 
levels of total Akt remained stable throughout the experiment. A decrease in 
phosphorylated Akt levels was observed at the beginning of the time-course 
and phospho-Akt expression was at its lowest at 4 h post treatment. An 
increase in phospho-Akt levels was observed at 8 h and phospho-Akt 
expression levels continued to rise up to 48 h post treatment, while a 
decrease in phospho-Akt levels was observed at 72 h. Hence, the expression 
patterns of phospho-Akt and phospho-FoxO3a were similar, indicating that 
the induction in Akt activity which occurred during the course of paclitaxel 
treatment resulted in the phosphorylation of FoxO3a on Thr32. However, it is 
important to note that the levels of phospho-FoxO3a only measure inactive 
FoxO3a and therefore have no bearing on active FoxO3a. As regards to the 
changes observed in the expression pattern of phospho-Akt, the decrease in 
phosphorylated Akt was expected as paclitaxel induces apoptosis, therefore 
inhibiting the pro-survival PI3K/Akt signalling pathway. However, the increase 
in phosphorylated Akt, observed at later time-points, was less expected. This 
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increase could be due to prolonged exposure of the cells to oxidative stress 
caused by paclitaxel treatment, as it has recently been shown that Akt can 
also be activated by oxidative stress through a PI3K dependent pathway 
(Lahair et al., 2006; Nishino et al., 2002). In order to determine if the increase 
observed in total FoxO3a expression consisted of transcriptionally active 
FoxO3a, I also examined the expression pattern of p27Kip1, a downstream 
target of FoxO3a. Up-regulation of p27Kip1 expression was observed, with 
expression levels peaking at 24 and 48 h after treatment. This correlated with 
the increase in the expression of total FoxO3a suggesting that the increase in 
p27Kip1 expression is due to activation of FoxO3a.  
Examination of the activation status of MAPKs signalling pathways 
demonstrated a biphasic expression pattern for phosphorylated JNK. An 
increase in phospho-JNK was observed as early as 2 h post treatment with 
levels remaining elevated 4 h post treatment. The second peak in phospho-
JNK expression was observed at 24-48 h after treatment began. No 
significant changes in the phosphorylation status of p38 were observed. A 
decrease in phospho-ERK1/2 was observed 8 h after treatment commenced, 
with an increase in phospho-ERK1/2 at 16 h and 24 h. Despite this increase 
in phosphorylation of ERK1/2, levels of phospho-ERK1/2 remained similar to 
those observed for the non-treated MCF-7 cells.  
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Figure 3-2: The effect of paclitaxel treatment on the expression of FoxO, p27Kip1 and 
the activity of MAPK signalling in MCF-7 cells.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO1, total FoxO3a, Akt-phosphorylated (Thr32) FoxO3a, Akt, phospho-Akt 
(Ser473),p27Kip, as well as the levels and activity of the, JNK, p38 and ERK signalling 
pathways were analysed by western blot using specific phospho (indicated by a P in-front of 
the protein name) and total antibodies. β-actin was used as a loading control. The arrow 
indicates the location of the FoxO3a-specific band. An experiment showing the same trend 
can be found in the supplementary data, figure7.2.  
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3.2.1.2 Paclitaxel treatment induces the expression of FoxO3a in BT-474 
cells 
 In order to confirm that the results obtained for MCF-7 cells were not cell-
type specific and in an effort to find a breast cancer cell line that expressed 
detectable levels of FoxO1, I also decided to test the response of another ER 
positive breast cancer cell line, BT-474, to treatment with 10nM paclitaxel 
during the course of 48 h. I decided to treat BT-474 cells with paclitaxel for 48 
h because the results obtained for the MCF-7 cell line showed that treatment 
with paclitaxel for longer than 48 h did not generate a further increase in 
FoxO3a expression. This could be attributed to paclitaxel induced cell death 
occurring at later time-points.  
Western blot analysis (Fig 3.3) of BT-474 cells treated with 10nM paclitaxel 
showed no detectable expression of FoxO1; however, an increase in the 
expression of FoxO3a occurred. Expression levels of FoxO3a were at their 
highest 16 to 24 h after treatment begun. An increase in phospho (Thr32)-
FoxO3a was also detected at the same time-points, interestingly, no 
significant changes in the levels of phospho(Ser473)-Akt were noted, 
Therefore, in order to confirm that FoxO3a activity was up-regulated in the 
cells, I examined the expression pattern of the downstream transcriptional 
target, p27Kip1. The expression of p27Kip1 was induced 24-48 h after treatment 
with paclitaxel. This induction occurred after the initial increase in FoxO3a 
expression, suggesting that FoxO3a is responsible for the induction observed 
in p27Kip1 and that FoxO3a was transcriptionally active in BT-474 cells 
following paclitaxel treatment.  
When examining the expression pattern of phospho(Thr183/Tyr185)-JNK, a 
biphasic expression pattern emerged, similar to the one noted for MCF-7 
cells. A peak in phospho-JNK expression was observed at 8 h followed by a 
decrease in expression at 16 h and another peak in expression at 24-48 h 
post treatment. A small increase in phospho(Thr180/Tyr182)-p38 levels were 
observed at 8 h and the levels remained elevated for up to 24 h after 
treatment.  
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Figure 3-3: The effect of paclitaxel treatment on the expression of FoxO, p27Kip1 and 
the activity of JNK and p38 in BT-474 cells.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO3a, Akt-phosphorylated (Thr32) FoxO3a, Akt, phospho-Akt (Ser473), p27Kip and the 
levles and activity of stress induced signalling pathways, JNK and p38 were analysed by 
western blot using specific phospho (indicated by a P in-front of the protein name) and total 
antibodies. β-actin was used as a loading control. An experiment showing the same trend 
can be found in the supplementary data, figure 7.3.  
FoxO3a
0 8 16 24 48 h
P-FoxO3a
Akt
P-Akt
P-JNK
JNK
ß-actin
P-p38
p38
FoxO1
p27Kip1
 104
3.2.1.3 The HEC-1-B endometrial cell line expresses FoxO1 
In attempt to find a cell line that expressed FoxO1, I decided to examine the 
response of the endometrial cell lines, HEC-1-B and Ishikawa, to paclitaxel 
treatment. Endometrioid endometrial cancer cells are estrogen-regulated and 
account for 80% of all endometrial carcinomas (Kong et al., 1997). FoxO1 
expression in endometrium increases during the secretory phase of the cycle, 
in contrast FoxO3a expression is repressed in differentiating endometrium 
(Labied et al., 2006). It has also been demonstrated that FoxO1 plays a role 
in endometrial homeostasis by regulating cyclic differentiation and apoptosis 
of stromal cells in response to changes in ovarian progesterone levels 
(Kajihara et al., 2006). FoxO1 is also abundantly expressed in endometrial 
epithelial cells, however its function in this cellular compartment remains to 
be confirmed. Hence, these cell lines were good candidates for expression of 
FoxO1. Indeed as seen in figure 3.4, HEC-1-B cells expressed FoxO1. In 
addition, these cells showed up-regulation in FoxO1 expression following 
10nM paclitaxel treatment. An increase in FoxO1 expression was observed 8 
h post treatment, which remained stable throughout the 48 h time-course. 
The expression levels of FoxO1 in the Ishikawa endometrial cell line were 
detectable but low; however no induction in the expression of FoxO1 
following paclitaxel treatment was observed. 
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Figure 3-4: Differential expression of FoxO1 in HEC-1-B and Ishikawa cells following 
paclitaxel treatment.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The 
expression of total FoxO1 was analysed using a specific total FoxO1 antibody. β-actin was 
used as a loading control. An independent experiment showing the same trend can be found 
in the supplementary data, figure 7.4. 
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3.2.1.4 Paclitaxel treatment causes an increase in ROS (Reactive Oxygen 
Species) in MCF-7 cells 
In order to test the hypothesis that oxidative stress may play a role in FoxO3a 
up-regulation in response to paclitaxel treatment, I decided to initially validate 
the observation that paclitaxel treatment can cause oxidative stress 
(Alexandre et al., 2006). Oxidative stress is exerted by the intracellular 
accumulation of ROS. Therefore, I conducted an assay, with the help of Dr. 
Stephen Myatt (CRUK Labs, Imperial College, London) to monitor the levels 
of ROS produced by MCF-7 cells following paclitaxel treatment. MCF-7 cells 
were treated with paclitaxel for 24 and 48 h and the level of oxidative stress 
was compared to that of MCF-7 cells treated with pure H2O2. Levels of 
oxidative stress were measured by monitoring oxidation of probes, which 
generate an increase in fluorescence and was analysed by flow cytometry. 
The results of the flow cytometer analysis are presented in figure 3.5A.  
MCF-7 cells were treated with 10nM paclitaxel for 24 and 48 h. The levels of 
florescence at each time-point were compared to that of the negative control, 
non-treated MCF-7 cells and to that of a positive control, MCF-7 cells treated 
with 200µM H2O2 for 15 min, which is supposed to cause an increase in the 
generation of ROS in the cells. As shown in figure 3.5A, cells treated with 
H2O2 for 15 min generated more florescence than non-treated MCF-7 cells, 
the fluorescence mean was larger and the median value was greater for the 
H2O2 treated cells in comparison to the non-treated MCF-7 cells. The values 
obtained for MCF-7 cells treated with paclitaxel for 24 h and 48 h were 
similar. The fluorescence median values for paclitaxel treated cells resided 
between that of non-treated cells to that of H2O2 treated cells. This indicates 
that cells treated with paclitaxel for 24 or 48 h generate ROS, but to a lesser 
extent than cells treated with pure H2O2 for 15 min. I next set out to examine 
whether the prolonged treatment was the cause of the lower levels of ROS 
observed. Therefore, I decided to treat MCF-7 cells with H2O2 for 24-48 h. As 
can be seen in figure 3.5B, cells treated with H2O2 for 24 and 48 h did 
generate ROS, but to a lesser extent than cells treated for only 15 min, in fact 
 107
the levels obtained were similar to those acquired with paclitaxel treatment. 
This suggests that paclitaxel treatment causes oxidative stress in a similar 
manner to H2O2; however examination of the levels of ROS following 15 min 
of paclitaxel treatment is required in order to validate this statement.  
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Figure 3-5: Treatment of MCF-7 cells with paclitaxel and hydrogen peroxide causes 
increase in oxidative stress.  
5µM of reduced fluorescein and calcein in DMSO were added to cells treated with paclitaxel 
(A) or with H2O2 (B) 1 h before measuring oxidation of these probes, which was detected by 
monitoring the increase in fluorescence with a flow cytometer. Mean and median 
measurements of fluorescence were taken. Cells treated with H2O2 for 15 min served as 
positive control and untreated cells served as negative control (A, B). 
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3.2.1.5 H2O2 treatment of MCF-7 cells results in up-regulation of the 
expression of FoxO3a 
Since the previous experiment had demonstrated that paclitaxel treatment 
does indeed cause oxidative stress, I next decided to examine whether 
treatment with H2O2 during the course of 48 h rendered the same effect as 
paclitaxel treatment. To that end, MCF-7 cells were treated with 200µM H2O2 
for 48 h and western blot analysis was performed (Fig 3.6).  
Western blot analysis revealed an increase in FoxO3a expression that was 
prominent at 24 h post treatment. Levels of phosphorylated FoxO3a were 
high in the non-treated cells (0 h), which is probably because these MCF-7 
cells were not exposed to oxidative stress and therefore should be 
proliferating and growing, due to the abundance of growth factors in the 
medium. An anticipated decrease in Akt-phosphorylation of FoxO3a was 
observed at 4 h post H2O2 treatment. An increase in phospho-FoxO3a was 
noted at later time-points, which correlated with the up-regulation in total 
FoxO3a expression. Hence, I also examined the expression pattern of active 
Akt (phospho-Akt). Interestingly, elevated levels of phospho-Akt expression 
were observed almost throughout the entire time-course. This could be due to 
oxidative stress because, as mentioned above, Akt can also be activated by 
oxidative stress (Lahair et al., 2006; Nishino et al., 2002). Therefore, it is 
plausible that the increase in phosphorylation of FoxO3a could be attributed 
to the up-regulation in Akt activity. Thus, in order to find out if FoxO3a is 
activated in the cells, I examined the expression pattern of the FoxO3a 
transcriptional downstream target, p27Kip1. A clear increase in total p27Kip1 
was observed, indicating that FoxO3a activity was up-regulated in cells 
treated with H2O2.  
Examination of the activation status of the MAPKs signalling pathways 
ERK1/2, JNK and p38, which have been implicated in cellular response to 
paclitaxel treatment (Amato et al., 1998; Lei and Davis, 2003; MacKeigan et 
al., 2000; Seidman et al., 2001) revealed that the levels of activated ERK 
(phospho-ERK) remained stable, while a slight decrease in phospho-p38 
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levels was detected 16 h after treatment. Similar to the results obtained with 
paclitaxel treatment, a biphasic expression pattern was detected for phospho-
JNK. The first peak in expression was observed at 4-8 h after paclitaxel 
treatment and the second increase was observed at 24-48 h post treatment. 
Hence, both paclitaxel and H2O2 treatment induce the expression of FoxO3a 
and activate the JNK signal transduction pathway in a similar manner.  
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Figure 3-6: Oxidative stress generated by H2O2 causes an increase in FoxO3a 
expression in MCF-7 cells. 
Whole cell lysates were prepared at indicated time-points following treatment with 200µM 
H2O2, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO3a, Akt- phosphorylated (Thr32) FoxO3a, Akt, phosho-Akt (Ser473), p27Kip and the 
levels and activity of the signalling pathways, JNK, p38 and ERK were analysed by western 
blot using specific phospho (indicated by al P in-front of the protein name) and total 
antibodies. β-actin was used as a loading control. The arrow indicates the location on the 
FoxO3a-specific band. An experiment showing the same trend can be found in the 
supplementary data, figure 7.5.  
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3.2.2 FoxO mRNA expression levels  
3.2.2.1 The effect of paclitaxel and H2O2 treatment on FoxO mRNA 
expression levels in MCF-7 cells  
Since it was established that both paclitaxel treatment and H2O2 treatment 
can induce FoxO expression at protein level, I examined if this up-regulation 
could also be detected at the transcriptional, mRNA level.  
To this end, I treated MCF-7 cells with either 10nM paclitaxel or 200µM H2O2 
for 48 h and determined the mRNA levels of FoxO1 and FoxO3a using Real 
Time quantitative PCR (RT-qPCR). The results were normalised with 
ribosomal protein L19 mRNA. When examining the levels of FoxO1 mRNA 
expression (Fig 3.7A, B) following either paclitaxel or H2O2 treatment, no 
significant changes in normalised FoxO1 mRNA levels were observed. This 
could be due to the fact that FoxO1 expression levels in MCF-7 cells are low, 
as indicated by western blotting experiment (figure 3.1). Results obtained for 
FoxO3a mRNA expression following paclitaxel treatment (Fig 3.7C) 
demonstrated a relatively stable level of mRNA expression with an increase 
in expression at 16 h. When monitoring FoxO3a mRNA expression following 
H2O2 treatment (Fig 3.7D), an increase in FoxO3a mRNA expression was 
noticeable at 8 h and at 48 h, with expression levels remaining relatively 
stable at other time-points examined. The increase at 16 h in FoxO3a mRNA 
expression following paclitaxel treatment is not likely to solely account for the 
up-regulation observed in FoxO3a protein expression, as levels of protein 
expression increased at 8 h and remained high for up to 48 h post treatment. 
When comparing FoxO3a protein expression to FoxO3a mRNA expression 
after H2O2 treatment, an increase in both protein and mRNA expression were 
observed 8 h after treatment commenced, however while protein expression 
levels peaked at 24 h, mRNA levels returned to a level similar to that of the 
non-treated MCF-7 cells (with the exception of elevated mRNA levels at 48 
h). Hence, although the increase in FoxO3a mRNA expression may have 
contributed to the up-regulation in FoxO3a protein expression levels, it seems 
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unlikely that it explains the high levels of expression observed at later time-
points, unless FoxO3a has a very long half-life. 
 
Figure 3-7: The effect of oxidative stress on the levels of FoxO3a and FoxO1 mRNA in 
MCF-7 cells.  
MCF-7 cells were treated with either 10nM paclitaxel (A and C) or 200µM H2O2 (B and D) for 
indicated times. Total RNA was extracted and analysed for the expression levels of either 
FoxO1 mRNA (A and B) or FoxO3a mRNA (C and D) using RT-qPCR and normalised to the 
level of L19 mRNA expression. All data shown represent the average of three independent 
experiments, and the error bars show the standard deviation, * p<0.05 in comparison to 0 h.  
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3.2.2.2 FoxO3a mRNA expression levels increase in BT-474 cells following 
paclitaxel treatment 
Due to the fact that the RT-qPCR results obtained using MCF-7 did not match 
the protein expression pattern observed in these cells; I decided to also 
examine the levels of FoxO3a mRNA expression in BT-474 cells, as these 
cells also showed an increase in FoxO3a protein expression following 
paclitaxel treatment. BT-474 cells were treated for duration of 48 h with 10nM 
paclitaxel and levels of FoxO3a mRNA expression were assessed. As seen 
in figure 3.8A, an increase in FoxO3a mRNA was clearly observed, from as 
early as 8 h post treatment with expression levels peaking at 16 h. This 
expression pattern is similar to that of the FoxO3a protein (Fig 3.3) with the 
exception that FoxO3a protein levels remained elevated at 24 and 48 h, while 
mRNA levels returned to levels similar to those observed for non-treated 
cells. Hence, the increase in FoxO3a mRNA expression detected following 
paclitaxel treatment could account for the increase observed in FoxO3a 
protein expression. 
In light of these results, I decided to examine the levels of p27Kip1 mRNA 
expression in BT-474 cells after paclitaxel treatment (Fig 3.8B). A gradual 
increase in p27Kip1 mRNA was observed 8-24 h after paclitaxel treatment, 
with mRNA expression levels peaking 24 h post treatment and then 
plummeting sharply at 48 h. This decrease could be due to the cell 
“switching-off” transcription of the p27Kip1 target gene. The peak observed in 
p27Kip1 protein expression occurred 24-48 h following paclitaxel treatment 
(Fig 3.3). Therefore, it is possible that the up-regulation in p27Kip1 protein 
expression occurred due to the increase in p27Kip1 transcription. Since the 
increase in p27Kip1 mRNA and protein expression occurred after the increase 
in FoxO3a mRNA and protein expression, it is likely that the up-regulation in 
FoxO3a was responsible for the increase in p27Kip1 expression in BT-474 
cells. 
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Figure 3-8: FoxO3a and p27Kip1 mRNA expression levels of are up-regulated in BT-474 
cells following paclitaxel treatment.  
BT-474 cells were treated with 10nM paclitaxel (A and B) for indicated times. Total RNA was 
extracted and analysed for the expression levels of either FoxO3a mRNA (A) or p27Kip1 
mRNA (B) using RT-qPCR and normalised to the level of L19 mRNA expression. All data 
shown represent the average of three independent experiments, and the error bars show the 
standard deviation, *p<0.05 in comparison to 0 h (non-treated cells). 
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3.2.2.3 FoxO1 mRNA expression levels are up-regulated in the HEC-1-B cell 
line following paclitaxel treatment 
Since the levels of FoxO1 mRNA expression did not change following 
paclitaxel treatment in MCF-7 cells and previously, when using the HEC-1-B 
cell line, an increase in FoxO1 protein expression was observed (Fig 3.4); I 
decided to treat the endometrial cancer cell lines, HEC-1-B and Ishikawa with 
paclitaxel and monitor the levels of FoxO1 mRNA. 
RT-qPCR analysis of the expression pattern of FoxO1 mRNA in the Ishikawa 
cell line (Fig 3.9A) showed no significant up-regulation in FoxO1 mRNA 
expression following paclitaxel treatment. The levels of FoxO1 mRNA 
remained constant throughout the course of treatment. When examining the 
expression levels of FoxO1 mRNA in HEC-1-B cells following paclitaxel 
treatment (Fig 3.9B), an increase in FoxO1 mRNA expression was evident. 
The levels of FoxO1 mRNA expression peaked 48 h post treatment. These 
results are in agreement with the data obtained for FoxO1 protein expression 
in the Ishikawa and HEC-1-B cell lines (Fig 3.4). Thus, following paclitaxel 
treatment, up-regulation in the transcription and protein expression of FoxO1 
occurs in the HEC-1-B but not the Ishikawa cell line. 
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Figure 3-9: FoxO1 mRNA levels are induced in response to paclitaxel treatment in 
HEC-1-B but not Ishikawa cells.  
Total RNA was extracted from Ishikawa cells (A) or HEC-1-B cells (B) and analysed for the 
expression level of FoxO1 mRNA using RT-qPCR and normalised to the level of L19 mRNA 
expression. All data shown represent the average of three independent experiments, and the 
error bars show the standard deviation. *p<0.05 **p<0.001 when compared to non-treated 
cells (0 h).  
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3.2.2.4 Oxidative stress increases the stability of FoxO3a in MCF-7 cells 
In previous experiments, I was able to detect an increase in FoxO3a protein 
expression in MCF-7 cells treated with the oxidative stress inducing agents, 
paclitaxel and H2O2 (figures 3.1, 3.2, 3.6). However, I was unable to detect an 
increase in FoxO3a mRNA expression levels (figure 3.7C, D) of a magnitude 
that could account for the accumulation in FoxO3a protein observed in these 
cells. Hence, I decided to examine the stability of the FoxO3a protein in MCF-
7 cells and determine if exposure of the cells to oxidative stress increased 
FoxO3a protein stability.  
To that end, I pre-treated MCF-7 cells with either paclitaxel or H2O2 for 16 h 
and then conducted an 8 h time-course with cycloheximide, an inhibitor of 
protein biosynthesis. I then compared the rate of FoxO3a protein degradation 
in the pre-treated cells to that of MCF-7 cells that were not pre-treated with 
oxidative stress inducing agents. In order to confirm that the cycloheximide 
was indeed inhibiting the activity of the 60S ribosome, I also monitored the 
rate of degradation of the Id1 protein, which is known to have a short half-life 
(Bounpheng et al., 1999; Trausch-Azar et al., 2004). β-actin was used as an 
equal loading control, as this protein is relatively stable. The results obtained 
(figures 3.10, 3.11) demonstrate that both paclitaxel (Fig 3.10) and H2O2 (Fig 
3.11) treatment affect the stability of FoxO3a. While a decrease in FoxO3a 
expression was noted for the non-pre-treated MCF-7 cells (Fig 3.10, 3.11 
right panel), no prominent changes in FoxO3a levels were observed for cells 
pre-treated with either paclitaxel or H2O2 (Fig 3.10, 3.11 respectively, left 
panel). Hence, it is possible that exposure of MCF-7 cells to oxidative stress 
increases FoxO3a protein stability. The mechanism behind the increase in 
protein stability remains to be determined.  
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Figure 3-10: Paclitaxel treatment increases the stability of FoxO3a in MCF-7 cells.  
Cells were either pre-treated with 10nM paclitaxel for 16 h (left panel), or not pre-treated 
(right panel). After which cells were treated with 10μg/ml cycloheximide for up to 8 h. whole 
cell lysates were prepared at indicated time-points, then separated on SDS-polyacrylamide 
gels and immunoblotted. The expression levels of FoxO3a and Id1, a protein with a short 
half-life were analysed by western blot. β-actin, a protein with a longer half life, was used as 
a loading control. An independent experiment showing the same trend can be found in the 
supplementary data, figure 7.6.  
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Figure 3-11: Oxidative stress increases the stability of FoxO3a in MCF-7 cells.  
Cells were either pre-treated with 200µM H2O2 (left panel) or not pre-treated (right panel) for 
16 h. Following which, cells were treated with 10μg/ml cycloheximide for up to 8 h. whole cell 
lysates were prepared at indicated time-points, and then separated on SDS-polyacrylamide 
gels and immunoblotted. The levels of FoxO3a and Id1, a protein with a short half-life were 
analysed by western blot. β-actin, a protein with a longer half life, was used as a loading 
control. An independent experiment showing the same trend can be fond in the 
supplementary data, figure 7.7. 
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3.2.3 FoxO regulation at the DNA promoter level 
3.2.3.1 Both paclitaxel H2O2 induce FoxO promoter activity in MCF-7 cells  
In an attempt to further understand how FoxO genes are transcriptionally 
regulated, I decided to clone the regulatory 5’ region of the human FoxO1 (-
1609/+230) and FoxO3a (-1480/-25) genes into the luciferase reporter vector, 
pGL3 (Fig 3.12 top panel). The 5’ regulatory regions were identified using 
http://genome.ucsc.edu/ and http://www.ensembl.org/index.html. Briefly, the 
5’ up-stream region of the genes was found by identifying the genomic 
coordinates of the genes and requesting the DNA sequence 5’ the 
transcription start site of the genes. In order to examine the activity level of 
these promoters in response to oxidative stress, I transiently transfected 
MCF-7 cells with either the FoxO1 or FoxO3a promoter/luciferase constructs 
and pRLTK Renilla (serves to normalise transfection activity/efficiency) after 
which, I treated the transfected cells with either paclitaxel or H2O2.  
FoxO1 promoter activity in MCF-7 cells (figure 3.12A, B) was up-regulated 
following both paclitaxel (Fig 3.12A) and H2O2 treatment (Fig 3.12B). Relative 
luciferase activity values obtained for paclitaxel treatment were higher 
(approximately double) than those obtained using H2O2. Both treatments 
induced the promoter activity 16 h after treatment. Paclitaxel treatment 
generated a gradual effect on FoxO1 promoter activity, with values peaking at 
48 h post treatment. H2O2 treatment caused an increase in FoxO1 promoter 
activity at 16 h and its levels remained constant and high throughout the 48 h 
time-course.  
FoxO3a promoter activity levels following paclitaxel (Fig 3.12C) and H2O2 
treatment (Fig 3.12D) yielded similar results to those obtained with cells 
transiently transfected with the FoxO1 promoter construct. Both treatments 
caused an up-regulation in the promoter activity of FoxO3a that was noted 16 
h post treatment. Like the FoxO1 promoter, FoxO3a promoter activity 
increased gradually following paclitaxel, but not H2O2 treatment, and reached 
levels twice as high as those observed for H2O2 treatment. Thus, paclitaxel 
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treatment is more effective than H2O2 in inducing FoxO promoter activity, 
suggesting that the mechanism by which paclitaxel induces FoxO promoter 
activity may be due to additional factors and not just oxidative stress. 
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Figure 3-12: The activity levels of FoxO3a and FoxO1 promoters in response to 
oxidative stress in MCF-7 cells.  
Top panel, schematic representation of the human FoxO1 and FoxO3a promoters cloned into 
the pGL3 luciferase reporter construct. MCF7 cells were transiently transfected with 20ng of 
either the FoxO1 promoter construct (C and D) or the FoxO3a promoter construct (A and B) 
together with either 10nM paclitaxel (A and C) or 200µM H2O2 (B and D) for times indicated. 
The time-course was performed in a manner that enabled all samples to be harvested 
together, 72 h after transfection. Samples were assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.001 when 
compared to non-treated cells (0 h). 
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3.2.3.2 Paclitaxel treatment increases the FoxO1promoter activity in HEC-1-B 
cells  
Since an increase in both FoxO1 protein and mRNA expression was noted in 
the HEC-1-B cell line following paclitaxel treatment, I decided to examine 
FoxO1 promoter activity in this cell line in response to paclitaxel treatment.  
To this end, I transiently transfected HEC-1-B and Ishikawa cells with the 
FoxO1 promoter construct and then treated the cells with paclitaxel (figure 
3.13). The basal level of FoxO1 promoter activity was lower in the Ishikawa 
cells in comparison to the HEC-1-B cells. While an increase in FoxO1 
promoter activity was observed in the HEC-1-B cell line, no significant change 
was detected for the Ishikawa cell line. The promoter activity level was at its 
highest 24-48 h post-paclitaxel-treatment. Therefore, FoxO1 is expressed in 
the HEC-1-B cell line in a detectable manner at protein (Fig 3.4) mRNA (Fig 
3.8) and promoter (Fig 3.13) levels. This expression can be induced at 
transcriptional (promoter, mRNA) and translational (protein) levels following 
paclitaxel treatment. 
 125
 
Figure 3-13: The activity of the FoxO1 promoter is up-regulated in response to 
paclitaxel treatment in HEC-1-B but not Ishikawa cells.  
16 h after HEC-1-B and Ishikawa cells were transiently transfected with 20ng of the human 
FoxO1 promoter construct, cells were treated with 10nM paclitaxel for indicated times. Time 
course was performed in a manner that enabled all samples to be harvested together, 72 h 
after transfection and samples were assayed for luciferase activity. Values are corrected for 
co-transfected renilla activity. All data shown represent the average of three independent 
experiments, and the error bars show the standard deviation. *p<0.001 in comparison to non-
treated HEC-1-B cells (0 h). 
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3.2.3.3 Analysis of the activity levels of FoxO3a promoter truncation 
constructs 
In order to map region/s in the FoxO3a promoter important for up-regulation 
of FoxO3a transcription, truncated forms of the original FoxO3a promoter 
construct were generated (by Dr. Ines Soerio, CRUK Labs, Imperial College, 
London). These constructs were transiently transfected into cells and their 
activity levels were compared to that of the full-length construct. The FoxO3a 
promoter construct and the truncated forms are illustrated in figure 3.14A. 
The FoxO3a full-length and truncated promoter constructs were transiently 
transfected into MCF-7 cells and their activity levels were normalised to that 
of co-transfected renilla (Fig 3.14B). The full-length FoxO3a promoter 
construct (-1480/-25) yielded the highest activity level, while the second 
largest construct (-1349/-25) was less active. Interestingly, both the -1155/-25 
and the -984/-25 FoxO3a promoter constructs exhibited very low basal 
activity levels, while an even shorter form of the FoxO3a promoter (-478/-25) 
was more active. These results indicate that regulation of FoxO3a at the gene 
level is complex. The low levels of activity observed for the -1155/-25 and -
984/-25 constructs could be due to the binding of a transcriptional repressor 
to a region between -478 to -1155bp upstream to the FoxO3a transcription 
start site. This effect was masked when using the longer construct (-1349/-
25) owing to binding of a transcriptional activator to a region between -1155 
to -1349bp upstream to the FoxO3a transcription start site. This hypothesis 
remains to be validated. 
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 Figure 3-14: The activity levels of FoxO3a promoter truncation constructs in MCF-7 
cells.  
(A), Schematic representation of the human full length FoxO3a promoter construct and the 
derived truncated constructs cloned into the pGL3 luciferase reporter construct. (B), MCF-7 
cells were transiently transfected with 20ng of either of the FoxO3a promoter constructs. 
Cells were harvested 24 h after transfection and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. 
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3.2.3.4 Mapping a region in the FoxO3a promoter responsive to paclitaxel 
treatment in MCF-7 cells  
Previously, I was able to demonstrate that paclitaxel treatment up-regulates 
FoxO3a transcription at promoter level (Fig 3.12C). Examination of the basal 
activity levels of the truncated FoxO3a promoter constructs suggested the 
existence of regions in the FoxO3a promoter that negatively regulate 
transcription, while other regions generally have a positive effect on FoxO3a 
transcription (Fig 3.14B). Therefore, I next examined whether the up-
regulation in FoxO3a transcription following paclitaxel treatment could be 
attributed to a specific region or regions within the FoxO3a promoter.  
To this end, I transiently transfected MCF-7 cells with either the full length or 
one of the truncated FoxO3a promoter constructs (illustrated in Fig 3.14A) 
and treated the transfected cells with paclitaxel for 24 h. Normalised 
luciferase activity values are presented in figure 3.15A. As previously noted 
(Fig 3.12C), the full-length FoxO3a promoter construct (-1480/-25) was 
responsive to paclitaxel treatment and its activity levels increased following 
this treatment. The truncated FoxO3a promoter construct (-1349/-25) showed 
no change in FoxO3a promoter activity following paclitaxel treatment. This 
suggests that the region between -1349bp to -1480bp upstream to FoxO3a 
transcription start site is responsible for the increase in FoxO3a promoter 
activity observed for the full-length promoter construct. As observed before 
(3.14B), the basal promoter activity levels of the -1155/-25 and -984/-25 
FoxO3a promoter constructs was very low and although these constructs 
showed an increase in activity levels following paclitaxel treatment, the values 
obtained were still very low (practically indetectable in comparision to the 
other constructs) and might be due to an experimental error rather than true 
up-regulation in activity following paclitaxel treatment. The activity level of the 
shortest truncated FoxO3a promoter construct tested (-478/-25) increased 
following paclitaxel treatment, indicating that the region between -478bp to -
25bp upstream to the transcription start site, is positively regulated by 
paclitaxel treatment. A schematic representation of the results obtained can 
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be found in figure 3.15B. Areas within the promoter coloured in black 
represent regions in the promoter which are positively regulated by paclitaxel 
treatment. 
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Figure 3-15: The activity of the FoxO3a promoter truncation constructs in response to 
paclitaxel treatment in MCF-7 cells.  
(A), MCF-7 cells were transiently transfected with 20ng of either of the FoxO3a promoter 
construct. Cells were treated with 10nM paclitaxel 16 h after transfection and were harvested 
24 h following initiation of treatment and assayed for luciferase activity. Values are corrected 
for co-transfected renilla activity. All data shown represent the average of three independent 
experiments, and the error bars show the standard deviation. (B), Schematic representation 
of the full-length FoxO3a promoter construct, regions responsive to paclitaxel are indicated in 
black. *p<0.001 in comparison to cells transfected with the same construct but not treated 
with paclitaxel. 
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3.2.3.5 Mapping a region in the FoxO3a promoter responsive to paclitaxel 
treatment in BT-474 cells 
In order to confirm the results obtained in the previous experiment, which 
indicated that two regions in the FoxO3a promoter construct are responsive 
to paclitaxel treatment (Fig 3.15), I decided to conduct a similar experiment 
using the BT-474 breast cancer cell line. Other experiments using this cell 
line showed that the FoxO3a protein expression is up-regulated following 
paclitaxel treatment (Fig 3.3) and that this up-regulation can also be observed 
at the mRNA level (Fig 3.8A). Hence, BT-474 cells were transiently 
transfected with either the full-length or the truncated forms of the FoxO3a 
promoter construct (illustrated in Fig 3.16A) and then treated with paclitaxel 
for up to 48 h. The results obtained for all five constructs are presented in 
Figure 3.16C, while the activity levels for untreated transfected cells are 
presented in figure 3.16B. 
When examining the normalised promoter activity level of these constructs (0 
h, Fig 3.16B), a similar pattern to that obtained using MCF-7 cells emerged. 
Using these cells, the -1155/-25 and -984/-25 constructs exhibited low levels 
of FoxO3a promoter activity. Furthermore, similar to the results acquired with 
the transfected MCF-7 cells, the activity levels of the full-length construct (-
1480/-25) and the -478/-25 construct were up-regulated following paclitaxel 
treatment, while the -1349/-25 promoter construct was not responsive to 
paclitaxel treatment. A schematic representation of the regions responsive to 
paclitaxel treatment can be found in figure 3.16D.  
 
In conclusion, the results attained from transfecting the BT-474 cell line with 
the FoxO3a promoter constructs supports the data acquired from the 
experiment conducted using MCF-7 cells. Taken together, these experiments 
suggest that the FoxO3a promoter contains two separate regions that are 
responsive to paclitaxel treatment and up-regulate the promoter activity 
following paclitaxel treatment. 
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Figure 3-16: The activity levels of the truncated FoxO3a promoter constructs in 
response to paclitaxel treatment in BT-474 cells.  
(A), schematic representation of the human full length FoxO3a promoter construct and the 
derived truncated constructs cloned into the pGL3 luciferase reporter construct. (B, C), BT-
474 cells were transiently transfected with 20ng of either of the FoxO3a promoter construct. 
(C) Cells were treated with 10nM paclitaxel 16 h after transfection and were harvested at 
time-points indicated, up to 48 h following initiation of treatment and assayed for luciferase 
activity. Values are corrected for co-transfected renilla activity. All data shown represent the 
average of three independent experiments, and the error bars show the standard deviation. 
*p<0.001 in comparison to cells transfected with the same construct but not treated with 
paclitaxel (0 h). (D), Schematic representation of the human full-length FoxO3a promoter 
construct, regions responsive to paclitaxel are indicated in black.  
A)
B)
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
C)
-1349
luc-1480/-25
-478
-1480/-25 luc
-1349
-984
-1155
-478
Relative luciferase activity
D)
FoxO3a promoter constructs
0
10
20
30
40
50
60
-1480/-25 -1349/-25 -1155/-25 -984/-25 -478/-25
0 h
8 h
16 h
24 h
48 h
0 5 10 15 20
-478/-25
-984/-25
-1155/-25
-1349/-25
-1480/-25
*
*
*
*
 133
3.2.3.6 The role of putative MEF2 DNA consensus binding sites in the 
regulation of FoxO3a promote activity 
In order to further investigate the regulation of FoxO3a transcription at 
promoter level, I decided to map the transcription factor DNA consensus 
binding sites located in the promoter, using the Transcription Element Search 
System (TESS) (www.cbil.upenn.edu/tess) website. 
Analysis of the FoxO3a promoter sequence revealed the presence of two 
putative myocyte enhancer factor 2 (MEF2) DNA consensus binding sites (-
1072 and -922 upstream to FoxO3a transcription start site). Studies have 
shown that the MEF2 family of transcription factors play an important role in 
linking calcium-dependent signalling pathways to genes which play key roles 
in cell division, differentiation and death (McKinsey et al., 2002). Four 
vertebrate MEF2 genes have been identified, MEF2A, -B, -C and -D, which 
are expressed in distinct, but overlapping, patterns during embryogenesis, 
and in adult tissues. MEF2 proteins have a MADS domain in their nearly 
identical N-terminal. This domain mediates dimerization and binding to the 
DNA sequence CTA(A/T)4TAG/A. An adjacent MEF2-specific domain 
influences DNA-binding affinity and interactions with cofactors. The C-
terminal regions of MEF2 proteins are necessary for activation of 
transcription. Like other MADS domain proteins, MEF2 protein interact with 
an array of transcriptional cofactors to control specific sets of downstream 
target genes. The p38 and ERK pathways have been shown to increase 
MEF2 activity. The PI3K signalling pathway has also been implicated in the 
regulation of MEF2 (Tamir and Bengal, 2000; Xu and Wu, 2000). Activated 
forms of PI3K and its downstream effector, Akt, have been shown to increase 
MEF2-dependent transcription (Xu and Wu, 2000). Therefore, both MEF2 
and FoxO are regulated by the PI3K/Akt signalling pathway. The p38 MAPK 
signalling pathway has been implicated in cellular response to paclitaxel 
treatment (Seidman et al., 2001). Taken together these data may indicate a 
possible link between MEF2 and FoxO, in particular in response to paclitaxel 
treatment.  
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A schematic illustration of the FoxO3a promoter constructs and the relative 
location of the MEF2 DNA consensus binding can be found in figure 3.17A. 
Results presented in figure 3.17B, show the relative basal activity levels of 
the truncated FoxO3a promoter constructs in reference to the location of 
MEF2 DNA consensus binding sites. This data was previously presented in 
figure 3.14B, with the exception of the locations of the MEF2 DNA consensus 
binding sites in each of the constructs. Analysis of the data presented in 
figure 3.17B divulged that the MEF2 DNA consensus binding sites are 
located in a region of the FoxO3a promoter which displayed low levels of 
basal promoter activity (the -1155/-25 and the -984/-25 truncated constructs). 
Therefore, it is possible that MEF2 binding represses FoxO3a promoter 
activity. However, in the context of the longer promoter constructs (-1349/-25 
and -1480/-25) an activator of FoxO3a transcription binds to the promoter, 
therefore masking the negative effect of MEF2 on FoxO3a transcription. In 
order to further examine the role of MEF2 in the regulation of FoxO3a 
transcription experiments were conducted to determine whether exogenous 
expression of MEF2 affects FoxO3a promoter activity levels and if exogenous 
expression of MEF2 increases FoxO3a promoter activity in response to 
paclitaxel treatment.  
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Figure 3-17: FoxO3a promoter constructs and activity levels with reference to the 
location of MEF2 DNA consensus binding sites.  
(A), Schematic representation of the location of MEF2 DNA consensus binding sites in the 
full-length FoxO3a promoter construct and the derived truncated constructs cloned into the 
pGL3 luciferase reporter construct (as before). (B), Relative activity of the truncated FoxO3a 
promoter/reporter constructs in reference to the location of MEF2 DNA consensus binding 
sites. All data shown represent the average of three independent experiments, and the error 
bars show the standard deviation The grey oval shape represents MEF2 DNA consensus 
binding site.  
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3.2.3.7 Over-expression of MEF2 increases the activity of the FoxO3a 
promoter in MCF-7 cells 
At first, I set out to examine the effect of MEF2 over-expression on the activity 
of the wt FoxO3a promoter construct. To that end, I cloned the MEF2A and 
the MEF2B cDNA (acquired from RZPD Deutsches Ressourcenzentrum für 
Genomforschung GmbH) into the pCDNA3 expression vector. MCF-7 cells 
were transiently co-transfected with the FoxO3a (wt) promoter construct and 
increasing amounts of either the MEF2A or the MEF2B expression plasmid 
(method explained in 2.1.6.2) and the activity levels of the FoxO3a promoter 
were monitored (Fig 3.18).  
Both MEF2A and MEF2B were found to be able to induce FoxO3a promoter 
activity. This induction in FoxO3a promoter activity occurred even when 
relatively low amounts of MEF2 were co-transfected, indicating that the 
FoxO3a promoter may be highly sensitive to changes in MEF2 cellular 
concentrations.  
 137
 
Figure 3-18: The effect of MEF2 expression on the activity of the FoxO3a promoter in 
MCF-7 cells.  
MCF-7 cells were transiently co- transfected with 20ng of the FoxO3a promoter construct and 
increasing amounts of MEF2A or MEF2B. Cells were harvested 24 h after transfection and 
assayed for luciferase activity. Values are corrected for co-transfected renilla activity. All data 
shown represent the average of three independent experiments, and the error bars show the 
standard deviation. p<0.01 in comparison to cells transfected with 0ng MEF2. 
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3.2.3.8 Co-transfection of MEF2A can further increase FoxO3a promoter 
activity following paclitaxel treatment 
In order to further analyse the role of MEF2 in the regulation of FoxO3a 
transcription, the FoxO3a promoter construct was either transiently 
transfected or transiently co-transfected with 10ng MEF2A into MCF-7 cells 
(Fig 3.19) following the transfection some of the cells were also treated with 
10nM paclitaxel. As previously observed (Fig 3.18), co-transfection of MEF2A 
resulted in an increase in FoxO3a promoter activity. An increase in FoxO3a 
promoter activity was also observed for cells which were transfected with the 
FoxO3a promoter construct alone, and then treated with paclitaxel. 
Nonetheless, a further increase in FoxO3a promoter activity was noted for 
cells which were co-transfected with MEF2A and then treated with paclitaxel, 
indicating that exogenous expression of MEF2 can augment the activity of the 
FoxO3a promoter in response to paclitaxel. Hence, it seems that over-
expression of MEF2 may serve as a mean to induce the activity of the 
FoxO3a promoter, in particular in response to paclitaxel, which suggests that 
the MEF2 consensus binding sites identified in the FoxO3a promoter may 
facilitate the up-regulation observed. Analysis of FoxO3a promoter activity in 
cell in which MEF2 has been knockdown, with and without paclitaxel 
treatment, may help clarify the role of MEF2 in the regulation of FoxO3a 
promoter activity.  
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Figure 3-19: Co-transfection of MEF-2 increases FoxO3a promoter activity in paclitaxel 
treated MCF-7 cells.  
MCF-7 cells were either transiently transfected with 20ng of the FoxO3a promoter construct 
or transiently co-transfected with 20ng of the FoxO3a promoter construct and 10ng MEF2A. 
16 h post-transfection the cells were either not-treated or treated with 10nM paclitaxel 16 h 
for duration of 24 h. Cells were then harvested and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.01 when 
compared to non treated (NT) cells transfected with just the FoxO3a promoter construct.  
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3.2.3.9 Over-expression of MEF2A induces FoxO1 promoter activity 
In light of the results obtained from studying the role of MEF2 in regulating 
FoxO3a promoter (Fig 3.17-Fig 3.19), I analysed the FoxO1 promoter 
sequence using TESS (www.cbil.upenn.edu/tess) and found three putative 
MEF2 DNA consensus binding sites within the region cloned into the pGL3 
vector (-1690/+230). In order to examine the role of MEF2 in the regulation of 
FoxO1 promoter activity, I conducted a similar experiment to the one 
performed using the FoxO3a promoter construct (figure 3.19). The FoxO1 
promoter construct was either transiently transfected or transiently co-
transfected with 10ng MEF2A into MCF-7 cells. Following the transfection 
some of the cells were also treated with 10nM paclitaxel. As shown in figure 
3.20 co-transfection of MEF2A resulted in an increase in FoxO1 promoter 
activity. As expected, an increase in FoxO1 promoter activity also occurred in 
cells which were transfected with the FoxO1 promoter and treated with 
paclitaxel. Furthermore, an additional increase in FoxO1 promoter activity 
was noted for cells which were co-transfected with MEF2A and then treated 
with paclitaxel, indicating that exogenous expression of MEF2 can further 
enhance the activity of the FoxO1 promoter in response to paclitaxel. 
Therefore, it seems that over-expression of MEF2 may serve as a 
mechanism to induce FoxO1 promoter, in particular in response to paclitaxel 
treatment. In order to further study the role of the MEF2A DNA consensus 
binding sites found in the FoxO1 promoter sequence, I mutated each one of 
the MEF2 DNA consensus binding sites within the FoxO1 promoter construct. 
A schematic representation of the constructs generated can be found in 
figure 3.21A. Following which, MCF-7 cells were transiently co-transfected 
with either the wild-type or one of the mutated FoxO1 promoter constructs 
(Fig 3.21 B). 
As shown in figure 3.21B, there were differences in the basal promoter 
activity level of the four promoter constructs. The wild-type FoxO1 promoter 
construct exhibited high levels of basal promoter activity which were 
comparable to that of the FoxO1mut3 construct. The FoxO1mut1 and 
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FoxO1mut2 constructs exhibited lower levels of promoter activity. These 
results suggest that mutating two of the three MEF2 DNA consensus binding 
sites (-1447 and -1370) identified in the FoxO1 promoter sequence may lead 
to a decrease in FoxO1 promoter activity. Therefore, these sites might be 
involved in positively regulating FoxO1 transcription. In order to confirm that 
these sites positively regulate FoxO1 transcription, by the binding of MEF2 to 
the promoter, a chromatin immunoprecipitation experiment need to be carried 
out. Analysis of FoxO1 promoter activity, with and without paclitaxel 
treatment, in cells in which MEF2 is knocked down, will help determine 
whether MEF2 plays a role in up-regulating FoxO1 promoter activity in 
response to paclitaxel.  
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Figure 3-20:. Co-transfection of MEF-2 increases FoxO1 promoter activity in the in 
paclitaxel treated MCF-7 cells.  
MCF-7 cells were either transiently transfected with 20ng of the FoxO1 promoter construct or 
transiently co-transfected with 20ng of the FoxO1 promoter construct and 10ng MEF2A. 16 h 
post-transfection the cells were either not-treated or treated with 10nM paclitaxel 16 h for 
duration of 24 h. Cells were then harvested and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.01 when 
compared to non treated (NT) cells transfected with just the FoxO1 promoter construct.  
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Figure 3-21: The effect of mutating MEF2 DNA consensus binding sites on the activity 
of the FoxO1 promoter in MCF-7 cells.  
(A), schematic representation of the human full-length wtFoxO1 promoter construct (top) and 
the derived constructs which are mutated in one of the three MEF2 DNA consensus binding 
sites. The grey oval shape represents MEF2 DNA consensus binding sites, the X symbol 
within the grey oval shape indicates a point mutation in the MEF2 DNA consensus binding 
site. (B) MCF-7 cells were transiently transfected with 20ng of the FoxO1 promoter construct 
shown in (A) and were harvested and assayed for luciferase activity 36 h post-transfection. 
Values are corrected for co-transfected renilla activity. All data shown represent the average 
of three independent experiments, and the error bars show the standard deviation. *p<0.05 
when compared to cells transfected with the wtFoxO1 promoter construct (-1690/+230). 
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3.3 Discussion 
The FoxO family of transcription factors have been have anti-proliferative and 
pro-apoptotic functions (Brunet et al., 1999; Dijkers et al., 2000a; Dijkers et 
al., 2000b; Medema et al., 2000; Nakamura et al., 2000; Stahl et al., 2002; 
Tran et al., 2002) and their activity is negatively regulated by the PI3K/Akt 
signalling pathway (Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999; 
Rena et al., 1999; Tang et al., 1999). FoxO transcription factors have been 
suggested to play an important role in preventing tumourigenesis (Yang et al., 
2005a). Hence, the FoxO family of transcription factors has been the focus of 
many recent studies in hope to better understand their function and 
regulation. Although progress has been made as regards to the post-
translational regulation of FoxO proteins, little is known about the 
transcriptional regulation of these proteins.  
Paclitaxel is used to treat breast cancer but the means by which paclitaxel 
promotes apoptosis has not been fully determined (Gelmon, 1994; Luck and 
Roche, 2002). Previously, it has been shown that in MCF-7 cells the levels of 
FoxO3a protein expression and its downstream pro-apoptotic transcriptional 
target, Bim, increase treatment with paclitaxel (Sunters et al., 2003). In this 
study, I was able to show that indeed paclitaxel treatment caused up-
regulation in the expression of FoxO3a and downstream target p27Kip1, in two 
ER positive breast cancer cell lines, MCF-7 and BT-474 (Fig 3.2, 3.3); 
strengthening the hypothesis that FoxO3a mediates paclitaxel induced cell 
death. Others have shown that over-expression of Akt can result in increased 
resistance to paclitaxel further emphasising the role of the PI3K/Akt/FoxO 
pathway in determining sensitivity to this drug (Page et al., 2000; 
VanderWeele et al., 2004).  
Since the ERK1/2, p38 and JNK signal transduction pathways may also affect 
paclitaxel sensitivity (Amato et al., 1998; Bacus et al., 2001; Lee et al., 1998; 
Lei and Davis, 2003; MacKeigan et al., 2000; Seidman et al., 2001), I also 
examined cellular levels and activation status of these kinases (Fig 3.1, 3.2, 
3.3) following paclitaxel treatment. In a dose-response experiment an 
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increase in levels of activated JNK, p38 and ERK1/2 were observed at 
concentrations ranging from 1-100nM paclitaxel 16 h post treatment (Fig 3.1). 
Since the largest induction in FoxO3a expression was observed at 10nM 
paclitaxel, MCF-7 cells were treated with 10nM paclitaxel for duration of 72 h 
(Fig 3.2). At this concentration of paclitaxel, prominent biphasic JNK 
activation was detected, while no significant induction in p38 activity was 
observed. Levels of activated ERK decreased during the course of treatment 
and then returned to levels similar to that of untreated cells, suggesting that 
this signalling pathway was not activated following treatment with 10nM 
paclitaxel. Results obtained for treatment of BT-474 cells with 10nM paclitaxel 
(Fig 3.3) also showed a biphasic increase in JNK activity, but no prominent 
change in p38 activation status was detected. Taken together, these results 
suggest that out of the three signalling pathways, the JNK signalling pathway 
is the predominant signal transduction pathway to become activated in 
response to treatment with 10nM paclitaxel in both the MCF-7 and BT-474 
cell lines.  
Since I was unable to detect FoxO1 expression in the MCF-7 and BT-474 cell 
lines, I examined the expression levels of FoxO1 in the endometrial cells 
lines, Ishikawa and HEC-1-B. Both cell lines expressed FoxO1, however the 
HEC-1-B cell line expressed FoxO1 at higher levels and expression was 
further induced following 10nM paclitaxel treatment (Fig 3.4). This result 
indicates that not only FoxO3a expression, but also FoxO1 expression can be 
induced following paclitaxel treatment and that this regulation depends on 
which isoform of FoxO is the predominantly expressed in the cell line.  
The molecular basis for the up-regulation in FoxO proteins in response to 
paclitaxel is unknown. I found that both paclitaxel and H2O2 treatment 
increased the levels of ROS in the cells and a previous report demonstrated 
that accumulation of H2O2 is required in order for paclitaxel to induce 
apoptosis (Alexandre et al., 2006). Oxidative stress results from an imbalance 
between the production and removal of ROS. One of the target genes of 
FoxO is catalase, an enzyme responsible for breakdown of peroxide (Nemoto 
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et al., 2004). Therefore, oxidative stress could play a key role in inducing 
FoxO expression. Treatment of MCF-7 cells with H2O2 induced the levels of 
FoxO3a expression and activated the JNK signalling pathway (Fig 3.6). 
Therefore, both paclitaxel and H2O2 treatment increase the levels of FoxO3a 
expressed in the cells and activate the JNK signalling pathway (schematically 
represented in figure 3.23). The role of the JNK signalling pathway in the 
regulation of FoxO3a will be discussed in detail in chapter 5.   
In order to determine the mechanism of induction in FoxO protein expression 
following exposure to oxidative stress, I examined the effect of paclitaxel and 
H2O2 treatment of transcription of FoxO genes. BT-474 cells and HEC-1-B 
cells showed an increase in FoxO3a and FoxO1 mRNA and promoter activity, 
respectively. Hence, paclitaxel treatment generates an increase in FoxO 
protein expression by up-regulation of FoxO transcription in BT-474 and 
HEC-1-B cells (schematically represented in figure 3.22B and C, 
respectively). However, the mechanism by which paclitaxel and H2O2 
treatments induced the expression of FoxO3a in MCF-7 cells differs from that 
observed in the HEC-1-B and BT-474 cell lines. Although both treatments 
caused up-regulation in FoxO3a promoter activity, the increase observed in 
FoxO3a mRNA levels was not sufficient to account for the accumulation in 
the FoxO3a protein (schematically represented in figure 3.22A). Examination 
of FoxO3a protein stability in MCF-7 cells showed an increase in FoxO3a 
half-life in MCF-7 cells that were exposed to oxidative stress (Fig 3.10, 3.11). 
This increase in the stability of FoxO3a could cause accumulation of the 
protein, augmenting protein expression levels without up-regulation in protein 
synthesis.  
An increase in protein stability could arise from either preventing or 
decreasing the rate of protein degradation. FoxO1 and FoxO3a have both 
been shown to be regulated by the ubiquitin–proteasome pathway (Aoki et 
al., 2004; Hu et al., 2004; Huang et al., 2005; Matsuzaki et al., 2003; Plas and 
Thompson, 2003). FoxO1 and FoxO3a ubiquitin dependent degradation 
occurs following phosphorylation of these proteins at the Akt regulatory sites 
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(Aoki et al., 2004; Matsuzaki et al., 2003). The Skp2 ubiquitin ligase was 
shown to be required for FoxO1 proteolysis (Huang et al., 2005), however the 
ubiquitin ligase responsible for the degradation FoxO3a is unknown. In 
addition, changes in the phosphorylation status of proteins have been shown 
to affect protein stability (Yaglom et al., 1995). Phosphorylation of certain 
protein residues can serve to mask motifs that ubiquitin proteasome pathway  
recognises (Khanday et al., 2006). Therefore, it is possible that in MCF-7 
cells oxidative stress stabilises FoxO3a expression by causing FoxO3a to 
become phosphorylated at a site/s which masks motif/s recognised by 
ubiquitin-26S proteasome, therefore preventing FoxO3a degradation. 
Maintaining constant levels of FoxO3a synthesis and increasing FoxO3a 
protein half-life, could generate an increase in total levels of FoxO3a 
expressed in the cells.  
 
Analysis of the regulation of FoxO at the promoter level demonstrated that 
both FoxO1 and FoxO3a can be regulated by oxidative stress inducing 
reagents (Fig 3.12, 3.13, 3.15, 3.16). FoxO1 promoter activity was up-
regulated in the MCF-7 cell line, despite the fact that no increase in FoxO1 
mRNA expression was observed and FoxO1 protein expression in this cell 
line was undetectable. This differs from the result obtained for the HEC-1-B 
cell line which showed up-regulation at the protein, mRNA and promoter 
levels of FoxO1 expression following paclitaxel treatment (schematically 
represented in figure 3.22C). Therefore, it seems that MCF-7 cells express 
the transcription factors required for up-regulation of FoxO1 activity at the 
promoter level, but under endogenous conditions these cells negatively 
regulate the expression of FoxO1. Previously it has been demonstrated that 
all FoxO proteins can regulate the expression of the same target genes. 
Hence, it is likely that since MCF-7 cells express FoxO3a at high and 
inducible levels that down regulation of FoxO1 expression occurred in this 
cell line and transcriptional regulation of FoxO targets genes occurs via 
FoxO3a. One way of negatively regulating gene expression is via methylation 
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of CpG islands on the gene promoter. Thus, negative regulation of FoxO1 
expression in MCF-7 cells could be achieved by methylation of the FoxO1 
promoter CpG islands; this waits to be determined. However, it has recently 
been shown that low levels of FoxO1 expression in Ishikawa cells were the 
result of an increase in mRNA turnover and promoter methylation or activity, 
(Goto et al., 2007). Therefore, increased mRNA turnover this is another 
mechanism cells can manipulate to decrease the expression levels of genes, 
and may also account for the low levels of FoxO1 expression in MCF-7 cells. 
Analysis of the activity levels of truncated FoxO3a promoter constructs in 
MCF-7 and BT-474 cells in response to paclitaxel treatment revealed 2 
regions in the promoter sequence which are responsive to paclitaxel 
treatment (Fig 3.15, 3.16). The first region located at -478 to -25bp and the 
second region located at -1480 to -1349bp upstream to the FoxO3a 
transcription start site. Since the first site is located at close proximity to the 
transcription start site it is possible that up-regulation in activity in this region, 
in response to paclitaxel treatment, is not exclusively related to paclitaxel 
treatment but to the binding of the general transcription machinery to the core 
promoter (Sadhale et al., 2007). The core promoter is about 50 bases 
upstream to the transcription initiation site of genes and usually contains 
binding sites for the basal transcription complex and RNA polymerase II 
(Thomas and Chiang, 2006). The second region responsive to paclitaxel 
treatment is located further upstream. The up-regulation in activity observed 
for this region may be related to binding of transcription factors which activity 
is up-regulated following paclitaxel treatment. Binding of these transcription 
factors to the promoter increases FoxO3a promoter activity in response to 
paclitaxel treatment. It is probable that these transcription factors are 
downstream targets of a signalling transduction pathway which is activated 
following oxidative stress, such as the JNK signalling pathway (Davis, 2000). 
Downstream targets of JNK include the AP-1 and ATF-1 transcription factors 
(Ahmed et al., 2003; Botteron and Dobbelaere, 1998; Caelles et al., 1997; 
Leppa et al., 2001; Zoumpourlis et al., 2000). Although the FoxO3a promoter 
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sequence contains several consensus binding sites for these transcription 
factors, none of them are located solely in this region of the promoter. Hence, 
further experiments need to be conducted in order to determine which 
transcription factor/s up-regulate FoxO3a mRNA expression in response to 
paclitaxel treatment. One possibility is to perform cDNA microarray analysis. 
Comparison of cDNA microarray of cells exposed to paclitaxel to those 
untreated will reveal which transcription factors’ expression is induced 
following treatment. If the transcription factors identified will be shown to bind 
the FoxO3a promoter at the -1480 to -1349bp region, responsive to paclitaxel 
treatment, this may imply that these transcription factors play a role in the up-
regulation of FoxO3a transcription following paclitaxel treatment.  
The MEF2A transcription factor was found to regulate transcription of both 
FoxO1 and FoxO3a in MCF-7 cells (Fig 3.18, 3.19, 3.20, 3.21). Over-
expression of MEF2A induced both FoxO1 and FoxO3a promoter activity in 
MCF-7 cells. Mutating two of the three MEF2 DNA consensus binding sites in 
the FoxO1 promoter led to a decrease in FoxO1 promoter activity (Fig 3.21B). 
Therefore, it seems that MEF2 may up-regulate FoxO promoter activity, by 
binding to MEF2 DNA consensus binding sites located in the promoter 
sequence. Since transcription factors are bound to the DNA in complexes it is 
possible that the nature of regulation depends on the presence or absence of 
other transcription factors in the complex which, in concert, determine 
whether the net effect on transcription will be positive or negative. It is also 
possible that regulation of FoxO genes by MEF2 could be cell type specific or 
isoform specific. Regulation of transcription by MEF2 may also be influenced 
by cross-talk between signalling pathways affecting the expression of other 
transcription factors. In order to further understand the role of MEF2 is the 
regulation of FoxO genes, an additional experiment in which MEF2 
expression is knocked down (siRNA) should be performed.  
Furthermore, it was shown that exogenous expression of MEF2A can result 
in an additional increase in FoxO promoter activity in response to paclitaxel 
(Fig 3.19, 3.20). Therefore, it is possible that paclitaxel treatment activates 
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signal transduction pathways upstream to MEF2, such as the p38 signalling 
pathway (Seidman et al., 2001) and this results in MEF2 activation and a 
further increase in FoxO transcription. In addition, paclitaxel treatment could 
affect signal transduction pathways involved in the regulation of transcription 
factors which bind with MEF2 to the DNA and activation or repression of 
these factors could result in an increase in FoxO transcription. Furthermore, 
since I was able to demonstrate, as previously observed (Alexandre et al., 
2006), that paclitaxel treatment generates ROS and since it has also been 
shown that oxidative stress can induce the activity of MEF2 (Al-Khalili et al., 
2004), it would be interesting to determine whether up-regulation of MEF2 
activity following oxidative stress and ROS production could lead to MEF2-
dependent increase in FoxO transcription.  
 
The work presented in this chapter demonstrates that paclitaxel and oxidative 
stress can induce the levels and activity of FoxO transcription factors, 
indicting that FoxOs may act as downstream effectors of chemotherapeutic 
drugs, such as paclitaxel. Up-regulation of FoxO activity can result in FoxO-
dependent increase in the transcription of target genes involved in apoptosis 
(Brunet et al., 1999; Dijkers et al., 2000a; Modur et al., 2002; Stahl et al., 
2002) and therefore, may be important in determining sensitivity to 
chemotherapy. However, since FoxOs can also up-regulate the transcription 
of genes involved in detoxification of ROS, such as catalase and MnSOD 
(Balaban et al., 2005; Kops et al., 2002a; Nemoto and Finkel, 2002), it is 
possible that FoxOs may also play a role in resistance to chemotherapy. 
Hence, better understanding of the regulation of FoxO transcription factors is 
required in order to prevent FoxOs from facilitating resistance to 
chemotherapy. 
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Figure 3-22: Schematic representation of the changes in FoxO expression at the 
promoter, mRNA and protein levels in the various cell lines examined.  
(A) Changes in FoxO3a expression levels in MCF-7 cells (based on figures 3.2, 3.7C and 
3.12C). (B) Changes in FoxO3a expression levels in BT-474 cells (based on figures 3.3, 3.8A 
and 3.16C). (C) Changes in FoxO1 expression levels in HEC-1-B cells (based on figures 3.4, 
3.9BA and 3.13). 
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Figure 3-23: Schematic representation of the levels of phosphorylated JNK (P-JNK) 
and FoxO3a in reference to the levels of ROS in MCF-7 cells.  
Levels of ROS produced were attained based on figure 3. 5, levels of P-JNK and FoxO3a are 
based on figures 3.2 and 3.6. 
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4 The Role of BTG1 in Breast Cancer 
4.1 Background and objectives  
In recent years many efforts have been made to better understand the 
function of FoxO transcription factors. This has been predominately 
performed by analysing the role and regulation of FoxO downstream target 
genes. FoxO proteins have been implicated in cell cycle arrest and apoptosis 
by inducing transcription of downstream targets such as p27Kip1, Bim, FasL 
(Brunet et al., 1999; Dijkers et al., 2000a; Essafi et al., 2005; Stahl et al., 
2002). However, some studies also point to a role for FoxO in regulation of 
differentiation. BTG1 was identified in a DNA microarray as a target gene of 
FoxO3a in erythroid progenitors and was shown to directly regulated BTG1 
transcription (Bakker et al., 2004).  
FoxO3a is suggested to induce erythroid differentiation by a mechanism 
dependent on BTG1 and protein arginine methyl transferase 1 (PRMT1), 
activity (Bakker et al., 2004). PRMT1 was also shown to play an important 
role in anti-proliferative functions in cells such as T-lymphocytes and 
fibroblasts (Berthet et al., 2002; Matsuda et al., 2001 2001; Prevot et al., 
2001; Sasajima et al., 2002). BTG1 is a member of the Tob/BTG anti-
proliferative protein family. The human family of Tob/BTG proteins has six 
members: BTG1, BTG2, PC3B, Tob, Tob2 and ANA/BTG3 (Matsuda et al., 
2001). One hundred and ten amino acids located in the N-terminal region of 
these proteins bear homology and termed the Tob/BTG homology domain. 
Within this domain there are two highly conserved regions, box A and box B. 
BTG1 and BTG2 have another homologous region called box C which 
associates with PRMT1. The box B and the C-terminal domain of BTG1 are 
responsible for its nuclear localisation. Deletion of box C, the PRMT1 binding 
domain in BTG1, has been found to stop BTG1 induced proliferation 
inhibition. The BTG1 protein lacks enzymatic activity but posses protein 
interaction domains, implying that BTG1 may be an adaptor protein or a 
cofactor (Bakker et al., 2004). BTG1 has also been shown to interact with 
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p/CAF1, a protein which may be involved in transcriptional regulation and is 
deleted  in many human tumours (Prevot et al., 2001). PRMT1 and p/CAF 
were shown to play a role in ER-dependent signalling in breast epithelial 
cells. In addition, it has also been suggested that down-regulation of BTG2, 
which shares 66% homology with BTG1, may be involved in the development 
of mammary tumours (Kawakubo et al., 2004). Therefore, in order to further 
understand role of FoxO3a in breast cells, I decided to examine whether 
BTG1 was also a target gene of FoxO3a in the breast cancer cell line, MCF-7 
and to determine its function of BTG1 in breast cells. 
4.2 Results  
4.2.1 BTG1 is a downstream target of FoxO3a in COS-1 and MCF-7 
cells 
In order to examine whether BTG1 is a downstream target of FoxO3a in 
breast epithelial cells, I amplified by PCR 871bp of the human BTG1 
upstream regulatory region and cloned it into the pGL3 luciferase vector (Fig 
4.1A). The region cloned into pGL3 includes a FoxO DNA consensus binding 
site located -211bp upstream to the BTG1 transcription start site. The 
construct was transiently co-transfected with increasing amounts of either 
wild-type FoxO3a or constitutively active FoxO3a (FoxO3aA3) into COS-1 
and MCF-7 cells (Fig 4.1B, C).  
As seen in figure 4.1B, both the wild-type FoxO3a and the constitutively 
active FoxO3a increased BTG1 promoter activity in COS-1 cells. The up-
regulation in activity observed when the constitutively active FoxO3a was co-
transfected was greater than that observed for the wild-type FoxO3a. Both 
constructs generated a dose dependent increase in the promoter activity 
which reached saturation at 40ng of co-transfected FoxO3a. This indicates 
that BTG1 is a transcriptional downstream target of FoxO3a. In order to 
determine if BTG1 was also a downstream target of FoxO3a in breast 
carcinoma cells, I co-transfected MCF-7 cells with the BTG1 
promoter/reporter construct and increasing amounts of either wild-type or 
constitutively active FoxO3a (Fig 4.1C). Co-transfection of both wild-type 
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FoxO3a and constitutively active FoxO3a increased BTG1 promoter activity, 
however only the increase observed with the wild-type FoxO3a was dose- 
dependent. The increase in activity observed with the constitutively active 
FoxO3a was larger than that noted with the wild type FoxO3a and activity 
levels peaked at 10ng of co-transfected FoxO3aA3. Hence, BTG1 
transcription can be up-regulated by FoxO3a in COS-1 cells and in MCF-7 
breast cancer cells. 
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Figure 4-1: BTG1 is a downstream target of FoxO3a.  
(A), Schematic representation of the BTG1 promoter/reporter construct generated. The 
human BTG1 upstream regulatory region was amplified by PCR and cloned into the pGL3 
luciferase vector. COS-1 cells (B), or MCF-7 cells (C), were transiently co-transfected with 
20ng of the BTG1 promoter construct and increasing amount of either FoxO3a or 
constitutively active FoxO3a (FoxO3aA3). Values are corrected for co-transfected renilla 
activity. All data shown represent the average of three independent experiments, and the 
error bars show the standard deviation, for all conditions it was found that p<0.05 in 
comparison to cells transfected with 0ng FoxO3a/FoxO3aA3. 
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4.2.2 Induction in BTG1 expression levels following paclitaxel 
treatment in MCF-7 cells 
In chapter 3, I was able to show that treatment of MCF-7 cells with paclitaxel 
induced the expression of FoxO3a and downstream target p27Kip1 (Fig 3.2, 
3.3, 3.8B). Therefore, I decided to examine whether BTG1 was also a target 
gene of FoxO3a following paclitaxel treatment. MCF-7 cells were treated with 
paclitaxel and the levels of BTG1 mRNA and protein expression were 
determined. As seen in figure 4.2A, BTG1 mRNA expression levels remained 
relatively stable throughout the course of treatment with paclitaxel, except at 
48 h when an increase in BTG1 mRNA expression was detected. Generally, 
BTG1 protein expression levels also remained constant throughout the 
course of treatment; although a slight increase in protein expression levels 
was detected 48 h after treatment commenced (Fig 4.2B). Hence, paclitaxel 
treatment caused up-regulation in BTG1 expression at both the protein and 
mRNA levels in MCF-7 cells. However, the increase was subtle and occurred 
at a late time-point.  
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Figure 4-2: BTG1 expression following paclitaxel treatment in MCF-7 cells.  
MCF-7 cells were treated with 10nM paclitaxel for indicated times. (A), Total RNA was 
extracted and analysed for the expression levels of BTG1 mRNA using RT-qPCR and 
normalised to the level of L19 mRNA expression. All data shown represent the average of 
three independent experiments and the error bars show the standard deviation. *p<0.05 in 
comparison to 0 h. (B), Whole cell lysates were prepared, then separated on SDS-
polyacrylamide gels and immunoblotted. The levels of total FoxO3a and BTG1 were 
analysed by western blot using specific total antibodies. β-actin was used as a loading 
control. The arrow indicates the location of the FoxO3a specific band. An experiment 
showing the same trend as 4.2B can be found in the supplementary data, figure 7.8. 
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4.2.3 BTG1 expression levels change during the cell cycle 
The FoxO transcription factors play a role in the regulation of cell cycle 
progression and cell cycle arrest, by regulating the expression of genes such 
as p27Kip1, p21Cip1 cyclin D1 and D2, cyclin G2 and p130 (Kops et al., 1999; 
Martinez-Gac et al., 2004; Medema et al., 2000; Nakamura et al., 2000; 
Ramaswamy et al., 2002; Schmidt et al., 2002; Seoane, 2004). BTG2, which 
shares several homologous domains with BTG1, was shown to inhibit cyclin 
D1 expression (Kawakubo et al., 2006). Therefore, to determine whether 
BTG1 expression changes throughout the cell cycle, I decided to examine the 
expression pattern of FoxO3a transcriptional target, BTG1 in cell cycle 
synchronised MCF-7 cells.  
As shown in figure 4.3, BTG1 expression increased 16 h after cells re-
entered the cell cycle. 24 h after release from G0, an increase in the 
expression of polo like kinase (Plk) was evident. Plk expression is up-
regulated during the M phase of the cell cycle (Lee et al., 1995), therefore the 
increase in BTG1 expression occurred prior to entry of the cells to the G2/M 
phase. An increase in the expression of FoxO3a was observed at 8 h, during 
the G1 phase of the cell cycle. It is notable that a corresponding decrease in 
the mobility of FoxO3a also occurred; this is probably due to an increase in 
FoxO3a’s phosphorylation during S phase. Taken together, BTG1 expression 
is cell cycle regulated and peaks at the early stages of the cell cycle, 
following an induction in FoxO3a expression.  
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Figure 4-3: BTG1 expression in synchronised MCF-7 cells.  
MCF-7 cells were synchronised at G0 by decreasing the concentration of foetal calf serum 
(FCS) from 10% to 0.5% in the growth medium for 36 h; after which growth medium was 
replaced by fresh media containing 10% FCS. Whole cell lysates were prepared, and then 
separated on SDS-polyacrylamide gels and immunoblotted. The levels of total FoxO3a, 
BTG1 and Plk were analysed by western blot using specific total antibodies. β-tubulin was 
used as a loading control. An experiment showing the same trend can be found in the 
supplementary data, figure 7.9. 
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4.2.4 Generation of an inducible BTG1 cell line 
Since previous experiments demonstrated that BTG1 is a downstream target 
of FoxO3a and that BTG1 expression changes through the course of the cell 
cycle, I next sought to examine the role of BTG1 in breast epithelial cells. In 
order to determine the function of the BTG1 in breast cancer cells, I decided 
to generate a stably transfected MCF-7 breast cancer cell line which 
expressed BTG1 in an inducible manner. To that end, I chose to use the ‘Tet-
On’ and ‘Tet-Off’ systems which enable expression of a gene under 
specifically regulated conditions. The process of cloning and selecting of 
BTG1 MCF-7 Tet On and Tet Off clones is explained in detail in chapter 2 
sections 2.1.5 and 2.5.8. One clone, BTG1 MCF-7 Tet Off clone #34 (hereby 
known as BTG1 Tet-Off), was found to express BTG1 at the highest inducible 
levels and was chosen for further analysis of the role of BTG1 in breast 
epithelial cells. As seen in figure 4.4A, BTG1 mRNA expression was up-
regulated upon withdrawal of doxycycline (Dox) from the medium. BTG1 
mRNA levels increased rapidly and peaked 8 h after removal of Dox to levels 
more than 3.5 times higher than those observed for non-induced cells (0 h). 
Levels of BTG1 mRNA remained elevated, in comparison to non induced 
cells, for the duration of the experiment. In order to examine whether up-
regulation of BTG1 mRNA expression generates an increase in BTG1 protein 
expression, western blot analysis was performed. As shown in figure 4.4B, 
the expression of BTG1 increased upon removal of Dox from the medium. 
The up-regulation in BTG1 expression was observed 8 h after Dox was 
removed from the media and remained elevated for the rest of the time-
course. At 24 h a slight decrease in the expression of BTG1 was observed. 
Results obtained in the previous experiment (Fig 4.3) indicate that BTG1 
expression is cell cycle regulated and peaks prior to M phase. Therefore, it is 
possible that up-regulation of BTG1 expression affects cell cycle progression 
by inducing a transient G1 cell cycle arrest, which results in the 
synchronisation of the cells at G1. Upon release from this transient cell cycle 
arrest, BTG1 expression levels decrease.  
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Figure 4-4: The BTG1 MCF-7 Tet Off clone #34 expresses BTG1 in an inducible manner 
upon withdrawal of doxycycline from the medium.  
MCF-7 Tet off cells, which were stably transfected with pTRE2Hyg-BTG1, were cultured in 
the presence of 100μg/ml of G418, 200μg/ml and 1μg/ml doxycyclin. At the beginning of the 
time-course (0 h) all antibiotics were removed from the media. (A) Total RNA was extracted 
and analysed for the expression levels of BTG1 mRNA using RT-qPCR and normalised to 
the level of L19 mRNA expression. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.01 and was 
determined comparing the levels of expression to 0 h. (B) Whole cell lysates were prepared, 
then separated on SDS-polyacrylamide gels and immunoblotted. The levels of BTG1 was 
analysed by western blot using specific total antibodies. β-tubulin was used as a loading 
control. An experiment showing the same trend as 4.4B can be found in the supplementary 
data, figure7.10  
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4.2.5 Over-expression of BTG1 decreases cell growth 
BTG1 was initially identified as target gene of FoxO3a in erythroid progenitors 
and appears to play a role in erythroid differentiation (Bakker et al., 2004). In 
an effort to discover the function of BTG1 in breast cancer cells, I decided to 
examine whether BTG1 played a role in regulation of cell growth by 
performing a Sulphorhodamine B (SRB) assay. To this end, BTG1 Tet-Off 
cells were induced to express BTG1 and cellular protein content was 
compared to that of cells harbouring the empty vector (MCF-7 Tet-Off 
pTRE2hyg, hereby known as pTRE Tet-Off). As seen in figure 4.5, cells 
expressing BTG1 had lower cellular protein content than cells harbouring the 
empty vector. A decrease in cellular protein content was also observed for 
BTG1Tet-Off cells, which were not induced to express BTG1 (grown in the 
presence of doxycycline), indicating that the inducible BTG1 expression 
system may be leaky. However, the decrease in cellular protein content for 
cells induced to express BTG1 (grown without doxycycline) was statistically 
significant in comparison to the cells which were not induced. Therefore, it 
seems that over-expression of BTG1 in MCF-7 cells reduces cell growth, 
suggesting that BTG1 may either negatively regulate cell cycle progression or 
play a role in inducing cell death.  
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Figure 4-5: Over-expression of BTG1 reduces cell growth.  
BTG1 MCF-7 Tet-Off Clone #34 cells (BTG1) and MCF-7 Tet Off pTRE2hyg (EV) cells were 
grown in 96 well plates for 48 h in DMEM medium without Dox and cellular protein content 
was determined every 24 h by performing SRB assay and measuring OD at 492nm. OD 
measurements were normalised using initial (0 h) OD measurement as the value 1. All data 
shown represent the average of three independent experiments, and the error bars show the 
standard deviation.*p<0.001 when comparing relative protein content of Tet-Off Clone #34 
cells (induce and not induced) to each other and  to that of MCF-7 Tet Off pTRE2hyg at 48 h.  
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4.2.6 Over-expression of BTG1 induces accumulation of cells in 
the G2/M phase of the cell cycle 
In the previous experiment, I was able to demonstrate that over-expression of 
BTG1 reduced cell growth, indicating that BTG1 plays a role in either cell 
cycle arrest or induction of apoptosis. In addition, I was also able to show that 
BTG1 expression is cell cycle regulated (Fig 4.3). Therefore, I next sought to 
examine the effect of BTG1 over-expression on the cell cycle profile by 
performing PI staining followed by FACS analysis.  
As seen in figure 4.6, BTG1 Tet-Off cells that were not induced to express 
BTG1 were found predominantly in the G1 phase of the cell cycle. Over-
expression of BTG1 induced accumulation of cells at G2/M phase of the cell 
cycle and a slight increase in sub-G1 population was also observed. 
Hence, previously I was able to demonstrate that expression of BTG1 peaks 
prior to M phase; in this experiment I was able to show that over-expression 
of BTG1 induces G2/M cell cycle arrest and that BTG1 over-expression may 
also increase cell death. Therefore, it is possible that BTG1 expression is 
induced at G1 or S phase of the cell cycle but causes cell cycle arrest and 
apoptotic cell death at the later G2/M phase of the cell cycle. 
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Figure 4-6:Over-expression of BTG1 induces accumulation of cells in the G2/M phase 
of the cell cycle.  
PI-FACS analysis was performed on BTG1 Tet-Off cells. Cells were induced to express 
BTG1 by removal of Dox from the medium 24 h before FACS analysis was performed.  
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4.2.7 The effect of BTG1 over-expression on cell cycle regulators 
In the last experiment, I was able to demonstrate that over-expression of 
BTG1 induced accumulation of the cells in the G2/M phase of the cell cycle. 
In attempt to find out how BTG1 inflicts this G2/M accumulation, I next 
examined the effect of BTG1 over-expression on the following cell cycle 
regulators: cyclin D1, cyclin E1, cyclin A, cyclin B cyclin-dependent kinase 4 
(CDK4), CDK2, retinoblastoma protein (pRb), CDK kinase inhibitors (CKI’s): 
p27Kip and p21Cip. In order to understand the results obtained in this 
experiment it is important to first clarify the role of each of these proteins in 
cell cycle regulation. Briefly, the literature shows that during the transition 
from quiescence into the cell cycle, levels of cyclin D1 increase in response 
to extracellular mitogens (Aktas et al., 1997; Cheng et al., 1998; Lavoie et al., 
1996) and cyclin D1, in combination with CDK4 and CDK6, can 
phosphorylate, pRb. The phosphorylation of pRb is leads to the release of 
E2F transcription factors, which then activate genes that are required for cell 
cycle progression. Cyclin E synthesis is mediated by E2F following pRb 
phosphorylation by CDK4/6–cyclin D complex (Harbour et al., 1999; 
Malumbres and Barbacid, 2001; Zhang et al., 1999) and that CDK2 is 
activated through binding to cyclin E., The CDK2-cyclin E complex 
phosphorylate target proteins, thereby initiating S phase. One important 
target of CDK2–cyclin E is pRb. In addition to promoting entry to S phase by 
phosphorylating pRb (on threonine 821) CDK2-cyclin E also phosphorylate a 
number of proteins which play important roles in DNA replication (Caldon et 
al., 2006; Hwang and Clurman, 2005). CKIs form heterotrimeric complexes 
with the G1/S CDKs. However, in stoichiometric amounts, they only kinase 
activity of CDK2–cyclin E complex is inhibited (Malumbres and Barbacid, 
2001). Cyclin A expression is required for progression through S and G2 
phases of the cell cycle and cyclin B1 is required for M phase progression 
(Clute and Pines, 1999; Lukas et al., 1999). 
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Hence, BTG1 Tet-Off cells were induced to express BTG1 for 16 h and the 
expression pattern of BTG1 and cell cycle regulators was analysed by 
western blot (Fig 4.7). As seen in figure 4.7, following the removal of Dox 
from the medium an increase in BTG1 expression was observed. I also 
examined the levels of FoxO3a expression, in order to determine if over-
expression of the FoxO3a downstream target, BTG1 caused a feedback 
effect; the result obtained showed no significant change in FoxO3a 
expression. However, a decrease in cyclin D1 expression was observed, 
while no significant change in the expression of CDK4 or phosphorylation of 
the tumour suppressor, pRb on Ser 801/807 was noted. A decrease in cyclin 
E1 expression was also observed, however no change in CDK2 expression 
and phospho-Thr821pRb was noted. Nonetheless, an increase in the 
expression of the p27Kip and p21Cip was observed. A slight decrease in cyclin 
A expression was observed. No change in the expression levels of cyclin B1, 
was detected (Clute and Pines, 1999; Lukas et al., 1999). The levels of total 
pRb and β-tubulin did not change, indicating equal loading, Taken together, 
over-expression of BTG1 correlates with a decrease in the expression levels 
of cyclin D1 and cyclin E1 which are required for G1 phase initiation and 
progression, respectively. Following the induction in BTG1 expression up-
regulation in the expression of p21Cip and p27Kip, which inhibit the activity of 
the CDK2-cyclin E complex, was also noted.  
 
Overall, I was able to show that induction in BTG1 expression results in 
accumulation of the cells at the G2/M phase of the cell cycle (Fig 4.6) and 
that BTG1 over-expression may have a negative effect on cell cycle 
progression at the G1 phase of the cell cycle, as it was shown that over-
expression of BTG1 results in increased expression of p21Cip and p27Kip 
which repress the activity of the CDK2-cyclin E complex (Fig 4.7).  
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Figure 4-7: The effect of BTG1 over-expression on cell cycle regulators.  
BTG1 Tet-Off cells were induced to express BTG1, by removal of Dox from the cell growth 
medium for a period of 24 h. After which cell lysates were prepared, separated on SDS-
polyacrylamide gels and immunoblotted with specific antibodies. The levels of BTG1, 
FoxO3a and cell cycle regulators was analysed using specific phospho and total antibodies. 
β-tubulin was used as a loading control. An experiment demonstrating the same trend an be 
found in the supplementary data, figure 7.11 
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4.2.8 Up-regulation of BTG1 expression increases p21Cip1 and 
p27Kip1 expression at the promoter and mRNA levels  
In the previous experiment, I was able to show an induction in both p21Cip1 
and p27Kip1 protein levels following an induction in BTG1 expression in BTG1 
Tet-Off cells. Therefore, I next set out to examine whether BTG1 could up-
regulate p21Cip1 and p27Kip1 expression at the transcriptional level. To that 
end, MCF-7 cells were co-transfected with either the p21Cip1 or p27Kip1 
promoter/reporter construct together with increasing amounts of BTG1 (Fig 
4.8 A, B).  
As shown in figure 4.8A, B, the activity levels of both the p21Cip1 and the 
p27Kip1 promoters were up-regulated following co-transfection with BTG1 in 
MCF-7 cells. The increase in the p21Cip1 promoter activity occurred at lower 
concentrations of BTG1 than the increase observed for the p27Kip1 promoter. 
The p27Kip1 promoter also exhibited a dose dependent increase in activity in 
response to BTG1. An increase in both p21Cip1 and p27Kip1 mRNA levels was 
observed 16 h after BTG1 expression was induced in BTG1 Tet-Off cells (Fig 
4.8 C,D). Therefore, over-expression of BTG1 seems to positively regulate 
transcription of p21Cip1 and p27Kip1 at both the promoter level and the mRNA 
levels.  
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Figure 4-8 : Induction in the expression of BTG1 affects the transcription of p21CIP1 and 
p27Kip1 at the promoter and mRNA levels.  
MCF-7 cells were transiently co-transfected with increasing amounts of BTG1 (p-BABE-
BTG1) and 20ng of either the p21Cip1 promoter construct (A) or the p27Kip1 promoter construct 
(B) samples were harvested 24 h after transfection and were assayed for luciferase activity. 
Values are corrected for co-transfected renilla activity. All data shown represent the average 
of three independent experiments, and the error bars show the standard deviation. *p<0.05 
when compared to cell transfected with 0ng. Total RNA was extracted from BTG1 Tet-Off 
cells (C, D) and the expression levels of p21Cip1 (C) and p27Kip1(D) mRNA were analysed 
using RT-qPCR and normalised to the level of L19 mRNA expression. All data shown 
represent the average of three independent experiments, and the error bars show the 
standard deviation. *p<0.05 when compared to levels at 0 h. 
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4.2.9 Over-expression of BTG1 decrease the transcription of cyclin D1 
and cyclin E1 
Since a decrease in both cyclin D1 and cyclin E1 expression was observed 
following an induction in BTG1 expression in the BTG1 Tet-Off cells (Fig 4.7), 
I decided to examine the effect of BTG1 over-expression on transcription of 
cyclin D1 and cyclin E1. To that end, I examined the levels of cyclin D1 and 
cyclin E1 mRNA following an induction in BTG1 expression in the BTG1 Tet-
Off cells (Fig 4.9A, C). A decrease in cyclin D1 mRNA expression was 
evident as early as 8 h after induction of BTG1 expression with a further 
decrease in cyclin D1 mRNA expression levels occurring 24 h after BTG1 
expression was induced (Fig 4.9A). A decrease in the levels of cyclin E1 
mRNA expression were only noticeable 24 h after BTG1 expression was 
induced (Fig 4.9C). This does not correlate with cyclin E1 protein expression 
levels which were found to decrease rapidly 16 h after induction in BTG1 
expression (Fig 4.7). A possible explanation may be that the cyclin E1 protein 
underwent rapid degradation, with not significant changes in the transcription 
levels, until 24 h post induction in BTG1 expression, by which time 
transcription of cyclin D1 was also down-regulated.  
In order to examine if the decrease observed in cyclin D1 expression at 
protein and mRNA expression levels also occurred at the promoter level, I co-
transfected the cyclin D1 promoter/reporter construct with increasing amounts 
of BTG1 into MCF-7 cells. A decrease in cyclin D1 promoter activity was 
observed when 30ng of BTG1 were co-transfected with the cyclin D1 
promoter. Therefore, over-expression of BTG1 can lead to a decrease in 
cyclin D1 mRNA expression and promoter activity levels. BTG1 over-
expression also appears to down-regulate cyclin E1 mRNA levels, but at a 
later time-point than observed at the protein level. 
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Figure 4-9: Over-expression of BTG1 decreases the transcription of cyclin D1 and 
cyclin E1.  
Total RNA was extracted from BTG1 Tet-Off cells (A,C) and the expression levels of cyclin 
D1 (A) and cyclin E1 (C) mRNA was analysed using RT-qPCR and normalised to the level of 
L19 mRNA expression. All data shown represent the average of three independent 
experiments, and the error bars show the standard deviation. *p<0.05 in comparison to 0 h. 
MCF-7 cells were transiently co-transfected with increasing amounts of BTG1 expression 
vector (p-BABE-BTG1) and 20ng of the cyclin D1 promoter construct (B), Samples were 
harvested 24 h after transfection and were assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.05 when 
compared to cells transfected with 0ng. 
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4.3 Discussion  
In chapter 3, I focused on the regulation of FoxO at the transcriptional level; 
in this chapter, I attempted to understand the function of FoxO3a in breast 
cancer by studying the role of FoxO3a downstream target, BTG1. 
As previously mentioned, BTG1 was initially identified as a downstream 
target of FoxO3a in erythroid development and differentiation (Bakker et al., 
2004). In this chapter, I examined whether BTG1 is a downstream target of 
FoxO3a in breast carcinoma cells and the role BTG1 plays in these cells. I 
was able to demonstrate that BTG1 is a transcriptional target of FoxO3a in 
MCF-7 cells (Fig 4.1C). However, the nature by which FoxO3a regulates and 
induces BTG1 expression in these cells is unclear, since induction of FoxO3a 
expression following paclitaxel treatment seemed to only slightly increase 
BTG1 protein and mRNA expression (Fig 4.2). Hence, it may be possible that 
up-regulation of FoxO expression following paclitaxel treatment does not lead 
to an increase in BTG1 expression, as it was previously mentioned that FoxO 
factors may differentially induce the transcription of target genes dependent 
on the form of cellular stress (Greer and Brunet, 2005). Analysis of BTG1 
expression levels following paclitaxel treatment in BT-474 cells, which have 
been shown to up-regulate FoxO3a expression following paclitaxel treatment 
(Fig 3.3), will help determine whether treatment of breast carcinoma cells with 
paclitaxel results in FoxO3a-dependent up-regulation of BTG1 expression. 
Furthermore, analysis of the cell cycle profile and survival status of cells over-
expressing BTG1 and cells in which BTG1 expression has been knocked 
down, in the presence and absence of paclitaxel, will help determine whether 
BTG1 expression is important in mediating FoxO3a-dependent effects of 
paclitaxel treatment in breast cancer cells. However, up-regulation of FoxO3a 
expression alone was not sufficient in inducing BTG1 expression in MCF-7 
cells.  
The BTG1 mRNA contains a long 3’ AU-rich untranslated region, typical of 
unstable mRNAs, like those found in cell cycle control genes (Kozak, 1991). 
This also implies that BTG1 may be a target for microRNA (Jing et al., 2005). 
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Furthermore, the BTG1 protein sequence contains PEST residues (Proline, 
Glutamine, Serine and Threonine), typical of highly unstable proteins (Rogers 
et al., 1986) including cyclins (Bai et al., 1994; Salama et al., 1994) and 
transcription factors (Bogdan et al., 1998; Ernst et al., 1995). Previous studies 
showed that BTG1 is expressed predominantly in quiescent cells, at the 
G0/G1 phase transition, with levels declining as cells enter S phase (Rouault 
et al., 1992). Indeed, I was able to show that in MCF-7 cells BTG1 expression 
peaks at G1/S prior to entry of the cells to G2/M (Fig 4.3). Furthermore, I also 
demonstrated that FoxO3a expression levels appear to be cell cycle 
regulated.  
Prior to this study, BTG1 was shown to play a role in cell cycle regulation, 
differentiation and apoptosis. Experiments conducted by other groups 
demonstrated that exogenous expression of BTG1 resulted in a reduction in 
proliferation, G1 arrest and/or apoptosis in several cell types (Corjay et al., 
1998; Lee et al., 2003a; Rodier et al., 1999; Rouault et al., 1992). Recently, 
BTG1 was also shown to upregulate apoptosis, by enhancing antisense Bcl-2 
related cytotoxic effects in breast cancer cells (Nahta et al., 2006). BTG1 has 
been suggested to play a role in cellular differentiation based on experiments 
that showed that BTG1 expression induces myoblast differentiation (Rodier et 
al., 1999) and that in leukemic cells following treatment with chemicals that 
induce differentiation, the expression of BTG1 is increased (Cho et al., 2004). 
However, it is unclear how BTG1 exerts its effect. Therefore, in order to learn 
more about the function of BTG1, in particular in breast epithelial cells, I 
generated a cell line that was able to express BTG1 in a controlled and 
inducible manner. The conditional MCF-7 cell line was designed to up-
regulate BTG1 expression upon removal of doxycycline from the medium (Fig 
4.4).  
Using these cells, I was able to show that over-expression of BTG1 reduced 
cell growth (Fig 4.5) and that cells accumulated at the G2/M phase of the cell 
cycle with a higher percentage of cells undergoing apoptosis (Fig 4.6). This 
result contradicts previous observations indicating that exogenous expression 
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of BTG1 causes G1 arrest (Rouault et al., 1992), but agrees with studies 
showing an increase in cell apoptosis (Corjay et al., 1998; Lee et al., 2003a). 
However, my results were attained using a stably transfected cell line. Hence, 
the region in the genome and the numbers of copies of the gene integrated 
into the genome may affect the outcome of the experiments (Murnane et al., 
1990; Wurm, 2004). Thus, it is possible that the results of the experiments 
were affected by the use of a stably transfected cell line and not just the over-
expression of BTG1 and therefore may account for the discrepancy in the 
outcome of my experiments in comparison to those previously published.   
Examination of the expression patterns of some cell cycle regulators following 
an induction in BTG1 expression revealed that BTG1 predominately affects 
the expression levels of G1 and G1/S cell cycle regulators (Fig 4.7). A 
decrease in cyclin D1 and cyclin E1 expression was observed while an 
increase in p21Cip1 and p27Kip1 expression was noted. Hence, BTG1 induced 
the expression of negative regulators of cell cycle progression while 
decreased the expression of positive cell cycle progression regulators. A 
recent study, showed that in ER positive breast tumours an increase in 
tumour grade and size, and over-expression of cyclin D1 correlated with loss 
of nuclear expression of BTG2 (Kawakubo et al., 2006). Therefore, it seems 
that BTG1 and BTG2 may have over-lapping effects on G1 phase cell cycle 
regulators.  
BTG1 over-expression increased transcription of p21Cip1 and p27Kip1 at the 
promoter and mRNA levels (Fig 4.8) and generated a decrease in both cyclin 
D1 promoter activity and mRNA expression levels. (Fig 4.9A, B) A decrease 
in cyclin E1 transcription was also noted (Fig 4.9C). Hence, it appears that 
BTG1 can influence gene transcription in both a positive and a negative way. 
However, the net effect of BTG1 regulation, in these experiments, resulted in 
the same outcome, generation of an expression pattern of G1 phase 
regulators which inhibits cell cycle progression. Since BTG1 has not been 
shown to bind to DNA and since it was previously suggested that BTG1 may 
act as an adaptor protein (Bakker et al., 2004), it seems likely that these 
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effects are mediated by transcription factor/s that bind to BTG1. Identifying 
which transcription factor/s bind to BTG1 will enable us to determine which 
promoters contain a DNA consensus binding site for these transcription 
factors, and therefore may be affected by the levels of BTG1 expression. 
Although I was able to demonstrate that BTG1 over-expression inhibits the 
expression of cyclin D1 and cyclin E1 and increases the expression of p21Cip1 
and p27Kip1, which agrees with previous observations that BTG1 can induce 
G1 cell cycle arrest (Rouault et al., 1992), these results disagree with the cell 
cycle analysis data which showed accumulation of the cells at the G2/M 
phase of the cell cycle (Fig 4.6). Since regulation of cell cycle progression 
depends on concerted activity of multiple regulators, over-expression of one 
may not on its own bring about changes in cell cycle status, as abundance of 
BTG1 binding partners may be a limiting factor. Therefore, it would be 
interesting to perform a complementary experiment, in which BTG1 
expression is knocked down via siRNA, and examining the effect on cell cycle 
progression. Identifying BTG1 binding partners may also help in further 
understanding the functional mechanistic role of BTG1 in cell cycle 
regulation. Moreover, I previously mentioned (section 4.2.4) that it may be 
possible that over-expression of BTG1 causes a transient G1 arrest, a 
hypothesis which is further strengthened by the observation that BTG1 
expression appears to have an overall negative effect on G1 phase cell cycle 
regulators that induce cell cycle progression. Therefore, taken together, 
theses results indicate that the accumulation of cells in G2/M, 24 h after an 
induction in BTG1 expression, may not be the direct effect of BTG1 
expression but may reflect synchronised cells coming out of G1 following the 
transient G1 arrest. Hence, in order to determine if BTG1 expression can 
indeed induce G1 arrest, synchronising the cells in a reversible manner, for 
instance at M phase, using a drug such as colcemid, may be beneficial. This 
is due to the fact that the G1 is the longest phase of the cell cycle and 
therefore the majority of unsynchronised cells reside in this phase, making it 
difficult to detect a G1 arrest using PI-FACS analysis. Analysis of the cell 
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cycle profile of non-induced BTG1 Tet-Off cells released from M phase 
synchronisation, followed by an induction in BTG1 expression for up to 24 h 
(approximant length of the cell cycle), will enable the detection of a G1 arrest. 
This is due to the fact that if BTG1 expression does indeed induces a G1 
arrest, cells will remain in this phase of the cell cycle and not be able to re-
enter G2/M.   
I also examined whether over-expression of BTG1 affected the expression 
levels of FoxO3a. However, no feedback mechanism appears to exists, as 
over-expression of BTG1 did not affect the levels of FoxO3a expression (Fig 
4.7) in MCF-7 cells.  
 
In summary, my data demonstrates that BTG1 is a downstream target of 
FoxO3a in breast cancer cells. BTG1 expression appears to generate 
accumulation of cells in the G2/M phase of the cell cycle as well as cause a 
slight increase in the levels of apoptosis. Hence, it is possible that BTG1 may 
play a role in mediating some of the effects of FoxO3a on cell cycle and cell 
death. 
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5 Regulation of FoxO3a by JNK1/2 
5.1 Background and objectives  
In chapter 3, I demonstrated that treatment of breast cancer cells with 
paclitaxel caused up-regulation in FoxO3a expression levels, which les to an 
increase in the transcription of the downstream target, p27Kip(Fig 3.2, 3.3, 3.6, 
3.8B), a gene implicated in the induction of cell cycle arrest (Dijkers et al., 
2000b). Other studies have shown that elevated levels of Akt activity can lead 
to resistance to paclitaxel treatment (Page et al., 2000; VanderWeele et al., 
2004), further implicating the PI3K/Akt/FoxO pathway in determining drug 
sensitivity (Sunters et al., 2006).  
In chapter 3, I was also able to show that the JNK signalling pathway may 
play a role in the response of breast cancer cells to treatment with paclitaxel 
and H2O2. Following treatment of breast cancer cells with paclitaxel a 
biphasic expression pattern of phosphorylated JNK (Thr183/Tyr185) was 
observed with the first peak in expression occurring prior to the increase in 
FoxO3a expression (Fig 3.2, 3.3. 3.6). The JNK signalling cascade has 
previously been shown to be activated in response to cell stresses such as 
UV irradiation (Tournier et al., 2000) and has been implicated in proliferation  
apoptosis, metabolism and DNA repair (Hayakawa et al., 2004; Lee et al., 
2005a; Sakurai et al., 2006; Davis, 2000; Weston and Davis, 2002,; Aguirre 
et al., 2000; Lee et al., 2003b). Deregulation of JNK signalling is believed to 
occur in many diseases such as chronic inflammation, neurodegeneration 
and cancer (Hunot et al., 2004; Kennedy and Davis, 2003; Su et al., 1998 
;Sumara et al., 2005). 
Recent studies have also demonstrated that JNK signalling is activated 
following paclitaxel treatment (Amato et al., 1998; Lee et al., 1998; Lei and 
Davis, 2003) and that inhibition of JNK reduces apoptosis following paclitaxel 
treatment (Lee et al., 1998). Taken together, my data and previous 
observations suggest possible cross-talk between the PI3K/Akt/FoxO and 
JNK signalling pathways. Therefore, I next sought to examine whether the 
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JNK signalling pathway plays a role in the regulation of FoxO3a in breast 
cancer, in particular in response to treatment with paclitaxel.  
5.2 Results 
5.2.1 Paclitaxel causes nuclear translocation of FoxO3a 
Previously, I was able to demonstrate that paclitaxel treatment can cause an 
increase in FoxO3a expression in the MCF-7 and BT-474 breast cancer cell 
lines. In addition, prior research conducted in Prof. Lam’s lab (Sunters et al., 
2003) showed that in MCF-7 cells treatment with paclitaxel upregulates 
apoptosis and this was found to be mediated by an increase in expression 
and transcriptional activity of FoxO3a, which resulted in increased 
transcription of Bim, a pro-apoptotic gene. However, in order to activate the 
apoptotic machinery, FoxO3a has to reside in the nucleus, suggesting that 
treatment with paclitaxel results in changes in the sub-cellular localisation of 
FoxO3a. To test this notion, I examined the sub-cellular localisation of 
FoxO3a in MCF-7 following 10nM paclitaxel treatment using confocal 
microscopy, with the help of Dr. Andrew Sunters, (CRUK labs, Imperial 
College, London). MCF-7 cells were either treated with DMSO vector alone 
(0nM) or treated with 10nM paclitaxel for 16 h. 
As shown in Figure 5.1A, FoxO3a resided almost exclusively in the cytosol of 
untreated MCF-7 cells. However, following 10nM paclitaxel treatment FoxO3a 
resided predominantly in the nuclei of MCF-7 cells. In order to further validate 
these results, I also conducted a nuclear and cytoplasmic fractionation 
experiment and analysed the relative amounts of FoxO3a in the nucleus and 
cytoplasm following 8 h of 10nM paclitaxel treatment. The results obtained 
are presented in figure 5.1B. These results show that the majority of FoxO3a 
in control cells (untreated with paclitaxel) was located in the cytoplasm, and 
that following treatment with paclitaxel, FoxO3a was predominantly located in 
the nucleus. In agreement with the data obtained from the 
immunocytochemical staining, treatment of MCF-7 cells with paclitaxel 
induced nuclear translocation of FoxO3a. These experiments were performed  
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at 8 and 16 h after paclitaxel treatment; in chapter 3, I was able to show that 
the predominate increase in p27Kip1 expression occurred 24 h after initiation of 
treatment and Sunters and colleagues (Sunters et al., 2003), demonstrated 
an increase in the pro-apoptotic target, Bim 48 h after treatment. Therefore, 
these data support the hypothesis that nuclear translocation of FoxO3a is 
required for the activation of anti-proliferative and pro-apoptotic genes, such 
as p27Kip1 and Bim, in response to paclitaxel. 
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Figure 5-1: Paclitaxel causes FoxO3a to translocate into the nucleus.  
(A), MCF-7 cells were cultured on sterile coverslips and treated for 16 h with paclitaxel (10 
nM), before being fixed in 4% formaldehyde. FoxO3a was using a rabbit polyclonal antibody 
and subsequent addition of the ALEX488 (green) labelled anti-rabbit antisera. TRITC-labelled 
phalloidin (red) and DAPI (blue) were also applied to visualize the cytoplasm and nuclei, 
respectively. (B), Western blot using cytoplasmic and nuclear extracts isolated from MCF-7 
cells that were either treated with 10nM paclitaxel or untreated (control) for 8 h The levels of 
total FoxO3a and Akt-phosphorylated FoxO3a (P-FoxO3a) was determined in both cellular 
components. β-actin was used as a loading control. An experiment showing the same trend 
as 5.1B can be found in supplementary data, figure7.12 
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5.2.2 Inhibition of JNK1/2 by SP600125 prevents FoxO3a nuclear 
localisation in MCF-7 cells treated with paclitaxel 
In chapter 3, I was able to show that JNK1/2 became activated 
(phosphorylated) following paclitaxel treatment (Fig 3.1, 3.2, 3.3). Research 
conducted in parallel in Prof Lam’s lab (Sunters et al., 2006), indicated that 
treatment of MCF-7 cells with SP600125, an inhibitor of JNK1/2, in 
combination with paclitaxel, attenuated the decrease in phospho-
Thr32FoxO3a (cytoplasmic FoxO3a) observed for cells treated with paclitaxel 
alone. This suggested that JNK1/2 may act upstream to FoxO3a and might 
affect FoxO3a sub-cellular localisation following paclitaxel treatment. 
To determine whether inhibition of JNK1/2 by SP600125 prevented nuclear 
translocation of FoxO3a, I performed, with the help of Dr. Andrew Sunters 
(CRUK Labs, Imperial College, London), confocal microscopy on MCF-7 cells 
treated with paclitaxel, SP600125, or the combination for 16 h. As shown in 
figure 5.2A, the majority of the endogenous FoxO3a remained in the 
cytoplasmic compartment in the untreated control cells and in the cells treated 
with SP600125. Morevoer, treatment with SP600125 almost completely 
prevented nuclear accumulation of FoxO3a in response to paclitaxel 
treatment. In order to confirm these results, I performed nuclear and 
cytoplasmic fractionation experiments and analysed the relative amounts of 
FoxO3a in the nucleus and cytoplasm. The results are presented in figure 
5.2B and show that the majority of FoxO3a in control (untreated) and 
SP600125-treated cells was located in the cytoplasm and after paclitaxel t 
FoxO3a was predominantly localised in the nucleus. As observed using 
confocal microscopy, SP600125 prevented FoxO3a nuclear accumulation 
following paclitaxel treatment. The observation that treatment of MCF-7 cells 
with a SP600125 blocked the paclitaxel-induced nuclear translocation of 
FoxO3a, indicates that JNK1/2 may play a role in nuclear translocation of 
FoxO3a following paclitaxel treatment. 
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Figure 5-2: Inhibition of JNK1/2 by SP600125 prevents FoxO3a nuclear localisation in 
MCF-7 cells treated with paclitaxel.  
(A) MCF-7 cells were grown on coverslips and then treated with paclitaxel (10 nM), 
SP600125 (20 µM), or a combination of paclitaxel and SP600125. Cells were fixed 16 h after 
treatment in 4% formaldehyde and FoxO3a was visualized with a rabbit polyclonal antibody 
and subsequent addition of the ALEX488 (green) labelled anti-rabbit antisera. TRITC-labelled 
phalloidin (red) and DAPI (blue) were also applied to visualize the cytoplasm and nuclei, 
respectively. (B), Western blotting of cytoplasmic and nuclear extracts isolated from MCF-7 
cells which were untreated, treated with paclitaxel (10 µM), SP600125 (20 µM), or SP600125 
and paclitaxel for 8 h. Protein levels were analysed using a specific phospho- FoxO3a (P-
FoxO3) antibody and specific total antibodies. β-actin was used as a loading control. * Non-
specific marking on he autorad. The mark left to the nuclear control sample may be part on 
the protein size marker which ran in that lane (Molecular weight of about 100kDa). An 
experiment showing a similar trend as 5.2B can be found in the supplementary data, figure 
7.13. 
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5.2.3 The effect of JNK1/2 on the sub-cellular localisation of FoxO3a is 
dependent on PI3K/Akt signalling  
The previous experiment showed that inhibition of JNK1/2 prevented nuclear 
translocation of FoxO3a following paclitaxel treatment and work conducted in 
Prof. Lam’s lab by Dr. Andrew Sunters and colleagues (Sunters et al., 2006) 
demonstrated that inhibition of JNK1/2 activity diminished the decrease in 
cytoplasmic, Akt phosphorylated (transcriptionally inactive) FoxO3a following 
paclitaxel treatment. Therefore, I next decided to examine whether the effect 
of JNK on the sub-cellular localisation of FoxO3a was dependent on PI3K/Akt 
signalling. To investigate this, MCF-7 cells were treated with either Triciribine 
(Akt inhibitior) or LY294002 (PI3K inhibitior) alone or in combination with 
SP600125, and the sub-cellular localisation of FoxO3a was examined by 
performing nuclear and cytoplasmic fractionation experiments (Fig 5.3). As 
seen in figure 5.3, the majority of FoxO3a in control (untreated cells) was 
located in the cytoplasm. Following treatment with SP600125 a decrease in 
FoxO3a expression in both the cytoplasmic and nuclear compartments was 
observed. Furthermore, FoxO3a was predominantly located in the nucleus of 
MCF-7 cells following treatment with LY294002 or Triciribine. However, 
treatment of cells with SP600125 failed to prevent the translocation of 
FoxO3a to the nucleus which is triggered by the inhibition of Akt activity 
through LY294002 or Triciribine. Together, these data suggest a role for 
JNK1/2 in the regulation of FoxO3a sub-cellular localisation. Moreover, these 
results also suggest that the main determinant of the sub-cellular localisation 
of FoxO3a is PI3K-acticated Akt activity, and that the effect of JNK1/2 on the 
sub-cellular distribution of FoxO3a occurs predominantly via modulating the 
PI3K/Akt pathway and not by acting directly on FoxO3a. 
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Figure 5-3: Inhibition of JNK1/2 by SP600125 fails to prevent FoxO3a nuclear 
localisation in MCF-7 cells treated with inhibitors of PI3K and Akt.  
Western blotting of cytoplasmic and nuclear extracts isolated from MCF-7 cells treated with 
inhibitors of PI3K and Akt. Cells were treated with either LY294002 (30 µM), Triciribine (30 
µM), or SP600125 (20 µM), or a combination of either LY294002 and SP600125 or Triciribine 
and SP600125 for 8 h. Protein levels were analysed using specific phospho (indicated by a P 
in-front of the protein name) and total antibodies. β-actin was used as a loading control. An 
experiment showing a similar trend can be found in the supplementary data, figure7.14 
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5.2.4 JNK1 affects FoxO3a promoter activity in MCF-7 cells 
In order to determine whether the JNK signalling pathway may also have a 
direct affect on FoxO3a, I decided to examine the effects of JNK activation on 
FoxO3a promoter activity in MCF-7 cells. Hence, MCF-7 cells were 
transiently co-transfected with the FoxO3a promoter/reporter construct and a 
plasmid which expresses constitutively active JNK1 (Fig 5.4A). This 
expression plasmid was a generous gift from Dr. Axel Berhrens, (CRUK 
Labs, Lincoln’s Inn Fields, London) and harbours a JNKK2-JNK1 fusion 
protein. Fusion of JNK1 to its upstream activator JNKK2 results in constitutive 
JNK1 phosphorylation and activation. The JNKK2-JNK1 fusion protein is 
highly specific for the JNK pathway and does not activate either p38 or ERK 
(Zheng et al., 1999).  
As shown in figure 5.4A, cells transiently transfected with constitutively active 
JNK1 showed an increase in FoxO3a promoter activity. Moreover, when 
MCF-7 cells were transiently transfected with the FoxO3a promoter/reporter 
construct and then treated with the JNK inhibitor, SP600125 for 8 h a 
decrease in FoxO3a promoter activity was observed (Fig 5.4B). Taken 
together, these data imply that the JNK signalling pathway, in addition to 
playing a role in the nuclear/cytosolic shuttling of FoxO3a, may also affect 
FoxO3a transcription at the gene promoter level. 
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Figure 5-4: Activation of JNK1 induces the promoter activity of FoxO3a in MCF-7 cells. 
Top panel, a schematic representation of the FoxO3a promoter/reporter construct. (A), MCF-
7 cells were transiently co- transfected with 20ng of pGL3-FoxO3a and either 30ng of 
pCDNA3 (EV) or 30ng of pCDNA3-JNKK2-JNK1. (B), Cells were transiently transfected with 
the FoxO3a promoter/reporter construct and 16 h post transfection cells were either 
untreated or treated with SP600125 (20 µM) for 8 h. Cells were harvested 24 h after 
transfection and assayed for luciferase activity. Values are corrected for co-transfected renilla 
activity. All data shown represent the average of three independent experiments, and the 
error bars show the standard deviation, *p<0.01. 
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5.2.5 JNK1 can phosphorylate FoxO3a 
JNK has been found to phosphorylate FoxO4 at threonine 447 and threonine 
451, which are located within the transactivation domain of FoxO4. This 
occurs following oxidative stress induced activation of the small GTPase Ral 
(Essers et al., 2004). Research conducted in Prof. Lam’s lab by Dr. Muriel 
Aubert revealed that JNK and FoxO3a interact and mass spectrometry 
performed in collaboration with Dr. Simon Arthur (MRC Unit, Dundee) 
identified two potential FoxO3a phosphorylation sites by JNK, serine 294 and 
serine 425. The relative location of these sites with reference to the Akt 
phosphorylation sites can be found in figure 5.5. In order to examine if these 
sites are indeed phosphorylated by JNK in MCF-7 cells, I decided to 
transiently transfect MCF-7 cells with a plasmid expressing constitutively 
active JNK1 (the JNKK2-JNK1 fusion protein as explained in 5.2.4) and 
monitor the phosphorylation status of FoxO3a at serine 294 and serine 425 
residues with specific phospho-antibodies generated against these sites. 
These antibodies were also kindly provided by Dr. Simon Arthur (MRC Unit, 
Dundee) and works best on precipitated protein rather than whole cell lysate. 
Therefore, I decided to immunoprecipitate (IP) cells transfected with the 
JNKK2-JNK1 fusion protein. Since I was experiencing some problems 
performing IP using the FoxO3a total antibody, I also co-transfected the 
MCF-7 cells with the pCMV-FoxO3a construct (a generous gift from Dr. 
Simon Arthur MRC Unit, Dundee) which enabled me to IP transfected cells 
using the Flag antibody which targets the Flag sequence fused to FoxO3a in 
this construct. The results are presented in figure 5.6.  
As seen in figure 5.6, transfection of the JNKK2-JNK1 fusion protein 
increased the levels of active JNK as indicated by the increase in 
phosphorylated JNK (Thr183/Tyr185) in total cell lysate, while the levels of 
total JNK remained the same in both cells transfected with the empty vector 
and cells transfected with the JNKK2-JNK1 expression plasmid. Immuno-
blotting with the total FoxO3a antibody revealed two bands and it is possible 
that the faster migrating band represents the endogenous FoxO3a, while the 
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top band represents transfected FoxO3a which is fused to Flag. In cells 
transfected with JNKK2-JNK1 fusion protein, an increase in the intensity of 
the lower band was observed. This may indicate an increase in the 
expression of endogenous FoxO3a. It is likely that transfection of active JNK1 
also generates an increase in the expression of exogenous FoxO3a, but that 
the increase in endogenous FoxO3a is more prominent because this band in 
the western blot is under-exposed. This implies that phosphorylated/active 
JNK1 can increase the level of FoxO3a expression. Western blotting of 
Immunoprecipitated flag-tagged FoxO3a transfected cells, using the 
phospho-specific antibodies, revealed an increase in FoxO3a phosphorylated 
at the serine 294 residue, but not at the serine 425 residue. Hence, these 
results demonstrate that JNK1 can phosphorylate FoxO3a at serine 294. 
However, it is also possible that JNK1 can phosphorylate FoxO3a at the 
serine 425 site but the antibody used was unable to detect this 
phosphorylation under these experimental conditions. In addition, it is also 
plausible that phosphorylation at the serine 425 site occurs at a lower level 
than phosphorylation at serine 294.  
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Figure 5-5: Akt and JNK phosphorylation sites on FoxO3a.  
Schematic representation of FoxO3a and the relative location of the Akt and JNK 
phosphorylation sites (FKH-forkhead domain, NLS-nuclear localisation signal, NES-nuclear 
export sequence, TA-transactivation domain). 
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Figure 5-6: JNK1 can phosphorylate FoxO3a on Serine 294.  
MCF-7 cells were co-transfected with either the combination of pCMV-FoxO3a and pCDNA3-
JNKK2-JNK1, or with PCMV-FoxO3a and the empty vector, pCDNA3. Cell lysates were 
prepared 36 h after transfection was performed and 20µg were used for western blot and the 
remaining 60µg of lysate was Immunoprecipitated (IP) with an antibody against Flag. The 
levels of total JNK and phospho-JNK (Thr183/Tyr185) and total FoxO3a in transfected cells 
was determined by western blot analysis of total cell lysate. The precipitated anti-Flag 
complexes were resolved on SDS-polyacrylamide gels and immunoblotted with a Flag 
antibody (Immunoprecipitated protein, indicating equal amounts of precipitated protein) and 
antibodies against phosphorylated FoxO3a (predicated JNK phosphorylation sites). An 
experiment demonstrating a similar trend can be found in the supplementary data, figure 
7.15. 
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5.2.6 The effect of mutating FoxO3a’s serine 294 and serine 425 to 
alanines on the activity FoxO3a 
As mentioned in section 5.2.5, JNK has been found to phosphorylate FoxO4 
following oxidative stress. This phosphorylation has been suggested to 
increase the interaction between FoxO4 and the basal transcription 
machinery (Essers et al., 2004). In addition, Akt phosphorylation of FoxO 
proteins induces the binding of 14-3-3 proteins to FoxO leading to the export 
of FoxO from the nucleus; whereas JNK has been shown to phosphorylate 
14-3-3, thereby leading to the release of FoxO from the complex with 14-3-3 
(Sunayama et al., 2005; Tsuruta et al., 2004).   
Previously, I was able to demonstrate that activation of the JNK signalling 
cascade was important for nuclear translocation of FoxO3a following 
paclitaxel treatment (Fig 5.2). Given that I was also able to show that JNK1 
can phosphorylate FoxO3a at serine 294 (Fig 5.6), I next examined the effect 
of mutating FoxO3a JNK phosphorylation sites, serine 294 and serine 425 to 
alanine, on the activity of FoxO3a. Mutating these serine residues to alanine 
residues prevents these sites from being phosphorylated; though these 
proteins mimic constitutively un-phosphorylated FoxO3a proteins at the JNK 
phosphorylation sites. To this end, I used pCMV5-Flag vectors (all of which 
were a generous gift from Dr. Simon Arthur) that harboured one of the 
following: FoxO3a (wt), FoxO3aS294A, FoxO3aS425A or FoxO3aS294A, 
S425A.  
5.2.6.1  Mutating FoxO3a’s serine 294 and serine 425 to alanines reduces 
the ability of FoxO3a to induce the activity of the p27Kip1 promoter  
MCF-7 cells were transiently co-transfected with the p27Kip1 promoter/reporter 
construct and with either wild-type FoxO3a or FoxO3a mutated at one or both 
of JNK phosphorylation sites. As seen in figure 5.7A, co-transfection of the 
wild-type FoxO3a resulted in an increase in p27Kip1 promoter activity, while 
co-transfection of either of the single mutants or the double mutant did not 
affect p27Kip1 promoter activity. I repeated the same transfection, but this 
time, in addition, treated the transfected cells with 30µM LY294002. This was 
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performed in order to inactivate the PI3K/Akt pathway which in turn should 
induce FoxO3a nuclear translocation and activity. As shown in figure 5.7B, 
treatment of the transfected cells with LY294002 for 8 h did no significantly 
alter the results previously attained; an increase in p27Kip1 promoter activity 
was only observed for cells co-transfected with the wild-type FoxO3a.  
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Figure 5-7: Mutating FoxO3a’s serine 294 and serine 425 to alanines impairs FoxO3a’s 
ability to induce p27Kip1 transcription at the promoter level.  
Top panel, schematic representation of the p27Kip1 promoter/reporter construct, the location 
of the FRE-FoxO-recognised element is indicated. (A), MCF-7 cells were transiently co- 
transfected with 20ng of pGL3-p27Kip1 and 10ng of either pCMV5-FoxO3a (wt), pCMV5-
FoxO3aS294A (S294A), pCMV5-FoxO3aS425A (S425A) or pCMV5-FoxO3aS294A,S425A 
(S294A,S425A). (B), Transfected cells were treated with LY294002 (30 µM) for 8 h. All cells 
were harvested 24 h after transfection and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation.*p<0.05 when 
compared to cells transfected with 0ng. 
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5.2.6.2 The Effect of mutating FoxO3a’s serine 294 and serine 425 to 
alanines on the ability of FoxO3a to induce BTG1 promoter activity 
MCF-7 cells were transiently co-transfected with the BTG1 promoter/reporter 
construct and with either wild-type FoxO3a or FoxO3a mutated at one or both 
of JNK phosphorylation sites. As shown in figure 5.8A, an increase in BTG1 
promoter activity was observed only when wild-type, and not mutated 
FoxO3a proteins, were co-transfected with the promoter/reporter construct. 
As shown in figure 5.8B, treatment of transfected cells with 30µM LY294002 
for 8 h induced an increase in BTG1 promoter activity, when wild-type 
FoxO3a, the single mutants (FoxO3aS294A and FoxO3aS425A), but not the 
double mutant (FoxO3aS294A, S425A) were co-transfected. These results 
imply that inhibition of PI3K/Akt pathway, which leads to FoxO3a nuclear 
translocation, is a prerequisite for induction of BTG1 promoter activity by the 
single site JNK phosphorylation mutants, albeit to levels lower than observed 
for wild-type FoxO3a. Nonetheless, inhibition of PI3K/Akt pathway did not 
result in an increase BTG1 promoter activity when FoxO3a mutated in both 
JNK phosphorylation sites was co-transfected, suggesting that at least one 
intact JNK phosphorylation site is required for FoxO3a to up-regulate BTG1 
promoter activity. 
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Figure 5-8: The effect of mutating FoxO3a’s JNK phosphorylation sites to alanine on 
the ability of FoxO3a to up-regulate BTG1 promoter activity.  
Top panel, a schematic representation of the BTG1 promoter/reporter construct, the location 
of the FRE-FoxO-recognised element is indicated. (A), MCF-7 cells were transiently co- 
transfected with 20ng of pGL3-BTG1 and 10ng of either pCMV-FoxO3a (wt), pCMV5-
FoxO3aS294A (S294A), pCMV5-FoxO3aS425A (S425A) or pCMV5-FoxO3aS294A,S425A 
(S294A,S425A). (B), Transfected cells were treated with LY294002 (30 µM) for 8 h. All cells 
were harvested 24 h after transfection and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation;*p<0.01, when 
compared to 0ng of the same construct ^ p<0.05 when compared to cells transfected with the 
wild-type construct and treated with LY294002.  
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5.2.6.3 Mutating both of FoxO3a’s JNK phosphorylation sites to alanine 
impairs FoxO3a’s ability to up-regulate Bim promoter activity 
MCF-7 cells were transiently co-transfected with the Bim promoter/reporter 
construct and with either wild-type FoxO3a or FoxO3a mutated at one or both 
of the JNK phosphorylation sites. As seen in figure 5.9A, an increase in Bim 
promoter activity was observed when both wild-type FoxO3a and FoxO3a 
harbouring one of the mutations (S294A or S425A), but not both of the 
mutations, was co-transfected into MCF-7 cells. Treatment of transfected 
cells with 30µM LY294002 for 8 h, figure 5.9B, also resulted in an increase in 
Bim promoter activity, for MCF-7 transiently co-transfected with either 
FoxO3a (wt), or one of the single-site mutants (FoxO3aS294A, 
FoxO3aS425A). Yet again, no increase in Bim promoter activity was 
observed for cell co-transfected with the double mutant. It appears that the 
FoxO3a S294A mutant can induce the activity of the Bim promoter to levels 
similar to that of the wild-type, while FoxO3a S425A induces Bim promoter 
activity to levels which are statistically lower than those of obtained for the 
wild-type. Taken together, these results indicate that the double FoxO3a 
mutant is unable to up-regulate, under the circumstances tested, the activity 
of the Bim promoter. In addition, inhibition of PI3K/Akt pathway, obtained by 
treatment of the transfected cells with LY294002, was not required in order to 
generate an increase in Bim promoter activity following transient transfection 
of either FoxO3a (wt) or one of single-site mutants.  
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Figure 5-9:. Mutating both of FoxO3a’s JNK phosphorylation sites to alanine impairs 
FoxO3a’s ability to up-regulate Bim promoter activity.  
Top panel, a schematic representation of the Bim promoter/reporter construct the location of 
the FRE-FoxO-recognised element, is indicated. (A), MCF-7 cells were transiently co- 
transfected with 20ng of pGL3-Bim and 10ng of either pCMV5-FoxO3a (wt), pCMV5-
FoxO3aS294A (S294A), pCMV5-FoxO3aS425A (S425A) or pCMV5-FoxO3aS294A,S425A 
(S294A,S425A). (B), Transfected cells were treated with LY294002 (30 µmol/L) for 8 h. All 
cells were harvested 24 h after transfection and assayed for luciferase activity. Values are 
corrected for co-transfected renilla activity. All data shown represent the average of three 
independent experiments, and the error bars show the standard deviation. *p<0.01, when 
compared to cells transfected with 0ng.  
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5.2.6.4 FoxO3a cannot induce Bim (mut -164/-170) promoter activity 
To determine whether the increase observed in Bim promoter activity when 
co-transfected with FoxO3a (wt), FoxO3aS294A and FoxO3aS425A was 
mediated through the FoxO DNA consensus binding site, located in the Bim 
promoter; I decided to perform the same co-transfection experiment, but 
instead of transfecting pGL3-Bim (wt), I transfected the pGL3-Bim (mut-
164/170) construct (mutated in the FoxO DNA binding site). 
MCF-7 cells were co-transfected with pGL3-Bim (mut-164/170), together with 
wild-type FoxO3a or FoxO3a mutated at one or both of the JNK 
phosphorylation sites. Half of the transfected cells were also treated with 
LY294002 in order to inhibit the activity of the PI3K/Akt signalling pathway, 
which should induce FoxO3a activation and translocation to the nucleus. As 
seen in figure 5.10A, no increase in the mutated Bim promoter activity was 
observed when cells were co-transfected with wild-type or mutated FoxO3a 
proteins. Treatment of the transfected cells with LY294002 (Fig 5.10B) also 
yielded the same result. Taken together, this experiment shows that the 
increase observed in Bim (wt) promoter activity, when co-transfected with 
either FoxO3a (wt), FoxO3aS294A or FoxO3aS425A (Fig 5,9A, B), was due 
to the presence of the FoxO DNA consensus binding site in the Bim promoter 
and that the increase in activity was FoxO specific. 
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Figure 5-10: FoxO3a in unable to induce the promoter activity of a Bim 
promoter/reporter construct mutated at the FoxO DNA consensus binding site.  
Top panel, schematic representation of the Bim promoter/reporter construct mutated in the 
FoxO DNA consensus binding site. FRE-FoxO-recognised element, black rectangular 
indicates mutation. (A), MCF-7 cells were transiently co- transfected with 20ng of pGL3-Bim 
(mut) and 10ng of either pCMV5-FoxO3a (wt), pCMV5-FoxO3aS294A (S294A), pCMV5-
FoxO3aS425A (S425A) or pCMV5-FoxO3aS294A,S425A (S294A,S425A). (B), Transfected 
cells were treated with LY294002 (30 µM) for 8 h. All cells were harvested 24 h after 
transfection and assayed for luciferase activity. Values are corrected for co-transfected renilla 
activity. All data shown represent the average of three independent experiments, and the 
error bars show the standard deviation.  
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5.2.7 Mutating FoxO3a’s serine 294 and serine 425 to alanines increases 
FoxO3a proteasomal degradation   
Previous experiments demonstrated that FoxO3aS294A, S425A (mutated at 
both of the potential JNK phosphorylation sites) was unable to up-regulate 
promoter activity of FoxO3a downstream targets in MCF-7 cells (Fig 5.7, 5.8, 
5.9). Treatment with LY294002 did not increase promoter activity levels, 
indicating that inducing nuclear translocation of this protein could not rescue 
this phenotype. Since induction of transcription by FoxOs has been shown to 
be affected by FoxO stability (Plas and Thompson, 2003), it is plausible that 
JNK phosphorylation of FoxO3a might play a role in modulating FoxO3a 
stability. Therefore, I next sought to examine the stability of wild-type FoxO3a 
in comparison to single mutants (FoxO3aS294A, FoxO3aS25A) and the 
double mutant (FoxO3aS294A, S425A). To that end, I transiently transfected 
MCF-7 cells with pCMV5-Flag vectors harbouring one of the following: 
FoxO3a (wt), FoxO3aS294A, FoxO3aS425A or FoxO3aS294A, S425A. After 
which cells were either untreated (NT) or treated with the proteasomal 
degradation inhibitor, MG132 for 4 h. Whole cell lysates were prepared and 
western blotting using a anti-flag antibody was performed.  
As shown in figure 5.11A, MG132 treatment of MCF-7 cells transfected with 
FoxO3a (wt) caused an increase in levels of FoxO3a, indicating that FoxO3a, 
as previously observed, is degraded at least partially, via the proteasomal 
pathway (Plas and Thompson, 2003). Both untreated FoxO3a single amino-
acid mutants (FoxO3aS294A, FoxO3aS425A) showed lower levels of protein 
expression (Fig 5.11A), although slightly higher levels of expression were 
observed for FoxO3aS294A in comparison to the FoxO3aS425A. This could 
be due to variations in transfection efficiency, or stability of the transfected 
proteins. However, this is not related to plasmid degradation as indicated by 
the results of the DNA gel electrophoresis of the plasmids, which is presented 
in Figure 5.11B.  
Treatment with MG132 was able to increase the levels of FoxO3aS294A 
expression, which appear similar to those observed for wild-type FoxO3a (Fig 
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5.11A). No increase in FoxO3aS425A expression was observed following 
treatment with MG132, indicating that this mutant form of FoxO3a was not 
degraded via the proteasome. However, it is possible that this result was 
caused by poor transfection efficiency of the cells as indicated by the very low 
levels of expression of the transfected protein. Untreated cells transfected 
with FoxO3a double amino-acid mutant (FoxO3aS294A, S425A) also 
demonstrated very low levels of protein expression, in comparison to cells 
transfected with wild-type FoxO3a (Fig 5.11A). Again, this could be due to 
either differences in transfection efficiency or stability of the transfected 
protein. Though, it is worth considering the possibility that other proteins 
might also modulate FoxO3a post-translationally and that this may affect 
FoxO3a’s stability and degradation via the ubiquitin-proteasome pathway. 
Nonetheless, treatment with MG132 caused a noticeable increase in 
FoxO3aS294A, S425A expression which appears to be even higher than 
observed for FoxO3aS425A and possibly than observed for wild-type 
FoxO3a. Taken together, these results suggest that the FoxO3a double-
mutant is prone to degradation via the proteasomal pathway, most probably 
more than the wild-type FoxO3a.  
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Figure 5-11: Mutating FoxO3a’s serine 294 and serine 425 to alanines promotes 
protosomal degradation of FoxO3a.  
MCF-7 cells were transfected with either pCMV-FoxO3a (wt), pCMV-FoxO3aS294A (S294A), 
pCMV-FoxO3aS425A (S425A) or pCMV-FoxO3aS294A, S425A (S294A, S425A). 24 h post-
transfection cells were treated with proteasome inhibitor MG132 (50 µmol/L) for 4 h or not 
treated (NT). (A), Whole cell lysates were prepared and separated on SDS-polyacrylamide 
gels and immunoblotted. Flag protein levels were analysed by western blot. β-tubulin was 
used as a loading control. An experiment showing a similar trend can be found in the 
supplementary data, figure 7.16 (B), DNA agarose gel electrophoresis of the four constructs 
transfected in (A). 1µg.of plasmid DNA construct was run on a gel, 1- pCMV-FoxO3a, 2- 
pCMV-FoxO3aS294A, 3- pCMV-FoxO3aS425A, 4- pCMV-FoxO3aS294A, S425A. 
WT S294A S425A
S294A
S425A
NT MG132 NT MG132 NT MG132 NT MG132
Flag (high exp)
β-tubulin
Flag (low exp)
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5.2.8 Mutating FoxO3a’s serine 294 and serine 425 residues to either 
alanine or aspartic acid affects FoxO3a’s stability 
In order to further understand the role of JNK post-translational regulation of 
FoxO3a, I decided to monitor the stability of wild-type FoxO3a in comparison 
to two different FoxO3a mutants, one which cannot be phosphorylated by 
JNK (FoxO3aS294A, S425A) and one which mimics a constitutively JNK-
phosphorylated FoxO3a (FoxO3aS294D, S425D). To that end, MCF-7 were 
transiently transfected with one of the following constructs: pCMV5-Flag-
FoxO3a (wt), pCMV5-Flag-FoxO3a (S294A, S425A) or pCMV5-Flag-FoxO3a 
(S294D, S425D), (which was generated by Dr. Ho Ka Kei, CRUK Labs, 
Imperial College, London), and then treated with 10µg/ml cycloheximide for 
up to 6 h. Western blot analysis was performed using the anti-Flag antibody. 
As shown in figure 5.12, a decrease in the expression levels of wild-type 
FoxO3a and FoxO3a S294A, S425A was noticeable 6 h after treatment with 
cycloheximide commenced. However, there appeared to be no noticeable 
decease in the expression levels of FoxO3aS294D, S425D through the time-
course. Take together, it seems that FoxO3aS294D, S425D is less 
susceptible to degradation than wild-type FoxO3a and FoxO3a S294A, 
S425A. Therefore, it is possible that phosphorylation of FoxO3a by JNK, at 
serine 294 and serine 425, increases the stability of FoxO3a by reducing its 
degradation rate.  
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Figure 5-12: Mutating FoxO3a’s serine 294 and serine 425 affects FoxO3a stability. 
MCF-7 cells were transfected with either pCMV5-FoxO3a (wt), pCMV5-FoxO3aS294A, 
S425A (S294A,S425A) or pCMV5-FoxO3aS294D, S425D (S294D, S425D). 24 h post-
transfection cells were treated with 10μg/ml cycloheximide for up to 6 h. whole cell lysates 
were prepared at indicated time-points, and then separated on SDS-polyacrylamide gels and 
immunoblotted. The levels of Flag were analysed by western blot. β-tubulin was used as a 
loading control. An experiment demonstrating a similar trend can be found in the 
supplementary data, figure7.17 
WT
S294A, 
S425A
S294D, 
S425D
β-tubulin
0     1     2     4     6 0    1     2     4      6 0     1     2     4     6 hCycloheximide:
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5.2.9 The effect of mutating FoxO3a’s serine 294 and serine 425 to 
aspartic acids on the induction of BTG1 promoter activity 
In order to examine whether phosphorylation of FoxO3a by JNK affects 
FoxO3a activity, I decided to transiently co-transfect MCF-7 cells with the 
BTG1 promoter/reporter construct and FoxO3a S294D, S425D, which mimics 
a constitutively JNK-phosphorylated FoxO3a, and compare the levels of 
BTG1 promoter activity to those attained co-transfecting either wild-type 
FoxO3a or FoxO3aS294A, S425A.  
As seen in figure 5.13A, co-transfection of both FoxO3a (wt) and 
FoxO3aS294D, S425D increased BTG1 promoter activity in a similar 
magnitude. However, as previously observed (Fig 5.8), FoxO3aS294A, 
S425A was unable to up-regulate BTG1 promoter activity. I next decided to 
conduct the same co-transfection experiment, but this time, in order to inhibit 
JNK, I also treated the transfected cells with SP600125 for 8 h. This was 
performed because previously, I was able to demonstrate that JNK is active 
in normal cycling MCF-7 (Fig 5.4B) and therefore the effect of JNK 
phosphorylation of FoxO3a may not be prominent in cells that were not 
treated with a JNK inhibitor. As shown in figure 5.13B, inhibiting JNK activity 
caused a decrease in the ability of FoxO3a (wt) to up-regulate BTG1 
promoter activity (p<0.01, when compared to 10ng FoxO3a (wt) non-treated 
in figure 5.13A). As observed for untreated cells, no change in BTG1 
promoter activity levels were observed when FoxO3aS294A, S425A was co-
transfected into MCF-7 cells. Nonetheless, a similar pattern of increase in 
BTG1 promoter activity was observed for FoxO3aS294D, S425D, as to that 
observed for untreated cells, suggesting that inhibition of the JNK signalling 
pathway does not render the ability of this mutant to increase BTG1 promoter 
activity. Taken together, these data imply that inhibition of the JNK signalling 
pathway reduces the ability of FoxO3a to up-regulate BTG1 transcription at 
the promoter level. Furthermore, this result strengthens the notion that JNK 
phosphorylates FoxO3a at serine 294 and serine 425 as the ability of 
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FoxO3aS294D, S425D to induce BTG1 promoter activity was not affected by 
treatment with SP600125. 
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 Figure 5-13: FoxO3aS294D, S425D can induce BTG1 promoter activity.  
Top panel, a schematic representation of the BTG1 promoter/reporter construct, the location 
of the FRE (FoxO recognising element) is indicated. (A), MCF-7 cells were transiently co- 
transfected with 20ng of pGL3-BTG1 and 10ng of either pCMV5-FoxO3a (wt), pCMV5-
FoxO3aS294A, S425A (S294A,S425A) or pCMV-5FoxO3aS294D,S425D (S294D,S425D). 
(B), transfected cells were treated with SP600125 (20 µM) for 8 h. All cells were harvested 24 
h after transfection and assayed for luciferase activity. Values are corrected for co-
transfected renilla activity. All data shown represent the average of three independent 
experiments, and the error bars show the standard deviation. *p<0.01 when compared to 
cells transfected with 0ng.  
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5.3 Discussion 
In chapter 3, I was able to show that in the MCF-7 breast cancer cell line 
paclitaxel treatment lead to up-regulation in FoxO3a expression, followed by 
an increase in the expression of FoxO3a downstream target p27Kip1. I also 
observed a raise in JNK1/2 phosphorylation after treatment with paclitaxel 
(Fig 3.1, 3.2, 3.3). Other work conducted in our lab (Sunters et al., 2006), 
showed that paclitaxel treatment of MCF-7 cells caused an increase in 
FoxO3a expression and downstream pro-apoptotic target Bim, resulting in 
apoptosis of the cells. In this chapter, I was able to show that paclitaxel 
treatment of MCF-7 cells led to an increase in nuclear FoxO3a (Fig 5.1) and 
that treatment of MCF-7 cells with SP600125, a JNK1/2 inhibitor, inhibited 
nuclear accumulation of FoxO3a (Fig 5.2), which is a essential for FoxO3a 
transcriptional activation of downstream proapoptotic and anti-proliferative 
target genes. However, the use of specific inhibitors of PI3K and Akt resulted 
in nuclear accumulation of FoxO3a, which could not be blocked by SP600125 
(Fig 5.3), indicating that the effect of JNK1/2 on FoxO3a nuclear localisation, 
in response to paclitaxel treatment, was dependent on PI3K/Akt signalling 
pathway. Hence, these results suggest that the main determinant of FoxO3a 
sub-cellular distribution is the PI3K/Akt signalling pathway and that this 
pathway may be subject to regulation by JNK1/2.  
In addition to the role of JNK1/2 in the regulation of FoxO3a sub-cellular 
localisation, this pathway also seems to be important for regulation of 
FoxO3a transcription. Activation of the JNK1 signalling cascade induced 
FoxO3a promoter activity in MCF-7 cells and treatment of MCF-7 cells with 
SP600125 appeared to reduce FoxO3a promoter activity (Fig 5.4). This effect 
remains to be tested at the mRNA level. However, it is plausible that a 
transcription factor downstream of JNK1 can up-regulate FoxO3a 
transcription. Indeed, examination of FoxO3a 5’ upstream regulatory region 
revealed the presence of several DNA consensus binding sites of 
transcription factors which are downstream targets of the JNK signalling 
pathway, such as c-Jun (Derijard et al., 1994; Murray et al., 2004), Elk-1 
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(Whitmarsh et al., 1995; Yang et al., 1998) and c-Myc (Alarcon-Vargas and 
Ronai, 2004). Conducting experiments such as chromatin 
immunoprecipitation (ChIP) could help determine whether these transcription 
factors do indeed bind to the FoxO3a promoter following activation of the JNK 
signalling pathway.  
Previously it was shown that JNK can phosphorylate FoxO4 in response to 
H2O2 treatment, leading to the translocation of FoxO4 from the cytoplasm to 
the nucleus (Essers et al., 2004). In the nuclear FoxO4 was found to be able 
to up-regulate the transcription of MnSOD, resulting in the detoxification of 
ROS and by doing so FoxO activiy may promote longevity (Essers et al., 
2004). I was able to show that activation of the JNK1 signalling pathway 
induced phosphorylation of FoxO3a on serine 294 (Fig 5.6). Other 
experiments conducted in Prof. Lam’s lab by Dr. Muriel Aubert and in 
collaboration with Dr. Simon Arthur (MRC Unit, Dundee) demonstrated that 
FoxO3a interacted with JNK both in vitro and in vivo and identified FoxO3a’s 
serine 425 and serine 294, as JNK phosphorylation sites.  
Phosphorylation of FoxO3a by JNK seems to be important for regulation of 
transcription by FoxO3a as mutating serine 294 and serine 425 to alanine 
residues inhibited FoxO3a induced up-regulation of p27Kip, BTG1 and Bim 
promoter activity (Fig 5.7, 5.8, 5.9). Interestingly, mutating each site 
individually showed a specific pattern of regulation unique to each of the 
promoters tested. p27Kip promoter activity was not induced by either 
FoxO3aS294A or FoxO3S425A. BTG1 promoter activity was induced by 
FoxO3aS425A and FoxO3aS294A, in the presence of LY24002, a PI3K 
inhibitor; whereas Bim promoter activity was induced by both FoxO3aS294A 
and FoxO3S425A in the presence and absence of LY294002. Therefore, 
phosphorylation of FoxO3a by JNK might be involved in tightly regulating the 
specificity of FoxO3a downstream target genes transcribed. These results 
suggest that phosphorylation of FoxO3a by JNK at both serine 294 and 
serine 425 preferentially induces transcription of genes important for inhibition 
of cell cycle progression, while phosphorylation of FoxO3a at just one of the 
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two serine residues, seems to be important for induction of BTG1, a gene 
implicated in differentiation of B-cells and the induction of transcription of 
genes involved in apoptosis, such as Bim. However, results obtained 
monitoring BTG1 promoter activity; indicate that inhibition of the PI3K 
pathway may reduce the effect of fine-tuning by JNK phosphorylation, as 
FoxO3aS425A and FoxO3aS294A were able to induce BTG1 only in the 
presence of LY294002. It is important to note that the induction in the activity 
of all of the promoter constructs tested by wild-type FoxO3a is statistically 
significant but moderate. This could be due to the fact that it has recently 
been shown that the main role FoxO3a play in induction of transcription 
appears to be chromatin remodelling (Hatta and Cirillo, 2007). FoxO proteins 
induce transcription by opening and remodelling the chromatin structure and 
since transfected DNA have little chromatin structure, the effect of FoxO 
remodelling of DNA is lost. 
Previously, it has been shown that FoxO3a is degraded via the proteasomal 
pathway (Plas and Thompson, 2003). Indeed, I was able to show that 
treatment of MCF-7 cells with the proteasome inhibitor, MG132 caused an 
increase in the expression levels of FoxO3a, indicating that this protein is 
degraded via the proteasome (Fig 5.11A). Interestingly, mutating both of the 
FoxO3a-JNK-phosphorylation-sites to alanines appeared to increase FoxO3a 
degradation rate, as suggested by what appears to be higher levels of protein 
expression after treatment with MG132 for FoxO3a S294A, S425A in 
comparison to wild-type FoxO3a. Interestingly, it seems as though mutating 
each site individually does not cause this effect, indicating the complexity of 
this regulation. Hence, it seems plausible that phosphorylation of FoxO3a by 
JNK at both of these sites inhibits degradation of FoxO3a. Examination 
whether FoxO3a phosphorylated by JNK at both sites is protected, at least 
partially, from proteasomal degradation could help validate this statement.  
I also examined the rate of degradation of wild-type FoxO3a, FoxO3a 
unphosphorylated by JNK (FoxO3aS294A, S425A) and FoxO3a mimicking a 
constitutively JNK-phosphorylated FoxO3a (FoxO3aS294D, S425D) (Fig 
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5.12). The results of this experiment indicate that phosphorylation of FoxO3a 
by JNK increases FoxO3a stability, as it appears that FoxO3aS294D, S425D 
may have a longer half-life than FoxO3a S294A, S425A following treatment 
with cycloheximide. Results presented in figure 5.12 do not clearly indicate 
whether FoxO3a S294D, S425D also has a longer half-life than wild-type 
FoxO3a, however, it is possible that the effect of JNK phosphorylation on 
FoxO3a’s stability is greater than observed in this experiment. This is 
because I was able to show that the activity level of JNK in normal cycling 
MCF-7 cells, grown in 10% FCS, is high (Fig 5.4B). Hence, it is possible that 
a percentage of the wild-type FoxO3a-Flag, transfected into the cells, got 
phosphorylated by JNK and therefore exhibited increased stability. 
Nonetheless, the results of this experiment strengthen the hypothesis that 
JNK phosphorylation of FoxO3a increases FoxO3a half-life by protecting 
FoxO3a from proteasomal degradation. It would be interesting to examine the 
half-life of FoxO3a harbouring a serine to aspartic acid mutation at each one 
of the JNK phosphorylation sites separately. This will help determine whether 
phosphorylation by JNK at both sites causes a cumulative increase in 
FoxO3a’s half-life, or if phosphorylation at only one of these sites is sufficient 
to cause an increase in the stability of FoxO3a.  
Phosphorylation of FoxO3a by JNK also seems to play a role in determining 
the ability of FoxO3a to induce transcription of target genes at the promoter 
level (Fig 5.13). The FoxO3a S294D, S425D mutant was able to induce the 
activity of the BTG1 promoter, while FoxO3aS294A, S425A was unable to do 
so. Treatment of cells with the JNK inhibitor, SP600125, did not affect 
FoxO3a S294D, S425D ability to up-regulate BTG1 activity, but did cause a 
decrease in ability of wild-type FoxO3a to do so. Therefore, it is plausible that 
phosphorylation of FoxO3a by JNK positively affects FoxO3a’s ability to up-
regulate transcription of target genes. However, this hypothesis needs to be 
tested at the mRNA and protein expression levels. In addition, this effect may 
also be target gene specific and therefore should be examined on other 
transcriptional targets of FoxO3a. 
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Taken together, the data presented here demonstrates that FoxO3a can be 
regulated by JNK at various levels. At the transcriptional (gene promoter) 
level, I found that JNK1 was able to induce FoxO3a promoter activity, while 
inhibition of this pathway had a negative effect on up-regulation of FoxO3a. 
At the post-translational level, I was able to show that JNK1/2 can regulate 
FoxO3a sub-cellular localisation following treatment with paclitaxel. 
Treatment of MCF-7 cells with paclitaxel induces FoxO3a translocation to the 
nucleus. This event seems to be predominantly regulated by the PI3K/Akt 
pathway. However, the activation of JNK1/2 and suppression of Akt following 
treatment with paclitaxel suggest that there may be cross-talk between these 
two signal transduction pathways. This assumption is further strengthened by 
work other published data. it has also been shown that DAF-16 (the 
homologue of mammalian FoxO) is directly phosphorylated by C.elegans JNK 
after heat shock, resulting in an  increase in stress resistance and longevity 
by a mechanism dependent on nuclear translocation of DAF-16 (Oh et al., 
2006). Moreover, binding of FoxO to 14-3-3 following Akt activation results in 
the translocation of FoxO from the nucleus to the cytoplasm. JNK has been 
shown to phosphorylate 14-3-3 proteins, which terminates the interaction 
between14-3-3 and FoxO  (Tsuruta et al., 2004).  
Data obtained in our lab, which was partly presented in this chapter, 
demonstrates that JNK can post-translationally regulate FoxO3a by 
facilitating phosphorylation at the serine 294 and serine 425 sites, and that 
this phosphorylation can affect the stability and perhaps even the activity of 
FoxO3a. It appears that phosphorylation of FoxO3a by JNK at both sites may 
increase FoxO3a’s stability by reducing FoxO3a proteasomal degradation. 
This phosphorylation may also increase FoxO3a’s ability to induce the activity 
of downstream target genes; however the results obtained in this experiment 
were inconclusive. Furthermore, this effect may be target-gene specific, 
related to the activation status of the PI3k/Akt pathway and may not 
necessarily require phosphorylation of FoxO3a by JNK at both sites 
identified. Nonetheless, a recent report using a C.elegans jnk-1 deletion 
 215
mutant revealed that JNK-1 plays a role in inducing the nuclear localisation 
DAF-16 and subsequent DAF-16 dependent transcription of the target gene 
sod-3 (Wolf et al., 2007). 
 
In summary, I was able to show that paclitaxel treatment of MCF-7 cells 
induces FoxO3a translocation to the nucleus and that this post-translational 
regulation involves both the PI3K/Akt and JNK signalling pathways, indicating 
that these two pathways cross-talk. Further analysis on the role of JNK in the 
regulation of FoxO3a revealed that at the gene promoter level, activation of 
JNK1 appears to induce the transcription of FoxO3a and that at the post-
translational level, JNK1 can phosphorylate FoxO3a at two different sites and 
this leads to an increase in FoxO3a’s stability, which is probably partially 
mediated by the ubiquitin-proteasome pathway. Moreover, mutating both of 
the JNK phosphorylation sites in the FoxO3a protein decreased FoxO3a’s 
ability to induce the promoter activity of downstream targets.  
5.4 Future work 
It would be interesting to explore whether treatment with paclitaxel induces 
JNK phosphorylation of FoxO3a and if inhibiting these phosphorylation 
events would decrease FoxO3a’s ability to induce cell death in response to 
paclitaxel. Furthermore, since treatment with paclitaxel can also up-regulate 
the activity of other signalling pathways, such as p38 (Bacus et al., 2001; 
Seidman et al., 2001), it would be beneficial to conduct a similar experiment 
in which only the activity JNK is up-regulated, such as treating MCF-7 cells 
with TNF-α, which activates JNK but not p38. In addition, an experiment 
using MEFs derived from wild-type mice, jnk1 and jnk2 double knockout mice 
and p38 knockout mice treated with paclitaxel; would help confirm the role of 
JNK in the nuclear translocation of FoxO3a and also indicate if this role is 
reserved to the JNK signal transduction pathway or whether p38 can also 
influence the sub-cellular localisation of FoxO3a in Jnk1/2 knockout cells.  
ΔMEKK3:ER cells, which express phospho-JNK1/2 in an inducible manner 
following treatment with 4-hydoxytamoxifen (and are available in Prof. Lam’s 
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lab), could be used in order to determine whether JNK can, in addition to 
inducing FoxO3a promoter activity, also up-regulate the expression of 
FoxO3a at the mRNA level. 
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6 Final Discussion 
6.1 Summary 
The FoxO family of transcription factors are negatively regulated by the PI3K 
signalling pathway. This pathway has been found to be deregulated and 
mutated in several cancers and has been implicated in tumourigenesis and 
tumour progression (Campbell et al., 2004; Ma et al., 2000; Mizoguchi et al., 
2004; Woenckhaus et al., 2002). 
The work presented in this thesis focused on the role and regulation of FoxO 
transcription factors. I initially studied the regulation of FoxOs at the 
transcriptional level, using breast epithelial and endometrial cells as model 
systems. Next, I examined the function of FoxO3a in cell proliferation through 
investigating the role of BTG1, a novel downstream target of FoxO3a (Bakker 
et al., 2004), in breast cancer. Finally, I studied the cross-talk between the 
PI3K signalling pathway and the JNK signalling cascade in the regulation of 
FoxO. Through my work, I was able to demonstrate that FoxO proteins are 
targets of the chemotherapeutic drug, paclitaxel. I was also able to show that 
FoxO3a integrates signals from both the PI3K signalling pathway and the 
JNK signalling cascade, to mediate an increase in the transcription of 
downstream targets, in response to paclitaxel and oxidative stress. FoxO 
proteins regulate the expression of a spectrum of genes which are important 
for both mediating cell death and for inducing longevity, such as genes 
involved in cell cycle arrest (De Ruiter et al., 2001; Medema et al., 2000; 
Nakamura et al., 2000; Seoane, 2004; Stahl et al., 2002; Tanaka et al., 
2001), apoptosis (Brunet et al., 1999; Modur et al., 2002), DNA repair 
(Furukawa-Hibi et al., 2002; Tran et al., 2002) and ROS detoxification 
(Balaban et al., 2005; Kops et al., 2002a; Nemoto and Finkel, 2002). BTG1 
was shown to up-regulate the expression and activity of some of FoxO3a’s 
target genes and to inhibit cell cycle progression.  
Taken together, these data validate the initial hypothesis that FoxO 
transcription factors are downstream targets of chemotherapeutic drugs, such 
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as paclitaxel and are important in cancer development and progression. 
Hence, by defining and exploiting a mechanism that would enable us to shift 
FoxO activity from stress resistance and longevity towards induction of cell 
death, we might be able to influence cancer cell fate through inducing 
apoptosis, restoring cell cycle arrest and senescence, and counteracting 
longevity in these cells.  
6.2 Transcriptional regulation of FoxO proteins 
The study detailed in chapter 3 examined whether FoxO transcription factors 
are regulated at the transcriptional level by paclitaxel, in cancer cells. I was 
able to demonstrate that indeed paclitaxel treatment caused an increase in 
FoxO3a protein expression, mRNA levels and promoter activity in the breast 
cancer cell lines. Consistent with this, work conducted on the endometrial cell 
line HEC-1-B, also indicated that FoxO1 expression is induced by paclitaxel 
at the protein, mRNA and promoter levels. However, in the MCF-7 breast 
cancer cell line, despite the increase observed in FoxO3a expression and 
promoter activity, FoxO3a mRNA levels remained unaffected by paclitaxel. 
The reason for this is unknown as previous work conducted in our lab by Dr. 
Sunters and colleagues (Sunters et al., 2003) showed an increase in FoxO3a 
mRNA levels following paclitaxel treatment. Nonetheless, further experiments 
led to the possibility that paclitaxel can regulate FoxO3a post-translationally 
by reducing FoxO3a protein turnover, which increases protein stability. In the 
literature it has been shown that oxidative stress can increase protein stability 
(Nguyen et al., 2003). In line with this, my results and previously published 
data (Alexandre et al., 2006), demonstrate that paclitaxel treatment can 
increase the levels of oxidative stress in the cells. Furthermore, similar to the 
results obtained with paclitaxel, I was also able to show that FoxO3a protein 
stability increases following H2O2 treatment in MCF-7 cells. However, the 
mechanism enabling the increase in protein stability remains to be elucidated.  
 
Another aspect of the work presented in chapter 3, is the regulation of FoxO 
transcription factors at the gene-promoter level. Generation of truncated 
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FoxO3a promoter constructs revealed that FoxO3a is most probably 
regulated at the transcriptional level by both negative and positive 
transcription regulators. These studies also enabled mapping a region of 
131bp in the FoxO3a 5’ regulatory region which is responsive to paclitaxel 
treatment.  
FoxO1 and FoxO3a were shown to be partially regulated at the promoter 
level by the MEF2 transcription factor. Over-expression of MEF2 was shown 
to increase FoxO promoter activity, while mutating the MEF2 DNA consensus 
binding sites located within the FoxO1 promoter, yielded mixed results. While 
I was able to show that mutating one of the three sites decreased FoxO1 
basal promoter activity, no statistically significant change in FoxO1 promoter 
activity were observed when mutating the other two sites. However, co-
transfection of MEF2 was found to augment both FoxO1 and FoxO3a 
promoter activity following paclitaxel treatment. This additive effect indicates 
that paclitaxel and MEF2 regulate FoxO promoter activity by two separate 
mechanisms. Therefore, targeting MEF2 may serve as a therapeutic strategy 
for treatment of cancer in synergy with classical chemotherapeutic 
treatments, such as paclitaxel. These results suggest that increasing the 
expression of MEF2 in the cells may increase the response of cells to 
paclitaxel treatment by further inducing the levels of FoxO expression, which 
could lead to an induction in the expression levels of downstream pro-
apoptotic target genes.  
 
These finding are important because this is the first time that FoxO 
transcription factors were shown to be regulated at the transcriptional level. 
Prior to this study, the regulation of FoxO transcription factors focused on the 
study of post-translational modifications. FoxO proteins were shown to be 
phosphorylated by Akt, which decreases the ability of FoxO transcription 
factors to bind to the DNA and leads to the translocation of FoxO from the 
nucleus to the cytosol and inhibition of FoxO’s activity (Biggs et al., 1999; 
Brunet et al., 1999; Kops et al., 1999; Rena et al., 1999; Tang et al., 1999). 
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Recently, it has also been shown that acetylation of FoxO proteins plays a 
role in the post-translational regulation of FoxO transcription factors (Brunet 
et al., 2004; Daitoku et al., 2004; Fukuoka et al., 2003; Kobayashi et al., 
2005; Mahmud et al., 2002; Motta et al., 2004; Perrot and Rechler, 2005; van 
der Horst et al., 2004; Yang et al., 2005b); however the significance of this 
only became known once I already started working on this dissertation.  
The significance of the regulation of FoxO at the transcriptional level is 
emphasised by the work of Dr. Sunters and colleagues (Sunters et al., 2003), 
which demonstrated that FoxO3a expression levels differs between breast 
cancer cell lines and that these differences are indicative of cell sensitivity to 
paclitaxel treatment. This work showed that paclitaxel treatment induced 
apoptosis in cell lines that expressed FoxO3a at elevated levels while G2/M 
arrest was induced in cells that expressed FoxO3a at lower levels.  
 
Overall, FoxO can be important bio-markers for monitoring the effectiveness 
of chemotherapeutic drugs, such as paclitaxel. Furthermore, treatment of 
cancer patients with paclitaxel in conjunction with a substance which would 
generate an increase in the number of FoxO transcripts in the cells may 
prove as an avenue worth exploring for the development of cancer therapy 
strategies. 
6.3 Sensitivity of ER negative and ER positive cells to 
paclitaxel 
A connection between FoxO activity and ER expression has been previousely 
suggested in the literature (Goto et al., 2007; Schuur et al., 2001; Sui et al., 
2007; Sunters et al., 2003; Zhao et al., 2001; Zou et al., 2008). Activation of 
the ER signalling pathway by estrogen has been shown to increase cell 
proliferation and contribute to the tumourigenic process, while FoxO 
activation can result in inhibition of cell proliferation and induction of 
apoptosis. As one study (Schuur et al., 2001) suggested that ER interacts 
with FoxO and represses FoxO-mediated transactivation of target genes, and 
thereby ER is inhibiting cell cycle arrest. Others studies suggest that FoxO 
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and ER interact, but that this interaction leads to inhibition of ER induced 
transactivation of target genes  (Zhao et al., 2001; Zou et al., 2008). Further 
discrepancies can be found in the literature regarding the sensitivity of ER 
negative and ER positive cells to treatment with paclitaxel. Whilst some 
reports suggest that ER negative cells are more sensitive to paclitaxel  
(Razandi et al., 2000; Sui et al., 2007), other reports suggest the opposite 
(Sunters et al., 2003; Zou et al., 2008). Sunters and colleagues found that ER 
negative breast cancer cells (MDA-MB-231) were less sensitive to paclitaxel 
and did not undergo apoptosis following treatment with paclitaxel, while the 
ER positive breast cancer cells (MCF-7) were sensitive to paclitaxel and the 
apoptotic programme was initiated in the cells following treatment with 
paclitaxel (Sunters et al., 2003). My data shows that FoxO3a expression is 
up-regulated, following paclitaxel treatment, in two ER positive breast cancer 
cell lines (MCF-7 and BT-474). This up-regulation resulted in nuclear 
localisation of FoxO3a in MCF-7 cells and for both cell lines, an increase in 
the expression of a FoxO3a downstream target (p27) was observed. Taken 
together, some of the data presented in the literature suggest that ER positive 
breast cancer cells may be less sensitive to paclitaxel-induced cell death and 
that ER expression may hinder FoxO induced transcription of target genes. 
My results and others’  (Zou et al., 2008) show that treatment of ER positive 
breast cancer cells with paclitaxel causes up-regulation in FoxO expression 
and nuclear translocation, signifying that treatment of ER positive breast 
cancer with paclitaxel may be beneficial. This could be dependent on whether 
the cells express FoxO at high and inducible levels (Sunters et al., 2003) and 
may also be affected by the cross-talk with other cellular signaling pathways. 
Elevated levels of HER2 and EGFR expression have been linked to 
resistance to treatment with SERMs (Sengupta and Jordan, 2008). 
Furthermore, clinical data suggest that treatment of breast cancer patients 
with trastuzumab (inhibits the HER2 signaling pathway) in combination with 
paclitaxel is more efficacious than treatment with paclitaxel alone (Nicolini et 
al., 2006; Smith and Chua, 2006). Therefore, the levels of activity of other 
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signaling pathways, such as HER2, may affect the activity of the ER signaling 
pathway and lead to phenotypes, such as reduced sensitivity to paclitaxel.  
6.4 Cross-talk between JNK1/2 signalling cascade and the 
PI3K/Akt signalling pathway 
Experiments conducted in chapter 5 demonstrated that treatment of MCF-7 
cells with paclitaxel led to an increase in nuclear FoxO3a and that this 
increase correlated with a paclitaxel induced reduction in active Akt. This 
suggested that paclitaxel-induced inhibition of Akt leads to a decrease in the 
levels of phosphorylated FoxO3a, which results in the nuclear localisation of 
FoxO3a. Furthermore, blocking the JNK signalling pathway in MCF-7 cells 
treated with paclitaxel prevented nuclear accumulation of FoxO3a, which is 
essential for FoxO-induced transcriptional activation of target genes (Sunters 
et al., 2006). The use of specific inhibitors of the PI3K/Akt pathway 
demonstrated that the effect of JNK on FoxO3a nuclear localisation, in 
response to paclitaxel, was dependent on PI3K/Akt signalling pathway. In 
fact, it has previously been shown that over-activation of Akt or expression of 
a constitutively active form of Akt protects cells from the cytotoxic effects of 
paclitaxel (MacKeigan et al., 2002; Page et al., 2000; Sunters et al., 2006; 
VanderWeele et al., 2004).  
The observation that following paclitaxel treatment Akt is inactivated and  
JNK1/2 is activated imply that these two signal transduction pathways cross-
talk. This notion is further strengthened by the observation that activation of 
JNK in an inducible MEKK3-expressing cell line resulted in reduced activity of 
Akt and that MEF cells derived from JNK null mice had elevated levels of 
active Akt (Sunters et al., 2006). Hence, these data suggest that stress-
induced JNK1/2 activity regulates FoxO3a by inhibiting Akt which results in 
the nuclear accumulation of FoxO3a.  
 
Further work conducted in chapter 5 (and data obtained from ongoing 
research in Prof. Lam’s lab) demonstrated that FoxO3a and JNK interact and 
that JNK can phosphorylate FoxO3a. This phosphorylation was shown to 
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increase FoxO3a’s stability, while preventing JNK-mediated phosphorylation 
was shown to cause a decrease in the stability of FoxO3a. It has previously 
been shown that phosphorylation of the p53 transcription factor reduces the 
affinity of p53 to the E3-ligase MDM2, resulting in an increase in the stability 
of p53 (Kubbutat et al., 1997). Taken together, it possible that 
phosphorylation of FoxO3a by JNK increases the stability of FoxO3a by 
preventing the binding of ubiquitin ligase to FoxO3a. JNK has been found to 
phosphorylate FoxO4 following exposure to ROS (Essers et al., 2004). 
Hence, it is possible that a link exists between the results obtained in chapter 
3, which demonstrated that treatment with paclitaxel and H2O2 increased 
FoxO3a stability, to the results attained in chapter 5, which showed that 
phosphorylation of FoxO3a by JNK also rendered the same effect. Taken 
together, this suggests that oxidative stress may cause JNK to phosphorylate 
FoxO3a which results in an increase in the stability of FoxO3a. 
 
This is not the first time that JNK signalling was shown to affect the activity of 
members of the FoxO family of transcription factors and affect lifespan. 
Previous research conducted in C.elegans, Drosophila and mammalian cells 
have shown that JNK regulates FoxO activity. In C.elegans DAF-16, the 
orthologue of mammalian FoxO, was found to be phosphorylated by JNK-1 
following heat shock, leading to the nuclear localisation of DAF-16 (Oh et al., 
2005). Furthermore, it has been suggested that JNK-1 induces DAF-16 
nuclear accumulation leading to the transcription of the target gene sod-3 
(Wolf et al., 2007). In Drosophila it was shown that JNK can extend the 
lifespan of Drosophila and that this was dependent on Drosophila FoxO, 
which was shown to translocate to the nucleus following JNK activation and 
induce transcription of target genes (Wang et al., 2005). In mammalian cells, 
it has been shown, in response to oxidative stress JNK becomes activated 
and phosphorylates FoxO4 at two residues, threonine 447 and threonine 451. 
This leads to the nuclear accumulation of FoxO4 and induction of the 
transcription of the downstream target MnSOD (Essers et al., 2004). 
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Therefore, another aspect of the work related to the regulation of FoxO3a by 
JNK focused on the function of FoxO3a following phosphorylation by JNK, 
however results obtained are insufficient to determine the effect of JNK 
phosphorylation on the transcription of FoxO target genes.  
 
The mechanism by which FoxO factors regulate diverse cellular fates such as 
cell death versus longevity is not entirely clear, but has been suggested to be 
related to environmental stimuli and other types of post-translational 
modification of FoxO factors, such as acetylation and de-acetylation (by 
SIRT1) (Brunet et al., 2004; Motta et al., 2004).Taken together, these data 
imply that FoxO transcription factors are able to specifically control the 
expression of downstream targets according to cellular conditions. This is 
achieved by differential post-translational modification of FoxO proteins, 
which enables FoxO transcription factors to participate in such varied and 
opposing processes, like longevity and apoptosis. One possibility is that 
under oxidative stress conditions, in the presence of growth factors, FoxO 
proteins are phosphorylated by JNK and translocate into the nucleus. In the 
nucleus, acetylated-JNK-phosphorylated-FoxO proteins induce cell death and 
apoptosis. However, if FoxO proteins are deacetylated by SIRT1 in the 
nucleus, a shift towards up-regulation of FoxO target genes involved in cell 
cycle arrest and detoxification of ROS occurs. 
6.5 The role of BTG1 
FoxO transcription factors haven been implicated in differentiation (Bakker et 
al., 2004; Birkenkamp et al., 2007; Hribal et al., 2003; Nakae et al., 2003). 
BTG1 was shown to be a downstream target of FoxO3a in erythroid 
progenitor cells; and expression of BTG1 appears to potentiate erythroid 
differentiation (Bakker et al., 2004). Recently, it has also been shown that 
FoxO3a induces differentiation of BCR-ABL transformed cells by down-
regulating the transcription of Id1 (inhibitor of DNA binding 1) (Birkenkamp et 
al., 2007). However, some reports have demonstrated that in adipocytes and 
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myoblasts expression of FoxO1 inhibits differentiation in vitro (Hribal et al., 
2003; Nakae et al., 2003).  
Research conducted in chapter 4 revealed that BTG1 was a downstream 
target of FoxO3a in breast epithelial cells. Although, I was unable to 
determine to the precise function of BTG1 in MCF-7 cells, I was able to 
demonstrate that over-expression of BTG1 resulted in a decrease in cell 
growth and accumulation of cells at the G2/M phase of the cell cycle. 
Furthermore, over-expression of BTG1 resulted in an increase in the 
expression of p21Cip1 and p27Kip1 at the protein, mRNA and promoter levels, 
while a decrease in the levels of cyclin D1 at the protein, mRNA and gene-
promoter levels was observed. A decrease in cyclin E1 expression was also 
noted at the protein and mRNA levels. PRMT1 and p/CAF are cofactors 
involved in ER-dependent signalling in breast cells and it was found that 
interaction of BTG1 with p/CAF can have either a negative or positive effect 
on the regulation of the function ER (Prevot et al., 2001). Hence, this 
observation further strengthens the possibility that BTG1 may be involved in 
both positive and negative regulation of transcription. Furthermore, it was 
shown that the rat homologue of BTG2 inhibits the expression of cyclin D1, 
which induces ER transactivation (Prevot et al., 2001). Therefore, it is 
possible that BTG1 may be a key factor in treatment of ER positive breast 
cancer patients. Moreover, results presented in chapter 4 imply that induction 
of BTG1 expression in breast cancer cells can lead to cell cycle arrest. Over-
expression of BTG1 was not shown to induce apoptosis; however, a slight 
increase in BTG1 expression was observed in MCF-7 cells following 
paclitaxel treatment. Therefore, it is possible that BTG1 may play a role in the 
induction of cell death following paclitaxel treatment in MCF-7 cells and that 
due to the fact that I was using an inducible gene expression system; I was 
unable to detect an increase in cell apoptosis. The inducible system enables 
up-regulation of only BTG1 mRNA and therefore if BTG1 requires the 
presence of other proteins or binding partners, such as transcription factors, 
to exert a pro-apoptotic effect, the abundance of these co-factors will 
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determine the ability of BTG1 to induce cell death. Nonetheless, the results 
obtained in chapter 4 emphasise the role of FoxO3a in breast cancer as 
BTG1, a downstream target of FoxO3a in MCF-7 cells, is involved in the 
regulation of the cell cycle in breast cancer cells. 
Previously it has been shown that FoxO transcription factors require co-
factors, in order to bind to the promoters of target genes and regulate their 
transcription specific target genes. In gastric cancer cells FoxO3a was shown 
to interact with the RUNX3 transcription factor on the  Bim promoter, leading 
to an induction in the expression of Bim (Yamamura et al., 2006). Smad and 
FoxO were found to interact following treatment with TGF-β (transforming 
growth factor β) resulting in an increase in the expression of the cyclin-
dependent kinase inhibitor p21Cip1 (Gomis et al., 2006; Seoane et al., 2004). It 
is possible that FoxO3a up-regulation of BTG1 expression requires the 
presence of other transcriptional co-factors. Determining which transcription 
factors have DNA consensus binding sites adjacent to that of FoxO’s on the 
BTG1 promoter, may help reveal possible candidates for co-regulation of 
BTG1 expression. One such candidate may be c-Jun, a target of the JNK 
signalling pathway, as its DNA consensus binding site is adjacent to that of 
FoxO’s. Mutating this DNA consensus binding site (or those of other 
candidates) and examining the ability of transfected FoxO3a to up-regulate 
BTG1 expression, and/or performing ChIP (chromatin immunoprecipitation), 
may help determine if indeed FoxO3a requires the presence and binding of 
other transcriptional factors in order to induce BTG1 expression in breast 
cancer cells.  
6.6 FoxO transcription factors as tumour suppressors 
The hypothesis that FoxO transcription factors may act as tumour 
suppressors is mainly based on their role in induction of cell cycle arrest and 
apoptosis (Essafi et al., 2005; Fernandez de Mattos et al., 2004; Hu et al., 
2004; Liu et al., 2005a; Park et al., 2005; Seoane, 2004; Sunters et al., 2006). 
However, since the formal definition of a tumour suppressor gene, is a gene 
which exhibits a loss of function mutation in cancer (Christophorou et al., 
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2005; Levine and Momand, 1990; Vogelstein and Kinzler, 2004), research 
has also focused on the implications of mutating FoxO genes and their 
regulators on the development of cancer. In human breast cancer, it has 
been suggested that the localisation of FoxO predominantly in that cytoplasm 
(inactive FoxO) is associated with a poor prognosis for patients (Hu et al., 
2004). Recently, FoxO factors in mice were found to have what appears as  
tissue specific tumour suppressors activities (Paik et al., 2007). The 
C.elegans defective in germ line development (gld-1) gene is considered to 
be a tumour suppressor (Francis et al., 1995). Mutating both the gld-1 gene 
and the DAF-2 gene has been shown to increase the lifespan of C.elegans by 
a mechanism that appears to be dependent on DAF-16 and p53 activity 
(Pinkston et al., 2006). Extensive screening using C.elegans mutated in both 
the gld-1 gene and the DAF-2 gene identified 29 DAF-16 target genes which 
were shown to have an affect on either tumour cell proliferation or apoptosis, 
some of which are orthologues of human oncogene and tumour suppressor 
genes. Of the 29 genes identified, half have also been shown to play a role in 
normal aging which implies that there is a link between the aging process and 
tumourigenesis (Pinkston-Gosse and Kenyon, 2007). Taken together, it 
appears that FoxO transcription factors act as tumour suppressors and that 
this feature is evolutionary conserved. However, these results also imply that 
this activity of FoxO may be tissue specific.  
 
Another link between FoxO activity and cancer development, is based on the 
fact the FoxO proteins are downstream targets of the PI3K/PTEN/AKT 
signalling pathway, which has been shown to be highly mutated in many 
different types of cancer (Bachman et al., 2004; Broderick et al., 2004; 
Samuels et al., 2005; Samuels et al., 2004; Altomare and Testa, 2005).. 
FoxO activity was found to oppose the effect of mutations in this signalling 
pathway (Kau et al., 2003;Trotman et al., 2006; Samuels et al., 2005).  
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The similarities between FoxO activity and the activity of p53, also suggest 
that FoxO may be a tumour repressor. The activity of both these proteins is 
regulated by environmental stimuli. FoxO proteins have been shown to be 
activated following exposure to oxidative stress leading to the transcription of 
target genes such as MnSOD and catalase (Kops et al., 2002a; Nemoto and 
Finkel, 2002) which play an important role in detoxification of oxidative stress; 
while p53 has been shown to become activated following genotoxic stress, 
leading to the transcription of GADD45 (Kastan et al., 1992). In addition both 
these transcription factors upregulate the transcription of genes involved in 
the regulation of the cell cycle and even share the same target gene. FoxO3a 
has been shown to induce the transcription of p27kip1 (Medema et al., 2000) 
and p21cip (Seoane, 2004)., while p53 has been shown to upregulate the 
transcription of p21 (el-Deiry et al., 1993). Furthermore, both FoxO and p53 
can induce apoptosis. FoxO3a has been found to increase the transcription of 
the pro-apoptotic genes Bim (Dijkers et al., 2000a) and FasL (Brunet et al., 
1999) and p53 has been shown to upregulate the transcription of PUMA 
(Nakano and Vousden, 2001).   
Furthermore, both FoxO and p53 are regulated post-translationally, and in 
same cases by the same enzymes, SIRT1, JNK and USP7 have been shown 
to deacetylate, phosphorylate and deubiquitylate FoxO and p53, respectively 
(Adler et al., 1997; Essers et al., 2004;Brunet et al., 2004; Luo et al., 2001; 
Motta et al., 2004; van der Horst et al., 2004; Vaziri et al., 2001; Li et al., 
2002; van der Horst et al., 2006). Deacetylation of FoxO3a by SIRT1 has 
been shown to affect the activity of FoxO; however, there is no clear 
agreement as to how this influences FoxO activity. Nonetheless, it has been 
suggested that deacetylation of FoxO by SIRT1 causes FoxO to selectively 
transcribe genes involved in increasing lifespan (Greer and Brunet, 2005). 
Deacetylation of p53 by SIRT1 results in the inhibition of the activity of 
p53(Luo et al., 2001). JNK has a positive effect on both FoxO and p53 
activity. JNK has been shown to phosphorylate and activate FoxO4 and 
induce nuclear localisation of FoxO3a (Essers et al., 2004; Sunters et al., 
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2006). The phosphorylation of p53 by JNK has been shown to increase the 
stability and activity of p53 (Buschmann et al., 2001). Deubiquitylation of 
FoxO and p53 by USP7 does not affect these proteins in the same way.  
USP7 deubiquitylation of FoxO results in the inhibition of FoxO activity, while 
USP7 deubiquitylation of p53 lead to an increase in the stability and thereby 
activity of p53 (Li et al., 2002; van der Horst et al., 2006). Overall, FoxO and 
p53 have been show to be regulated post-translationally by similar 
mechanisms, though not always leading to the same effect on their activity. In 
addition, FoxO and p53 have been found to be able to regulate the 
expression of target genes that participate in the same or similar cellular 
processes and even share some of the same transcriptional downstream 
targets. All this, is suggesting that FoxO, like p53, may also be a tumour 
repressor. 
6.7 Targeting FoxO in cancer therapy  
The necessity to increase the efficiency of cancer therapy is a longstanding 
goal. Therefore identifying cellular targets which may serve for chemotherapy 
is of utmost importance. As discussed above, FoxO transcription is up-
regulated following paclitaxel treatment. FoxO target genes have been 
implicated in a broad spectrum of activities, with induction of apoptosis at one 
extreme of the spectrum and induction of longevity at the other. To date, it 
has been shown that breast cancer cells that express FoxO3a at high levels 
are more susceptible to paclitaxel treatment in comparison with breast cancer 
cells that express FoxO3a at low and non-inducible levels (Sunters et al., 
2003). This has been mainly attributed to the up-regulation in the expression 
of FoxO3a’s pro-apoptotic target gene, Bim. Hence, expression and 
activation of FoxO3a in cancer cells may lead to the activation of the 
apoptotic pathway. In addition, it has also recently been shown that FoxO 
induced apoptosis occurs in tumour cells and not normal cells  (Pinkston-
Gosse and Kenyon, 2007).  
Furthermore, the PI3K/Akt pathway, which regulates vital processes, such as 
cell survival, proliferation, growth, metabolism and cell migration (see 
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introduction); has as mentioned above, been found to be deregulated or 
mutated in many cancers. FoxO factors are downstream effectors of this 
signalling pathway and although data suggests that there is a decrease in the 
function of FoxO in some cancers, no FoxO gene promoter methylation or 
mutations in the genes have been identified in human cancers. Nonetheless, 
chromosome translocations (Davis et al., 1994; Parry et al., 1994; Shapiro et 
al., 1993; So and Cleary, 2003) and deletions (Dong et al., 2006) have been 
identified. Therefore, taken together, these data imply that FoxOs may prove 
to be an attractive target for cancer therapy. 
However, targeting FoxO genes for cancer therapy may prove to be a 
complicated task as FoxO genes play vital roles at both the organismal and 
the cellular levels. FoxO1-null mice were found to be embryonic lethal 
(Hosaka et al., 2004), and conditional knock-out of three isoforms  of FoxO in 
mice (FoxO1, Foxo3a, FoxO4) has also been shown to lead to the 
development of certain malignancies (Paik et al., 2007). Furthermore, these 
proteins also play a vital role in up-regulating the expression of genes that 
control glucose metabolism; hence, their expression is essential in normal 
non cancerous cells (Nakae et al., 2001; Puigserver et al., 2003; Schmoll et 
al., 2000; Yeagley et al., 2001). In addition, FoxO factors exhibit functional 
redundancy, as they are able to bind the same target DNA sequence, 
regulate the transcription of the same target genes and knock-out of all three 
isoforms is required in order for some forms of tumours to develop (Castrillon 
et al., 2003; Hosaka et al., 2004; Paik et al., 2007). Therefore, targeting FoxO 
genes for cancer therapy must be done in a manner that would not hinder 
FoxO expression in cells but would modulate their activity in cancer cells 
 
In this thesis, I was able to show that JNK and PI3K/Akt pathway cross-talk. 
This was found to affect the sub-cellular distribution of FoxO3a. Furthermore, 
it was also appears that JNK and FoxO interact and that JNK can 
phosphorylate FoxO (Essers et al., 2004). Under stress conditions FoxO 
does not translocate to from the nucleus to the cytoplasm, regardless of 
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growth factors in the media (Brunet et al., 2004). This could be due to the 
activation of JNK (Brunet et al., 2004; Essers et al., 2004; Huang et al., 2006; 
Lehtinen et al., 2006; Sunayama et al., 2005). Therefore, it is plausible that 
exposure to oxidative stress generating agents leads to the activation of JNK, 
which in turn phosphorylates FoxO, thereby preventing FoxO from 
translocating from the nucleus into the cytosol (Essers et al., 2004). Hence, 
activation of JNK may be therapeutically desirable, as co-administration of 
agents that activate JNK may synergise with paclitaxel to promote tumour cell 
death. Though, since FoxOs can upregulate, following exposure to oxidative 
stress, the expression of a broad range of genes, some of which are involved 
in inducing cell cycle arrest (De Ruiter et al., 2001; Medema et al., 2000; 
Nakamura et al., 2000; Seoane, 2004; Stahl et al., 2002; Tanaka et al., 2001) 
and apoptosis (Brunet et al., 1999; Modur et al., 2002), and some of which 
are involved in detoxification of ROS (Balaban et al., 2005; Kops et al., 
2002a; Nemoto and Finkel, 2002) and DNA repair (Furukawa-Hibi et al., 
2002; Tran et al., 2002); inducing FoxO activity in cancer cells would only be 
beneficial if it was possible to selectively up-regulate the expression of target 
genes involved in induction of cell death. 
SIRT1 was found to be able to deacetylate FoxO transcription factors (Brunet 
et al., 2004; Daitoku et al., 2004; Fukuoka et al., 2003; Kobayashi et al., 
2005; Mahmud et al., 2002; Motta et al., 2004; Perrot and Rechler, 2005; van 
der Horst et al., 2004; Yang et al., 2005b). Although the role of acetylation 
and SIRT1 in FoxO post-translational regulation is not fully understood, it 
appears that SIRT1 expression alters FoxO activity (Brunet et al., 2004; 
Furukawa-Hibi et al., 2002; Motta et al., 2004; Tran et al., 2002). The 
presence of SIRT1 was found to increase FoxO3a-induced cell cycle arrest, 
while FoxO3a-induced expression of apoptotic genes such as Bim was 
further upregulated following inhibition of SIRT1 activity (Brunet et al., 2004). 
Thus, it appears that SIRT1 may shift FoxO function from cell death to 
survival. Therefore, it is logical that the best way to target FoxO in cancer 
therapy is by inducing FoxO activity in cancer cells, for instance by activating 
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JNK, and co-administration of a drug, such as Sirtinol (Ota et al., 2006), 
which would prevent the activity of SIRT1 in the cells, thereby restricting 
FoxO function to the up-regulation of genes involved in induction of 
apoptosis, such as Bim.  
Research into or understanding of the role and regulation of FoxO 
transcription factors in normal and cancer cells might help to open up new 
avenues in cancer therapy. We are currently only at the beginning of the 
process of learning how these transcription factors work and how to exploit 
this knowledge in cancer prevention and treatment. 
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Figure 6-1: Model summarising results obtained in this thesis coupled with predictive 
mechanism based on my results and available literature.  
Briefly (Regulation of FoxO), paclitaxel treatment was shown to induce oxidative stress in 
MCF-7 cells. This treatment results in an increase in FoxO transcription and protein 
expression in BT4-74 cells (FoxO3a) and HEC-1-B cells (FoxO1). In MCF-7 cells this 
treatment resulted in an increase in FoxO3a promoter activity and protein expression, which 
appeared to result from an increase in protein stability. JNK is activated following treatment 
with paclitaxel and phosphorylates FoxO3a, this phosphorylation may account for the 
increase observed in FoxO3a stability. The JNK and PI3K/Akt pathway cross-talk Inactivation 
of the PI3K/Akt pathway leads to FoxO3a nuclear localisation. Speculative, combined with 
inhibition of SIRT1 activity this will lead to an increase in transcription of target genes 
involved in promoting cell death. (Function of FoxO3a), BTG-1 is a downstream target of 
FoxO3a. Up-regulation of BTG1 leads to a decrease in cyclin D1 and cyclin E1 expression 
and an increase in p21and p27 expression. In addition, cells over-expressing BTG1 were 
shown to accumulate at the G2/M phase of the cell cycle. * only shown at protein and mRNA 
levels, rectangular ended arrow, only shown in MCF-7 cells  
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7 Supplementary Data 
 
 
Figure 7-1: Dose-dependent effect of 16 h paclitaxel treatment of MCF-7 cells.  
MCF-7 cells were treated with 0-200nM paclitaxel for 16 h. Following treatment cell lysates 
were prepared, separated on SDS-polyacrylamide gels and immunoblotted with specific 
antibodies. The expression levels of FoxO3a were analysed using a total FoxO3a antibody. 
The activity of FoxO3a upstream regulator, Akt and the levels and activity of stress induced 
signalling pathways, JNK and p38, were analysed using specific phospho (indicated by a P 
in-front of the protein name) and total antibodies. β-actin was used as a loading control. 
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Figure 7-2: The effect of paclitaxel treatment on the expression of FoxO, p27Kip1 and 
the activity of MAPK signalling in MCF-7 cells.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO3a, Akt-phosphorylated (Thr32) FoxO3a, Akt, phospho-Akt (Ser473),p27
Kip , and 
the levels and activity of the signalling pathways, JNK, p38 and ERK were analysed, using 
specific phospho (indicated by a P in-front of the protein name) and total antibodies. β-actin 
was used as a loading control. 
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Figure 7-3 The effect of paclitaxel treatment on the expression of FoxO, p27Kip1 and 
the activity of JNK and p38 in BT-474 cells.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO3a, Akt-phosphorylated (Thr32) FoxO3a, Akt, phospho-Akt (Ser473), p27Kip and 
the levles and activity of stress induced signalling pathways, JNK and p38 were analysed by 
western blot using specific phospho (indicated by a P in-front of the protein name) and total 
antibodies. β-actin was used as a loading control. 
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Figure 7-4: Differential expression of FoxO1 in HEC-1-B and Ishikawa cells following 
paclitaxel treatment.  
Whole cell lysates were prepared at indicated time-points following treatment with 10nM 
paclitaxel, and then separated on SDS-polyacrylamide gels and immunoblotted. The 
expression of total FoxO1 was analysed using a specific total FoxO1 antibody. β-actin was 
used as a loading control. 
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Figure 7-5: Oxidative stress generated by H2O2 causes an increase in FoxO3a 
expression in MCF-7 cells.  
Whole cell lysates were prepared at indicated time-points following treatment with 200µM 
H2O2, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
total FoxO3a, Akt- phosphorylated (Thr32) FoxO3a, Akt, phosho-Akt (Ser473), p27Kip and the 
levels and activity of the signalling pathways, JNK, p38 and ERK were analysed by western 
blot using specific phospho (indicated by al P in-front of the protein name) and total 
antibodies. β-actin was used as a loading control. The arrow indicates the location on the 
FoxO3a-specific band. 
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Figure 7-6: Paclitaxel treatment increases the stability of FoxO3a in MCF-7 cells. 
Paclitaxel treatment increases the stability of FoxO3a in MCF-7 cells.  
Cells were either pre-treated with 10nM paclitaxel for 16 h (left panel), or not pre-treated 
(right panel). After which cells were treated with 10μg/ml cycloheximide for up to 8 h. whole 
cell lysates were prepared at indicated time-points, then separated on SDS-polyacrylamide 
gels and immunoblotted. The levels of FoxO3a and Id1, a protein with a short half-life were 
analysed by western blot. β-actin, a protein with a longer half life, was used as a loading 
control. 
 
 
 
 
Figure 7-7: Oxidative stress increases the stability of FoxO3a in MCF-7 cells.  
Cells were either pre-treated with 200µM H2O2 (left panel) or not pre-treated (right panel) for 
16 h. Following which, cells were treated with 10μg/ml cycloheximide for up to 8 h. whole cell 
lysates were prepared at indicated time-points, and then separated on SDS-polyacrylamide 
gels and immunoblotted, the levels of FoxO3a and β-actin were analysed.  
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Figure 7-8: BTG1 expression following paclitaxel treatment in MCF-7 cells.  
MCF-7 cells were treated with 10nM paclitaxel for indicated times.Whole cell lysates were 
prepared at indicated times and then separated on SDS-polyacrylamide gels and 
immunoblotted. The levels of total FoxO3a and BTG1 were analysed by western blot using 
specific total antibodies. β-actin was used as a loading control. The arrow indicates the 
location of the FoxO3a specific band 
 
 
 
 
 
Figure 7-9:  BTG1 expression in synchronised MCF-7 cells.  
MCF-7 cells were synchronised at G0 by decreasing the concentration of foetal calf serum 
(FCS) from 10% to 0.5% in the growth medium for 36 h; after which growth medium was 
replaced by fresh media containing 10% FCS. Whole cell lysates were prepared, and then 
separated on SDS-polyacrylamide gels and immunoblotted. The expression levels of total 
FoxO3a, BTG1 and Plk were analysed by western blot using specific total antibodies. β-
tubulin was used as a loading control. 
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Figure 7-10: The BTG1 MCF-7 Tet Off clone #34 expresses BTG1 in an inducible 
manner upon withdrawal of doxycycline from the medium.  
MCF-7 Tet off cells, which were stably transfected with pTRE2Hyg-BTG1, were cultured in 
the presence of 100μg/ml of G418, 200μg/ml and 1μg/ml doxycyclin. At the beginning of the 
time-course (0 h) all antibiotics were removed from the media. Whole cell lysates were 
prepared, and then separated on SDS-polyacrylamide gels and immunoblotted. The levels of 
BTG1 were analysed by western blot using specific total antibodies. β-tubulin was used as a 
loading control. 
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Figure 7-11: The effect of BTG1 over-expression on cell cycle regulators.  
BTG1 Tet-Off cells were induced to express BTG1, by removal of Dox from the cell growth 
medium for a period of 24 h. After which cell lysates were prepared, separated on SDS-
polyacrylamide gels and immunoblotted with specific antibodies. The levels of BTG1, 
FoxO3a and cell cycle regulators was analysed using specific phospho and total antibodies. 
β-tubulin was used as a loading control. 
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Figure 7-12: Paclitaxel causes FoxO3a to translocate into the nucleus.  
Western blotting of cytoplasmic and nuclear extracts isolated from MCF-7 cells that were 
either treated with 10nM paclitaxel or untreated (control) for 8 h The levels of total FoxO3a 
and Akt-phosphorylated FoxO3a (P-FoxO3a) was determined in both cellular components. β-
actin was used as a loading control. 
 
 
Figure 7-13: Inhibition of JNK1/2 by SP600125 prevents FoxO3a nuclear localisation in 
MCF-7 cells treated with paclitaxel. 
Western blotting of cytoplasmic and nuclear extracts isolated from MCF-7 cells which were 
untreated, treated with paclitaxel (10 µM), SP600125 (20 µM), or SP600125 and paclitaxel 
for 8 h. Protein levels were analysed using a specific phospho- FoxO3a (P-FoxO3) antibody 
and specific total antibodies. β-actin was used as a loading control. 
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Figure 7-14: Inhibition of JNK1/2 by SP600125 fails to prevent FoxO3a nuclear 
localisation in MCF-7 cells treated with inhibitors of PI3K and Akt.  
Western blotting of cytoplasmic and nuclear extracts isolated from MCF-7 cells treated with 
inhibitors of PI3K and Akt. Cells were treated with either LY294002 (30 µM), Triciribine (30 
µM), or SP600125 (20 µM), or a combination of Triciribine and SP600125 for 8 h. Protein 
levels were analysed using specific phospho (indicated by a P in-front of the protein name) 
and total antibodies. β-actin was used as a loading control. 
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Figure 7-15: JNK1 can phosphorylate FoxO3a on Serine 294.  
MCF-7 cells were co-transfected with either the combination of pCMV-FoxO3a and pCDNA3-
JNKK2-JNK1, or with PCMV-FoxO3a and the empty vector, pCDNA3. Cell lysates were 
prepared 36 h after transfection was performed and 20µg were used for western blot and the 
remaining 60µg of lysate was Immunoprecipitated (IP) with an antibody against Flag. The 
levels of total JNK and phospho-JNK (Thr183/Tyr185) in transfected cells was determined by 
western blot analysis of total cell lysate. The precipitated anti-Flag complexes were resolved 
on SDS-polyacrylamide gels and immunoblotted with a Flag antibody (Immunoprecipitated 
protein, indicating equal amounts of precipitated protein) and antibodies against 
phosphorylated FoxO3a (predicated JNK phosphorylation sites).  
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Figure 7-16: Mutating FoxO3a’s serine 294 and serine 425 to alanines promotes 
protosomal degradation of FoxO3a.  
MCF-7 cells were transfected with either pCMV-FoxO3a (wt), pCMV-FoxO3aS294A (S294A), 
pCMV-FoxO3aS425A (S425A) or pCMV-FoxO3aS294A, S425A (S294A, S425A). 24 h post-
transfection cells were treated with proteasome inhibitor MG132 (50 µmol/L) for 4 h or not 
treated (NT).Whole cell lysates were prepared and separated on SDS-polyacrylamide gels 
and immunoblotted. Flag protein levels were analysed by western blot. β-tubulin was used as 
a loading control 
 
 
 
 
 
 
 
Figure 7-17: Mutating FoxO3a’s serine 294 and serine 425 affects FoxO3a stability. 
MCF-7 cells were transfected with either pCMV5-FoxO3a (wt), pCMV5-FoxO3aS294A, 
S425A (S294A,S425A) or pCMV5-FoxO3aS294D, S425D (S294D, S425D). 24 h post-
transfection cells were treated with 10μg/ml cycloheximide for up to 8 h. whole cell lysates 
were prepared at indicated time-points, and then separated on SDS-polyacrylamide gels and 
immunoblotted. The levels of Flag were analysed by western blot. β-tubulin was used as a 
loading control. 
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